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 i 
Abstract 
 
Autophagy is a cellular housekeeping process that drives the degradation of 
intracellular and extracellular components in the lysosomes. Defects in this 
process have been implicated with many diseases, among them cancer. Damage-
Regulated Autophagy Modulator (DRAM-1) is a p53 target gene that has been 
shown to regulate autophagy, and it is believed to act as a tumour suppressor. In 
addition to the full-length transcript (splice variant 1) that has previously been 
characterised, multiple splice isoforms of DRAM-1 have been identified. 
 
The first part of this thesis focuses on the investigation of the properties of the 
DRAM-1 isoforms 1, 4 and 5. These isoforms are localised to different cellular 
compartments. DRAM-1 isoforms are highly specific regulators of autophagy. They 
neither mediate the turnover of long-lived proteins nor do they decrease enhanced 
intracellular reactive oxygen species (ROS).  Although activation of DRAM-1 on its 
own does not promote cell death, it is required for effective p53-mediated cell 
death in vitro.  
 
The next step was to proceed to the characterisation of the cellular function of 
DRAM-1 in vivo. Loss of DRAM-1 in vivo is not embryonic lethal and DRAM-1 
knockout mice do not display any phenotypic changes. Additionally, genetic 
deletion of DRAM-1 does not impede p53-dependent cell death in the intestine 
upon exposure to ionising radiation. However, DRAM-1 is required for effective 
intestinal crypt proliferation and mitosis post radiation-induced injury in the small 
intestine. DRAM-1 does not modulate p53-induced senescence in the liver, but the 
loss of DRAM-1 increases apoptosis and possibly mitotic arrest in hepatocytes. 
Furthermore, the deletion of DRAM-1 does not accelerate spontaneous and 
radiation-induced tumourigenesis. Preliminary results indicate that the loss of 
DRAM-1 does not predispose to inflammation-driven tumourigenesis. However, 
DRAM-1-null mice are sensitised to DSS-induced inflammation in the colon. 
 
In the final part of the thesis, the role of DRAM-1 in mediating T cell activation was 
examined. Although DRAM-1 is coregulated with the T cell activating molecule, 
CD80, the loss of DRAM-1 in the professional antigen presenting cells (APCs) do 
 ii 
not affect their ability to activate T cells. However, p53 activation in the APCs 
inhibits antigen processing, and consequently T cell activation. 
 
In summary, these results contribute to the understanding of how autophagy is 
regulated by DRAM-1, and uncover novel roles for p53 and DRAM-1 beyond cell 
death and autophagy regulation. Still, these pathways necessitate further 
investigation and harness a great potential to be targeted therapeutically to 
enhance tumour cell death. 
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Chapter 1: Introduction 
1.1 The multiple flavours of autophagy 
Cellular homeostasis is in part maintained by the degradation of cellular materials via 
the ubiquitin-proteasomal and lysosomal pathways (Codogno and Meijer 2005). 
Concerted efforts to study the lysosomal degradation of various cellular components 
like superfluous or damaged organelles, proteins and protein aggregates as well as 
extracellular materials like viruses and bacteria have led to the identification of a 
conserved cellular process termed autophagy (Ciechanover 2005) (Gozuacik and 
Kimchi 2004) (Cuervo 2004).  
 
The term autophagy originates from the Greek roots “auto” (self) and “phagy” (eating), 
and is broadly defined as the transportation and lysosomal degradation of 
cytoplasmic material (Ravikumar, Sarkar et al. 2010). The emergence of autophagy 
research stems from the identification of lysosomes in 1955 by De Duve and 
colleagues (De Duve, Pressman et al. 1955). Shortly after this, the morphological 
process of autophagy was described in the 1960s by electron microscopy studies, 
revealing the sequestration of the cytoplasm and other cellular organelles into novel 
membrane-bound vesicles (Klionsky 2007) (De Duve and Wattiaux 1966).  
 
Depending on the delivery route and cargo specificity, three different types of 
autophagy have been distinguished – macroautophagy, microautophagy and 
chaperone-mediated autophagy (CMA) (Eskelinen and Saftig 2009). Macroautophagy 
(herein referred to as autophagy), which resembles De Duve’s initial description of 
autophagy, is characterised by the engulfment and delivery of bulk cytoplasm and 
specific organelles by the autophagosome (a double-membrane organelle) to the 
lysosome whereas microautophagy is the direct uptake and degradation of the 
cytoplasm by the invagination of the lysosomal membrane (Mizushima, Levine et al. 
2008). CMA is a cellular process whereby soluble proteins which are tagged with a 
specific pentapeptide, are shuttled into the lysosomal lumen across the lysosome 
membrane via the HSC70 chaperone protein, and the integral membrane receptor 
LAMP-2A (lysosome-associated membrane protein type 2A) (Cuervo 2004) (Ogier-
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Denis and Codogno 2003). Of these three pathways, macroautophagy is the most 
characterized form and has been extensively researched in yeast and mammals 
(Chen and Klionsky 2011). 
 
Autophagy is also frequently characterised into selective and non-selective 
autophagy. Non-selective autophagy involves the random engulfment and 
degradation of bulk cytosol to maintain the cytoplasmic volume and its contents in 
equilibrium (Liang and Jung 2010). On the other hand, selective autophagy is the 
highly specific recognition and digestion of specific cargoes (Liang and Jung 2010), 
ranging from nucleic acids, proteins, and lipids to organelle turnover (Munafo and 
Colombo 2001) (Tanida ; Sakai, Oku et al. 2006) (Bernales, Schuck et al. 2007) 
(Kraft, Deplazes et al. 2008) (Weidberg, Shvets et al. 2009). Some of these lysosomal 
degradation processes involve specific genes, such as Pex and Parkin which 
modulate the degradation of peroxisomes and mitochondria respectively (Sakai, Oku 
et al. 2006) (Xie and Klionsky 2007). Given this, selective autophagy has been 
proposed to evolve to specifically match the changing demands in different 
organisms, or even different tissues within the same organism to sustain cellular 
viability (Liang and Jung 2010).  
 
Autophagy is a fundamental and indispensable process that is required to maintain 
cellular homeostasis and to regulate or respond to other cellular pathways. A 
deregulation in autophagy could lead to cellular demise, and other diseases, such as 
cancer, which is discussed later in this thesis.  
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1.2 The mammalian autophagy molecular machinery  
Autophagy is initiated by the expansion of a membrane structure called 
autophagosomal structure, which expands into the isolation membrane, or 
phagophore where the cargoes are sequestered (Webber and Tooze 2010). The 
isolation membrane then closes to form double-membrane bound vesicles called 
autophagosomes, which fuse with lysosomes, where the inner autophagic vesicles 
and the contents are degraded by vacuolar or lysosomal hydrolases (Mizushima 
2007). Autophagosomes occasionally fuse with endosomal vesicles, such as 
endosomes and multivesicular bodies to form the intermediate organelle 
amphisomes, and the fusion of autophagosomes to endosomes and/or lysosomes are 
collectively termed autophagosome maturation (Mizushima 2007). 
 
The degraded products are released into the cytosol for recycling via lysosomal 
membrane permeases (Xie and Klionsky 2007). The morphological steps of 
autophagy are schematically shown in Fig. 1.1. Different names have been coined to 
describe autophagosomes or autophagosome-like structures, depending on the 
physiological conditions under which they are formed (Xie and Klionsky 2007). The 
origin of the isolation membrane has been researched extensively in yeast (Reggiori, 
Tucker et al. 2004; Reggiori, Shintani et al. 2005; He, Baba et al. 2008), and has 
facilitated the understanding of phagophore formation in eukaryotes. The isolation 
membrane is proposed to be formed from de novo lipid synthesis, or is derived from 
pre-existing organelles such as the ER, Golgi complex, plasma membrane and 
mitochondria (Webber and Tooze 2010) (Hailey, Rambold et al. 2010). 
 
The identification of a panel of genes that regulate autophagy, termed ATG 
(AuTophaGy-related genes) in yeast and mammals has provided insights into the 
study of the molecular machinery of autophagy. To date, about 30 ATG genes have 
been identified in yeast, Saccharomyces cerevisiae, and most of these genes have 
known orthologues in other eukaryotes (Suzuki and Ohsumi 2007). Many researchers 
have studied the participation of these ATG proteins in the cellular and molecular 
network of autophagy. 
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The formation of the isolation membrane for the sequestration of cytoplasmic 
materials is termed vesicle nucleation and is regulated by the formation of two 
complexes, as illustrated in Fig.1.2. The first complex consists of ATG13, focal 
adhesion kinase family interacting protein of 200 kD (FIP200), ULK 1 and ATG101 
(Hosokawa, Hara et al. 2009) (Itakura and Mizushima 2010). ULK1 and FIP200 are 
mammalian orthologues of ATG1 and ATG17, respectively, whereas ATG101 is a 
novel mammalian autophagy protein that is absent in yeast (Itakura and Mizushima 
2010). Upon exposure to autophagic stimuli, ATG13 (triphosphorylated when 
inacitve), is phosphorylated and associates with ULK1 and FIP200 (Maiuri, Zalckvar 
et al. 2007) (Itakura, Kishi et al. 2008). ATG101 binds to human ATG13 and also 
interacts with ULK1 (Mercer, Kaliappan et al. 2009). ULK 1 and ATG14 are 
occasionally found in punctate structures that are tightly associated with the ER and 
the ER protein vacuole membrane protein 1 (VMP1) has been demonstrated to 
transiently associate with this early autophagic structure (Itakura and Mizushima 
2010). ATG17 has been shown to recruit the integral transmembrane protein, ATG9 
to the pre-autophagosomal site (PAS) in yeast (Sekito, Kawamata et al. 2009), and 
the trafficking of ATG9 to PAS is proposed to facilitate membrane flow for membrane 
formation (He, Baba et al. 2008). Albeit this, mammalian ATG9 has been observed to 
cycle between the transgolgi network (TGN) and LC3-II positive components, 
hypothesised to be phagophores during starvation (Young, Chan et al. 2006) 
(Webber and Tooze 2010). The cycling of ATG 9 is proposed to be regulated by 
p38IP (p38 interacting protein) and PI3K (Webber and Tooze 2010) (Young, Chan et 
al. 2006).  
 
The second complex, which is known as the autophagy-specific class III PI3-kinase 
complex, comprises of Beclin 1 (Atg6/Vps30 homologue), Atg14, Vps34 and the 
myristylated kinase p150 (Vps15) (Itakura and Mizushima 2010). Beclin 1 is a Bcl-2-
interacting protein that also interacts with ATG14 and activating molecule in Beclin 1-
regulated autophagy (AMBRA-1) (Itakura and Mizushima 2010). Whereas AMBRA-1 
positively regulates the Beclin 1-dependent programme of autophagy (Fimia, 
Stoykova et al. 2007), ultraviolet radiation resistance-associated gene (UVRAG) and 
ATG14 are thought to form distinct Beclin 1 complexes, which are involved in 
membrane trafficking and protein sorting, respectively (Itakura, Kishi et al. 2008).  
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Autophagosome elongation and completion involves two ubiquitin-like conjugation 
systems (Figure 1.3).  This process involves the conjugation of Atg12 to Atg5 which is 
catalysed by Atg7 (E1-like enzyme) and Atg10 (E2-like enzyme) (Maiuri, Zalckvar et 
al. 2007). The conjugation of phosphatidylethanolamine (PE) to LC3 (one of the 
mammalian orthologues of yeast Atg8) is catalysed by the protease, Atg4 and the E1- 
and E2-like enzymes - Atg7 and Atg3 respectively (Maiuri, Zalckvar et al. 2007).  
 
The fusion of autophagosomes to endosomal vesicles is mediated by the endosomal 
sorting complex required for transport (ESCRT) proteins, and the subsequent fusion 
of the amphisome and lysosome is facilitated by Fab 1 and Rab 7 (Rusten, Vaccari et 
al. 2007) (Fader and Colombo 2009). The final fusion of both autophagosomes and 
amphisomes to lysosomes is also thought to be mediated by Beclin 1, UVRAG, 
Vacuolar protein sorting 34 (Vps34), p150, and ESCRT (Matsunaga, Saitoh et al. 
2009) (Fader and Colombo 2009) (Fig. 1.4). 
 
There may well be other proteins that are involved in the step-wise formation of 
isolation membrane up to the degradation of autophagosomes that have yet to be 
identified. This is reflected in the robust discovery of new interactors of the core 
autophagic machinery. For instance, the recently characterised Bif-1 (also known as 
Endophilin B1) is reported to bind to UVRAG and Beclin 1 (Takahashi, Coppola et al. 
2007). Additionally, Barkor, has been shown to form a complex with Beclin 1 to 
facilitate LC3 conjugation and autophagosome assembly (Sun, Fan et al. 2008). 
Likewise, a novel PI(3)P-binding protein termed double FYVE-containing protein 1 
(DFCP1), translocates to a subdomain of the ER and generates the “omegasome” 
during starvation (Axe, Walker et al. 2008). Thus, the mapping of autophagy 
regulators to their role in the autophagy machinery requires the participation of 
different proteins at various steps.  
 
Autophagy can also proceed in the absence of ATG5 and ATG7. This form of 
autophagy, which does not rely on the cascade of ATG signalling, has been termed 
non-canonical or alternative autophagy (Nishida, Arakawa et al. 2009). This form of 
autophagy might be triggered when canonical autophagy is inactivated due to 
mutations in the panel of Atg genes (Scarlatti, Maffei et al. 2008). 
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Subsequent to the in vitro characterisation of these panels of autophagy regulators, 
elegant systemic and tissue-specific deletion of these genes in mice has greatly 
facilitated the involvement of autophagy in mammalian development (Section 1.3.1) 
and disease progression.  
 
Beclin 1 knockout mice failed to survive post embryonic day 7.5 (Yue, Jin et al. 2003), 
while Atg5 and Atg7 knockout mice die of starvation soon after birth due to the 
inhibition of autophagy (Kuma, Hatano et al. 2004) (Komatsu, Waguri et al. 2005).  
The difference in phenotype may suggest that Beclin 1 might have more complicated 
functions beyond autophagy. Indeed, it was later reported that Beclin 1 also regulates 
endocytosis (Ruck, Attonito et al. 2011).  
 
The genetic ablation of autophagy has also been shown to contribute to 
tumourigenesis, with some autophagy regulators playing more significant roles than 
others, as discussed in section 1.6. 
 
However, mice deficient for either of the Atg8 paralogues (Section 3.0), LC3B or 
GABARAP were able to develop normally and appear phenotypically normal. (Cann, 
Guignabert et al. 2008) (O'Sullivan, Kneussel et al. 2005). LC3B-/- embryonic 
fibroblasts were able to form autophagosomes normally under nutrient-limiting 
conditions (Cann, Guignabert et al. 2008). Additionally, GABARAP-/- do not show an 
upregulation of other GABARAP homologues (O'Sullivan, Kneussel et al. 2005). 
These scenarios probably reflect a biological redundancy in the regulation of 
autophagy, and that other autophagy regulators can compensate the functions of 
Atg8 paralogues.  
 
In short, autophagy is a multi-step process that is regulated by a panel of genes, and 
the majority of these genes are conserved from yeast to mammals. Some of the 
autophagy regulators, such as Beclin 1 may have other functions beyond autophagy 
regulation. The identification of novel mammalian regulators such as ATG101 
suggests that mammalian cells have evolved to sustain the escalating demand for 
autophagy regulation in a more complex environment. Thus, when there’s a block in 
the signalling cascade, one can imagine that cells must have adopted alternative 
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routes to activate autophagy, or may even switch to activate other types of autophagy 
to respond to intracellular and extracellular changes. However, functional redundancy 
may occur, as observed by the deletion of the ATG8 paralogues, LC3B and 
GABARAP.  
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1.3 Autophagy: Life and breath of cells 
Autophagy occurs constitutively at basal levels to maintain cellular homeostasis by 
regulating various cellular processes, some of which will be discussed in this section. 
 
1.3.1 Autophagy is required for development and hematopoiesis  
The investigation of the homeostatic role of autophagy in mammalian development 
and hematopoiesis has been greatly propelled by the genetic knockout studies of 
ATG genes. Mammalian embryogenesis begins with the fertilization of mature oocyte 
by sperm to form zygote, followed by early embryo development to form two-, four- 
and eight-cells structure (Al-Gubory, Fowler et al. 2010). Further cellular divisions 
result in the development of blastocyst in which the inner cell mass gives rise to the 
fetus, whereas the rest contribute to extra embryonic tissues such as the placenta 
(Surani and Tischler 2012).  The importance of autophagy in embryogenesis is 
highlighted by the findings the conventional knockout of BECN-1 and AMBRA is 
embryonic lethal due to the failure to develop structures that facilitate the stages of 
embryogenesis (Mizushima and Levine 2010).  
 
Downstream of embryogenesis, autophagy is required to sustain neonatal survival. 
Prior to birth, fetuses obtain the essential nutrients from the placenta (Mizushima and 
Levine 2010). Upon birth, this flow of nutrient is terminated and neonates rely on 
autophagy for the synthesis of essential nutrients (Mizushima and Levine 2010). Atg5-
/- and Atg7-/- neonates which are deficient for autophagy, despite being born at the 
expected Mendelian frequency, have decreased amino acid levels and succumbed to 
severe starvation-induced cell death soon after birth (Kuma, Hatano et al. 2004) 
(Komatsu, Waguri et al. 2005) (Mizushima and Levine 2010). 
 
The production of mature and specialised cells, which are required for normal tissue 
functions, arose from stem cells, a population of pluripotent and self-renewing cells 
which can differentiate into multiple cell types. (Herberts, Kwa et al. 2011).  In line 
with this, autophagy was found to be upregulated in human embryonic stem cells 
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(hESCs) induced to undergo differentiation by treatment with type I TGF-beta 
receptor inhibitor SB431542 or removal of MEF secreted maintenance factors (Tra, 
Gong et al. 2011). This suggests that autophagy might be required for cellular 
differentiation. Likewise, autophagy has been proposed to facilitate cellular 
reprogramming and the generation of the induced pluripotent stem (iPS) cells 
(Vessoni, Muotri et al. 2012). In this context, autophagy is hypothesized to provide 
ATP for chromatin remodelling and the subsequent induction or repression of genes 
involved for the maintenance of pluripotency and  differentiation (Vessoni, Muotri et 
al. 2012).  
 
Autophagy has also been implicated in the production of red blood cells, 
megakaryocytes, myeloid cells (monocyte/macrophage and neutrophil), and 
lymphocytes from hematopoietic stem cells – a process collectively termed 
hematopoiesis (Orkin and Zon 2008). The involvement of autophagy in hematopoiesis 
begins as early as maintaining the integrity of the HSC pool, where it is required to 
prevent the accumulation of mitochondria and reactive oxygen species (ROS) in the 
HSCs and progenitor cells (Mortensen, Soilleux et al. 2011). Upon genetic ablation of 
autophagy by Atg7 deletion, the bone marrow-derived Lin-Sca-1+c-Kit+ (LSK) cells, 
which are enriched for HSCs and early progenitors, exhibited an increase in DNA 
damage, proliferation and apoptosis, leading to reduced HSC cell count within this 
compartment (Mortensen, Soilleux et al. 2011). Thus, autophagy is critical to maintain 
a healthy pool of HSCs and progenitors for efficient production of blood cells.  
 
The autophagic removal of mitochondria is also required for erythroid and lymphocyte 
differentiation (Mizushima and Levine 2010). Inhibition of autophagy in red blood cells 
by deleting Atg7 causes pre-mature cell death (Mortensen, Ferguson et al. 2010). 
Likewise, the cell count of circulating T and B lymphocytes were significantly reduced 
upon Atg5 and Atg7 deletion (Pua, Dzhagalov et al. 2007) (Mortensen, Ferguson et 
al. 2010). Though this lymphopenia did not progress, ex vivo and in vitro cultures of 
CD4+ and CD8+ Atg7−/− T lymphocytes exhibited higher levels of mitochondrial 
number and mass, as well as increased mitochondrial superoxide and consequently 
more apoptosis (Mortensen, Ferguson et al. 2010). Although Atg5 is critical for the 
development of B cells in the bone marrow and the survival of certain types of 
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circulating B cells, the mechanism underlying autophagy and B cell defects is 
unknown and requires further investigation (Mizushima and Levine 2010).  While 
studies from mouse models lacking the core Atg genes do not implicate a defect in 
the production of platelets from megakaryocytes (megakaryocytopoiesis), 
megakaryocytic differentiation and the production of pro-platelets involves drastic 
morphological changes, which is most likely facilitated by autophagy (Colosetti, 
Puissant et al. 2009). The involvement of autophagy in this process is further 
suggested by the findings whereby caspases, which also regulates autophagy (refer 
to section 1.4), are required in the late steps of megakaryocytic differentiation (De 
Botton, Sabri et al. 2002). Thus, it would be of great interest to determine if autophagy 
plays a significant role in platelet formation. 
 
In summary, autophagy is required for cellular development and hematopoiesis. 
Thus, it is important to identify other autophagy regulators which contribute to these 
processes in order to reinforce our understanding between autophagy, cellular 
development and differentiation.      
 
1.3.2 Stimulating Autophagy - Survival or death? 
When cells are exposed to unfavourable conditions, autophagy is activated above 
basal levels to counteract ‘stress’ to achieve cellular equilibrium and to maintain a 
stable and favourable environment. This switch from its default housekeeping to a 
cytoprotective role is triggered by various stimuli, and will be discussed in this section. 
 
Nutrient withdrawal has been long considered as a potent stimulus of autophagy. 
When cells are deprived of amino acids, mature autophagic vacuoles have been 
reported to occupy ~1% of the cytoplasm (Mizushima, Yamamoto et al. 2001). 
Indeed, markers of autophagy are rapidly detected within 10 minutes of starvation 
(Munafo and Colombo 2001). The dependence on autophagy for survival under 
nutrient-limiting conditions is conserved from yeast to higher eukaryotes. During 
nitrogen starvation, autophagy-defective yeast mutants were susceptible to cell death 
compared to the wild-type controls (Suzuki, Onodera et al. 2011). This is attributed to 
the inability of the mutants to prevent ROS accumulation, thus leading to the fatal loss 
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of mitochondria function (Suzuki, Onodera et al. 2011). Recently, another group of 
protein - ubiquilins (UBQLNs) - were shown to be upregulated upon nutrient 
starvation to activate autophagy to sustain survival (N'Diaye, Kajihara et al. 2009).  
 
However, autophagy may have dual roles in survival during starvation. Excessive 
autophagy induced by starvation can cause irreversible cellular damage beyond 
rescue. It has been shown that physiological levels of autophagy promotes survival 
in Caenorhabditis elegans during starvation, but excessive levels of autophagy can 
lead to cell death (Kang, You et al. 2007). Occasionally, autophagy has also been 
demonstrated to potentiate cell death upon serum withdrawal (Steiger-Barraissoul 
and Rami 2009). Thus, autophagy may act as a double-edged sword in cellular 
survival upon nutrient withdrawal. The decision to invoke cell death or cellular 
processes could be affected by cell type and other reasons that have yet to be 
elucidated. 
 
The link between vacuolization and autophagy, and corresponding cell death has led 
to the coinage of the term autophagic cell death. In fact, this process has been well-
studied in the model organism Dictyostelium discoideum (Tresse, Giusti et al. 2008). 
This form of cell death accompanied by autophagy activation has also been reported 
in the Drosophilla midgut (Lee, Cooksey et al. 2002). It was later revealed that 
autophagic cell death is required for development. Elegant in vivo studies by Berry 
and Baehrecke (2007) reported that autophagy promotes cel death in Drosophila 
salivary glands upon growth arrest. They also demonstrated that the developmental 
degradation of salivary glands is inhibited when autophagy is blocked by mutating atg 
genes, despite the presence of caspases, and that autophagy induces cell death in a 
caspase-independent manner (Berry and Baehrecke 2007).  
 
Autophagy is also implicated in cellular regeneration. The regenerative role of 
autophagy has been demonstrated in the simple metazoan, planarian (Gonzalez-
Estevez, Felix et al. 2007). In planarian, autophagic degradation generates energy 
and the building blocks for cell proliferation and differentiation to facilitate organism 
remodeling and cellular regeneration (Gonzalez-Estevez, Felix et al. 2007). 
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Alternatively, autophagy is also required for the clearance of degenerated axons 
during the regeneration of rat striatic nerve (Piao, Wang et al. 2004).  
 
Metabolic stress caused by oxygen limitation has also been shown to induce 
autophagy. During hypoxia, platelet-derived growth factor receptors (PDGFR), an 
orthologue of the human tyrosine kinase Poliovirus receptor (Pvr) selectively induces 
HIF-1α- dependent hypoxia-induced autophagy, leading to cellular survival 
(Wilkinson, O'Prey et al. 2009).  The pro-survival role of autophagy in this context is 
not attributed to the removal of defective mitochondria, but rather the degradation of 
cytosolic protein (Wilkinson, O'Prey et al. 2009).   
 
Reactive oxygen species (ROS) are potent DNA damaging agents (Wiseman and 
Halliwell 1996), and have been shown to induce autophagy (Scherz-Shouval, Shvets 
et al. 2007) (Bensaad, Cheung et al. 2009). Other DNA damaging agents such as 
ionising radiation and cisplatin were also shown to induce autophagy in the paneth 
cells of the small intestine (Gorbunov and Kiang 2009) and the renal proximal tubular 
cells (Periyasamy-Thandavan, Jiang et al. 2008) respectively. In the renal cells, 
autophagy is required for sustaining cellular survival (Periyasamy-Thandavan, Jiang 
et al. 2008). Whether occurring at physiological levels or induced above the basal 
levels, the role of autophagy to maintain genome integrity for cellular survival has 
been well characterised.  In vitro cultures of autophagy-defective tumour cells 
accumulate more DNA damage and exhibit an impaired survival when compared to 
the wild-type counterparts upon exposure to metabolic stress (Karantza-Wadsworth, 
Patel et al. 2007). This is attributed to the failure of autophagy-defective cells to adapt 
to metabolic stress, which leads to insufficient ATP generation and the built-up of 
damaged mitochondria with excessive ROS (Jin 2006). Direct DNA insult by ROS 
may cause replication stress and DNA damage response activation, which normally 
arrests cell cycle progression or triggers apoptosis (Karantza-Wadsworth, Patel et al. 
2007). 
 
Other known agents which activate autophagy include hormones (Deng, Feng et al. 
2010), and certain chemicals or drugs (Kanzawa, Germano et al. 2004). The novel 
estrogen-induced gene EIG121 which is associated with the endosome–lysosome 
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compartments, is speculated to induce autophagy and promote cell survival upon 
exposure to nutrient-limiting conditions and cytotoxic agents (Deng, Feng et al. 2010). 
Autophagy also facilitates cell death in sarcoma cell lines which were treated with the 
genotoxic chemotherapy agent doxorubicin and cyclin-dependent kinase inhibitors 
(Lambert, Qiao et al. 2008).  
 
In addition, heat stress, osmotic and mechanical pressure have also been 
documented to induce autophagy (Swanlund, Kregel et al. 2008) (Han, Kim et al. 
2010) (King, Veltman et al. 2011). The effect of autophagy in this context, whether to 
induce cell death or sustain cell survival requires further investigation.  
  
In conclusion, autophagy is activated upon exposure to various forms of stress such 
as nutrient deprivation, metabolic stress, and DNA damage. Although most evidence 
demonstrate that autophagy in these contexts promotes cellular viability, it can also 
induce cell death. On the other hand, autophagy occurring at physiological levels 
facilitates cellular regeneration, which is critical for homeostasis. 
 
1.4 Autophagy and apoptosis crosstalk 
Apoptosis is characterized by cell shrinking, nuclear condensation and fragmentation, 
membrane blebbing and the engulfment of cellular components into apoptotic bodies 
(Kerr, Wyllie et al. 1972). This form of cell death requires the participation of caspases 
- a group of cysteine proteases that play important roles in regulating apoptosis 
(Degterev, Boyce et al. 2003). The interplay of both autophagy and apoptosis in cell 
death has been documented by many studies.  
 
Both pathways have been demonstrated to occur in parallel for effective cell killing. 
This is evident in the p53 and DRAM-1 signalling network, whereby DRAM-1, a direct 
target of p53, promotes autophagy, and is required for effective p53-mediated 
apoptosis (Crighton, Wilkinson et al. 2006).  Similarly, Yee et al. (2009) showed that 
the potent pro-apoptotic protein, Puma, activates Bax, thus resulting in mitochondrial 
outer membrane permeabilisation. Autophagy induction was also detected alongside 
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the release of cytochrome c into the cytoplasm, proposing the occurrence of 
mitophagy in response to mitochondrial perturbations (Yee, Wilkinson et al. 2009). 
The inhibition of autophagy by silencing Atg5 diminishes the PUMA- and Bax-induced 
apoptotic response (Yee, Wilkinson et al. 2009). These lines of evidence suggest that 
the cross talk between autophagy and apoptosis is required for effective cell killing.  
 
Other inhibitors of apoptosis that also inhibit autophagy are the well-characterised 
anti-apoptotic proteins of the Bcl-2 family, which primarily repress the activation of the 
pro-apoptotic Bax/Bak proteins (Pattingre, Tassa et al. 2005).  In line with this, Bcl-XL 
binds to the BH3-domain of Beclin 1, resulting in an inhibition of starvation-induced 
autophagy (Pattingre, Tassa et al. 2005). Additionally, Bcl-2, which is found in the 
mitochondria and ER inhibits apoptosis, but only ER-localised Bcl-2 functionally 
inhibits autophagy by preventing calcium release from the ER, resulting in the 
subsequent activation of mTOR and the repression of autophagy (Pattingre, Tassa et 
al. 2005). These studies suggest that autophagy and apoptosis are regulated in a 
similar manner. 
 
Regulators of the extrinsic apoptotic pathway also interact with the conventional ATG 
proteins. For instance, the ATG5 protein has been documented to interact with Fas-
associated protein with death domain (FADD) to induce apoptosis (Pyo, Jang et al. 
2005). In an independent study, calpain-cleaved ATG5 has been documented to 
translocate from the cytosol to mitochondria and associate with the anti-apoptotic 
molecule Bcl-XL to trigger cytochrome c release and caspase activation (Yousefi, 
Perozzo et al. 2006). The cleaved form of ATG5, however, does not modulate 
autophagy, but the fact that calpain activity is required for autophagy induction by 
rapamycin treatment and amino acid starvation (Demarchi, Bertoli et al. 2006) 
suggests that the cleavage of ATG5 only occurs below a certain threshold to ensure 
that there is enough uncleaved and cleaved ATG5 to modulate both autophagy and 
apoptosis. These lines of evidence indicate that apoptosis and autophagy share 
common regulators. Additionally, the specific processing or cellular localisation of the 
protein is the key factor which determines whether cells undergo apoptosis or 
autophagy, or both.  
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Nevertheless, apoptosis and autophagy occasionally occur in a mutually exclusive 
manner. Caspases, effectors of the apoptotic pathways, have been shown to cleave 
and inactivate Beclin 1, and the resulting suppression of Beclin 1 increases apoptosis 
in HeLa cervical cancer cells (Cho, Jo et al. 2009). In a less drastic scenario, 
Campthothecan (CPT) treatment in breast cancer cells results in autophagy activation 
and delayed apoptosis (Munoz-Gamez, Rodriguez-Vargas et al. 2009). These lines of 
evidence imply that apoptosis is either inhibited, or delayed when autophagy is 
activated. In this context, autophagy maybe activated to protect cells from dying.  
 
Thus, autophagy and apoptosis share a common panel of regulators, and the 
decision to activate either or both of these cellular processes is governed by the 
specific post-translational modification and the cellular localisation of these proteins. 
Both autophagy and apoptosis can occur together to enhance cell killing, or in a 
mutually exclusive manner. The decision to activate either of these pathways is most 
likely governed by the health status of the cell, or perhaps the nature of the stimuli.  
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1.5 Autophagy and the regulation of the immune system 
Immunity confers protection to the host by resisting and destroying pathogens or 
pathogenic materials, and is mainly classified into the innate and adaptive immune 
system.  Innate immunity is the first line of defence and consists of the physical and 
chemical barriers such as skin, mucous membranes and stomach acids; phagocytic 
cells such as neutrophils and macrophages; the complement system and various 
cytokines which mediate inflammation and other non-specific responses which can in 
turn, activate the adaptive immune system (Rabb 2002). The adaptive immune 
system consists of T and B cells which function to invoke the cell mediated and 
humoral response for effective pathogen killing, in addition to establishing a long-lived 
immunological memory against reinfection (Dunkelberger and Song 2010).  
Autophagy and immunity is now considered as two inseparable entities, as autophagy 
has been demonstrated to modulate both the innate and adaptive immune responses, 
as discussed in this section. 
 
1.5.1 Autophagy mediates innate immunity 
When cells are attacked by pathogens such as viruses or bacteria, autophagy is often 
stimulated in parallel to the immune response. These integrated responses are 
coordinated by various players of the innate immunity including pathogen recognition 
receptors (PRRs) including the Toll like receptors (TLR), NOD-Like Receptors (NLR), 
RIG-1 like receptors, and C-type lectin receptors (Kroemer, Marino et al. 2010) 
 
Members of the PRR family such as TLR and NLR have been demonstrated to be 
involved in the autophagic pathway upon pathogen invasion. Activation of TLR3 and 
TLR7 by viruses results in autophagy induction (Delgado, Elmaoued et al. 2008; Shi 
and Kehrl 2008).  The tight cross talk between TLRs and autophagy regulators is 
reflected when the autophagic response is diminished upon acute silencing of TLR7 
and myeloid differentiation factor 88 (MyD88), a component of the TLR7 signalling 
cascade (Shi and Kehrl 2008). Additionally, the recognition of bacterial 
peptidoglycans by NOD2 results in the activation of autophagy for bacterial clearance, 
and these processes are compromised in individuals harbouring mutations in either 
 
 
21 
NOD2 or ATG16L1 (Cooney, Baker et al. 2010). A more direct role of autophagy in 
innate immunity is by facilitating the delivery of pathogens to designated cellular 
compartments for lysosomal digestion or sensing by PRRs (Lee, Lund et al. 2007) 
(Jia, Thomas et al. 2009). 
 
Autophagy also suppresses innate immune response by toning down the production 
of inflammatory cytokines. In conjunction with this, many autophagy proteins have 
been demonstrated to regulate innate immunity beyond autophagy. Atg5 and Atg12, 
down-regulate another group of PRRs, the cytoplasmic viral nucleic acid sensors to 
suppress type1 interferon (IFN) production (Jounai, Takeshita et al. 2007). Similarly, 
deletion of Atg16L1 in hematopoietic cells results in increased production of the pro- 
inflammatory cytokines, IFN-β and IL-18, following endotoxin stimulation (Saitoh, 
Fujita et al. 2008).  
 
The influence of autophagy on innate immunity is not only limited to the immune cells. 
In fact, elegant in vivo studies done by Cadwell and colleague showed that the 
deletion of the bona-fide autophagy gene, ATG16L1 drastically disrupts the function 
of paneth cells of the small intestine, leading to aberrant exocytosis, and increased 
expression of a subset of inflammatory cytokines (Cadwell, Liu et al. 2008). Elevated 
expression of adipocytokine and other inflammatory cytokines are often associated 
Crohn’s disease, a complex inflammatory disease of the small intestine (Yamamoto, 
Kiyohara et al. 2005) (Cadwell, Liu et al. 2008). In this context, autophagy is most 
likely to be activated to limit the production of inflammatory cytokines above a certain 
threshold that would cause dire consequences to the cell.  
 
Based on these lines of evidence, autophagy induction is required to trigger innate 
immune responses upon initial pathogen attack. However, autophagy also 
downregulates innate immunity by suppressing the production of inflammatory 
cytokines. This is mostly the case when the production of inflammatory cytokines 
reaches a certain threshold that would jeopardise the health status of the cells, or 
when innate immunity fails to contain or kill off the pathogen, autophagy then limits 
the magnitude of the innate immune response to switch on the more potent adaptive 
immune response for complete destruction of the pathogen. 
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1.5.2 Autophagy modulates adaptive immunity 
The adaptive immune response is evoked when the innate immune response fails to 
contain or destroy the pathogenic attack. When this occurs, antigens are picked up by 
antigen presenting cells (APCs) and presented on either major histocompatibility 
complex (MHC) class I or class II molecules to CD8+ and CD4+ T cells (Munz 2010; 
Munz 2012) (Munz 2006) (Fig.1.5). MHC class I molecules are expressed by all 
nucleated cells whereas, the expression of MHC class II molecules is restricted to 
antigen presenting cells  (APCs), like B cells, macrophages and dendritic cells (Neefjes, 
Jongsma et al. 2011) (Munz 2012). However, MHC class II expression can be 
induced by various stimuli such as the cytokine interferon gamma and other stimuli in 
non-APCs such as mesenchymal stromal cells, fibroblasts, endothelial cells, epithelial 
cells, and enteric glial cells (Neefjes, Jongsma et al. 2011). MHC class I molecule, 
which was conventionally thought to present endogenous antigens which are 
processed within the cytoplasm, has been demonstrated to also process exogenous 
peptides which are originally presented by MHC class II molecules by a pathway 
called cross presentation. (Amigorena and Savina 2010) (Fig. 1.5). Vice versa, 
intracellular antigens have also been found on MHC class II molecules (Nimmerjahn, 
Milosevic et al. 2003) (Fig.1.5).  
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The participation of the autophagic machinery in regulating antigen presentation on 
MHC molecules has been demonstrated in many studies. Acute silencing of Atg5 in 
apoptosis-deficient mouse embryonic fibroblasts (Bax/Bak-/-) decreases antigen 
presentation on MHC class I molecules and subsequently diminishes the CD8+ T cell 
activation upon infection with the influenza virus A (Uhl, Kepp et al. 2009). Consistent 
with this, Li et. al (2008) showed that the priming of CD8+ T cells by melanocytes and 
epithelial cells  presenting the tumour antigen gp100 and the model antigen 
ovalbumin was greatly reduced when Atg6 and Atg12 were silenced in these cell 
lines, or when the earlier stages of autophagy were pharmacologically blocked with 3-
MA.  The authors also found that inhibiting autophagy at later stages by blocking 
autophagosome turnover with the lysosomotropic agent, NH4Cl strikingly augmented 
antigen presentation. This suggests that the presence of autophagosomes, 
regardless of autophagy status is crucial for CD8+ activation, and impinges a role for 
autophagosomes as efficient antigen transporters from endosomes to MHC class I 
molecules.  
 
However, the late-stage inhibition of autophagy with another lysosomotropic agent, 
chloroquine, is reported to block antigen presentation of the tumour antigen mucin1 
(MUC1) onto MHC class II molecules, but with no obvious effects on MHC class I 
machinery (Dorfel, Appel et al. 2005). The significance of autophagy in promoting 
efficient MHC class II processing is further highlighted when autophagy stimulation 
enhances, whereas siRNA knockdown of Atg5 and Atg8 in dendritic cells decreases 
HIV antigen presentation on MHC class II due to a defect in forming 
immunoamphisomes (Blanchet, Moris et al. 2010). The mechanism by which 
autophagy affects MHC class II presentation was further dissected by Lee and 
colleagues (2010) who observed that Atg5-/- dendritic cells displayed a reduced 
capacity to form phagolysosomes, leading to a decreased ability to prime CD4+ 
lymphocytes. However, they also discovered that autophagy induced by starvation 
and rapamycin treatment decreases class II presentation, thus proposing that a non-
metabolic autophagy pathway mediates antigen presentation by DC on Class II. 
These lines of evidence emphasises that the induction and completion of autophagy 
is critical for efficient endosome cargo delivery to amphisomes and lysosomes for 
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degradation which results in increased antigen processing for MHC class II 
presentation to CD4+ cells.  
 
Nonetheless, autophagy status does not seem to play a significant role in facilitating 
antigen processing on MHC class I molecules, as long as autophagosomes are 
present at a reasonable level to facilitate the transport of the cargoes for loading (Li, 
Wang et al. 2008). However, the presence of autophagsomes, as well as the 
completion of a ‘non-metabolic’ autophagic process is critical for proper regulation of 
antigen loading onto MHC class II molecules (Lee, Mattei et al. 2010) (Dorfel, Appel 
et al. 2005) (Blanchet, Moris et al. 2010).  Despite these recent discoveries, there are 
many questions pertaining to autophagy and immunity that have yet to be answered. 
Given that these two pathways are tightly linked, pathogens have also evolved to 
avoid from being targeted, and in some circumstances sabotage autophagy 
components to ‘multiply and prosper’ (Mostowy and Cossart 2012). In this case is 
there any way to induce selective destruction of the hijacked compartments? Aside 
from autophagy, the role of chaperone-mediated autophagy in the regulation of the 
host defence system is slowly being revealed, particularly in the presentation of 
endogenous antigen of the cytoplasm origin (Deretic 2005). It is conceivable that 
more than one form of autophagy operates in innate and adaptive immunity, and the 
dissection of this network is an encouraging step towards understanding the interplay 
of autophagy and immunity. 
 
To summarise this section, autophagy initiation is required for both MHC class I and II 
processing. Weighing the observations between Li et al (2008) and Dorfel (2005), the 
synthesis, but not degradation of autophagosomes, is the determining factor for class 
I, whereas for class II, both synthesis and degradation of autophagosomes are 
crucial. Pathogens have also evolved to evade being targeted, and in some 
circumstances sabotage autophagy components for their own benefit.  
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1.6 Autophagy from molecules to cancer.  
The deregulation of autophagy has been associated with the pathogenesis of many 
diseases. In fact, a plethora of autophagic proteins which are targets for oncogenic 
transformation have been identified (Rosenfeldt and Ryan 2009). As such, the 
modulation of autophagy is perceived to be an alternative therapeutic target for these 
diseases. However, this strategy is very tricky, as autophagy activation can limit or 
exacerbate the amplitude of these diseases, especially cancer. 
 
The pivotal discovery which links autophagy and cancer was initiated by the finding 
that BECN1, the gene which codes for Beclin 1 is mono-allelically deleted in breast 
and ovarian cancer, and that restoration of this gene in multiple human cancer cell 
lines results in autophagy activation and growth inhibition, overall limiting 
tumourigenesis (Liang, Jackson et al. 1999; Koneri, Goi et al. 2007; Kang, Kim et al. 
2009).   Following from this, mutations in the clusters of ATG genes - Atg2B, Atg5, 
Atg9B and Atg12 are associated with the onset of gastric and colorectal cancers 
(Kang, Kim et al. 2009). The involvement of Atg genes in tumourigenesis is confirmed 
by in vivo models of cancer in genetically modified mouse models lacking these 
autophagy regulators. Mice harbouring hemizygous deletion of beclin 1, or lacking the 
Atg4C and bif-1 have an increased predisposition to tumour formation (Qu, Yu et al. 
2003) (Yue, Jin et al. 2003) (Marino, Salvador-Montoliu et al. 2007) (Takahashi et al. 
2007).  However, some autophagy regulators may be redundant with respect to 
tumour suppression in certain tissues. Takamura et al (2011) demonstrated that 
mosaic deletion of Atg5 and liver-specific deletion of Atg7 results only in benign 
lesions, with no obvious effect on tumour formation.   
 
Clearly, autophagy is a double-edged sword in cancer. The overexpression of the 
receptor for advanced glycation end products (RAGE) – also known as MHC class III 
ligand, is prominent in many cancer cell type and tumours, and is associated with 
diminished apoptosis, enhanced autophagy and tumour survival (Kang, Tang et al. 
2010). In fact, the role of autophagy in mediating resistance of cancer cells to 
anticancer therapy has been reviewed by many researchers (Vazquez-Martin, 
Oliveras-Ferraros et al. 2009).  
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Additionally, a variety of genes that are often mutated in cancer have been reported 
to promote and repress autophagy. The classical tumour suppressor p53 induces 
autophagy by upregulating a subset of autophagy promoters such as Sestrin-2 and 
damage-regulated autophagy modulator-1 (DRAM-1) (Maiuri, Malik et al. 2009) 
(Crighton, Wilkinson et al. 2006) and also by inhibiting mTOR (Feng, Zhang et al. 
2005). Another example is the potent oncogene Ras, which induces the expression 
Beclin 1 and Noxa to promote autophagy and cell death (Elgendy, Sheridan et al. 
2011). Ras also represses starvation-induced autophagy through the class I PI3-
kinase signaling pathway (Furuta, Hidaka et al. 2004). 
 
The significance of autophagy in limiting or accelerating cancer progression is 
emerging into the limelight. Some of the well-studied cellular pathways that are 
modulated by autophagy is this context have been studied by many researches, as 
reviewed by Mah and Ryan (2012). Autohagy may potentially act as a tumour 
suppressor during the early stages of cancer, by maintaining the integrity of the 
genome (Karantza-Wadsworth, Patel et al. 2007) and proteome (Mathew, Karp et al. 
2009).  However, autophagy may promote tumour immunity by facilitating tumour 
antigen presentation and mediating the clearance of immune cells. This is suggested 
by the finding that the core autophagy regulators, ATG6 and ATG12 are required for 
the presentation of the tumour antigen gp100 by melanocytes to CD8+ T cells (Li, 
Wang et al. 2008). Furthermore, autophagy has been shown to mediate the release 
of ATP from dying cells and the clearance of cancer cells by immune cells (Michaud, 
Martins et al. 2011). However, since autophagy can modulate cell death in both 
directions, its implication in cancer cell killing can be perceived as having both tumour 
suppressive and promoting effects. Furthermore, autophagy can be exploited by 
transformed cells at later stages to sustain their viability in less-favourable conditions 
and the development of drug resistance (Cuervo 2004) (Kondo, Kanzawa et al. 2005).  
These lines of evidence show that autophagy is a double-edged sword in cancer, as 
illustrated in Fig. 1.6.  Given this, the key to the development of tumour therapies 
targeted at autophagy is encrypted in the identification of novel autophagy modulators 
and subsequently unravelling the effects of autophagy on cellular mechanisms which 
are involved during cancer development, progression or regression.  
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1.7 The tumour suppressor p53  
1.7.1 Introduction to the biology of p53 
The p53 protein is a transcription factor, which is often mutated, in human cancers 
(Dehay and Kennedy 2007; Vousden and Lane 2007). Consistent with this, many 
mouse models lacking the wild-type p53 function succumbed to tumourigenesis 
(Donehower and Lozano 2009). With these observations over the years, p53 
eventually gained its rightful reputation as an important tumour suppressor. The 
regulation and functional roles of p53 have been studies extensively, and are 
reviewed in this section.   
 
p53 is activated upon exposure to various types of stress, and modulates the 
transcription and repression of numerous target genes to bring about various cellular 
responses (Chene 2003). Given that p53 regulates multiple cellular functions, it is of 
critical importance that p53 is maintained at relatively low levels in unstressed cells 
(Kubbutat and Vousden 1998). Several tiers of p53 regulation have been described, 
ranging from transcriptional to translational and protein stability control (Kubbutat and 
Vousden 1998).   
 
One of the well studied mechanism of p53 control is the proteasomal turnover, which 
is mediated by several E3 ubiquitin ligases, as illustrated in Figure 1.7 (Meek 2009) 
(Liu, Urbe et al. 2012). Of these ligases, the murine double minute 2, commonly 
known as MDM2 (termed HDM2 for its human equivalent) is proposed to be the main 
regulator of p53 levels (Meek 2009). Apart from directing p53 for proteasomal 
degradation, MDM2 has been shown to bind to N-terminal end of p53 to inhibit its 
transcriptional activity. (Oliner, Pietenpol et al. 1993) (Momand, Zambetti et al. 1992). 
A negative feedback loop exists between p53 and MDM2, as MDM2 itself is in turn 
activated by p53 (Manfredi 2010). The tight control between p53 and MDM2 is 
reflected in mouse models of Mdm2 deletion, which results in aberrant apoptosis and 
lethality at the blastocyst stage (Jones, Roe et al. 1995). This phenotype can be 
rescued upon p53 deletion (Jones, Roe et al. 1995). MDM2 is frequently 
overexpressed in certain cancers (Momand, Jung et al. 1998), and may potentially 
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reduce the  effectiveness of p53-dependent cancer therapies (Harris 2006). This led 
to the development of a class of small molecules, nultins, which bind to the p53-
binding site in MDM2 (Vassilev 2005). The association of nutlins with MDM2 disrupts 
the interaction between p53 and MDM2, subsequently restoring the activity of p53 
(Vassilev 2005).  
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1.7.2 The many functional roles of p53  
The role of p53 in mediating apoptosis has long been established. p53 transactivates 
many members of the pro-apoptotic family, such as Puma and Noxa (Yee, Wilkinson 
et al. 2009) (O'Prey, Crighton et al. 2010). However, the mechanism to bring about 
cellular demise could be slightly different in different cell types, and may have 
different therapeutic outcomes in cancer (Shibue, Suzuki et al. 2006). Recently, the 
pro-survival transcription factor NFκB, has been shown to be required for efficient 
activation of the p53 target genes, Noxa and p53AIP1, suggesting a complex 
interplay between p53 and pro-survival regulators to potentially invoke effective cell 
death (O'Prey, Crighton et al. 2010). However, not all p53 target genes promote 
apoptosis. The recently identified TP53-induced glycolysis and apoptosis regulator 
(TIGAR) protects cells from genomic instability by inhibiting glycolysis and reducing 
intracellular reactive oxygen species (ROS) (Bensaad, Tsuruta et al. 2006). As a 
result, this protects cells from ROS-induced apoptosis (Bensaad, Tsuruta et al. 2006). 
Decreased TIGAR expression sensitised cells to p53-induced death (Bensaad, 
Tsuruta et al. 2006). Thus, p53 activation can mediate the expression of pro-apoptotic 
and pro-survival genes. Perhaps the activation of pro-survival genes serves to rescue 
or limit the accumulation of cellular stress before cell killing begins, and the decision 
to live or die reflects the flexibility of p53 in the regulation of cellular functions. 
 
p53 has also been shown to regulate autophagy. Various cellular stress stimuli that 
induce p53 activation also induce autophagy. Upon exposure to DNA damaging 
agents, p53 is activated and signals through the AMPK and the TSC1/TSC2 complex 
to inhibit mTOR and subsequently activate autophagy (Feng, Zhang et al. 2005). p53-
induced autophagy can both have pro-survival and pro-death effects. For example, 
p53-driven autophagy via the autophagy modulator DRAM-1, is pro-apoptotic and this 
effect can be rescued by the silencing of DRAM-1 (Crighton, Wilkinson et al. 2006). 
On the other hand, p53-mediated autophagy in c-myc-driven lymphomas increases 
cell survival (Levine and Abrams 2008). p53 has also been demonstrated to 
negatively regulate autophagy. The inhibition or genetic ablation of p53 induces 
autophagy in various human, mouse and nematode cells (Tasdemir, Maiuri et al. 
2008).  Additionally, forced autophagy activation in p53-deficient cancer cells has 
 
 
32 
been shown to sustain cellular viability under hypoxic and nutrient-limiting conditions, 
implying that autophagy activation in the absence of p53 promotes tumourigenesis 
(Tasdemir, Maiuri et al. 2008). This form of autophagy can be inhibited by the 
reinforcement of cytoplasmic or ER-targeted, but not nuclear-targeted p53 (Tasdemir, 
Maiuri et al. 2008). Thus, p53 plays dual roles in the regulation of autophagy, and the 
decision to activate or inhibit autophagy is largely governed by the localisation of p53 
in the cell. 
 
Cellular senescence is a process where cells enter a state of irreversible cell cycle 
arrest, and undergo significant changes in gene expression profile and cellular 
phenotypes (Zilfou and Lowe 2009). p53 has been indirectly implicated in senescence 
(Sugrue, Shin et al. 1997). For instance, near-senescent fibroblasts can prolong their 
proliferative life span when wild-type p53 activity is disrupted by the introduction of 
mutant p53 (Bond, Wyllie et al. 1994). Furthermore, p53 expression and the 
transcription of its target genes that are involved in inhibiting the cell cycle, were 
found to be elevated in fibroblasts which are approaching senescence. (Kulju and 
Lehman 1995) (Bond, Haughton et al. 1996) (Noda, Ning et al. 1994) Recently, it has 
also been found that the reactivation of p53 in p53-deficient human tumours results in 
the onset of rapid senescence (Sugrue, Shin et al. 1997). This finding is reinforced by 
the observation that p53 restoration in p53-knockdown murine liver carcinomas 
causes tumour regression, and that the primary response to this was the acquisition 
of the senescence-associated phenotype characterised by an upregulation of a panel 
of inflammatory cytokines (Xue, Zender et al. 2007). From these lines of evidence, the 
activation of p53 promotes cellular senescence, and subsequently promotes tumour 
regression. 
 
p53 is also involved in regulating the progression of the cell cycle. The cell cycle of 
eukaryotes is comprised four successive phases: M phase/ mitosis (division of the 
nucleus and the cytoplasm); S phase (DNA synthesis), and two gap phases, G1 and 
G2, as illustrated in Fig. 1.8 (Dehay and Kennedy 2007).  
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In response to genotoxic stress, cells which accumulate DNA damage undergo 
mitotic arrest at the cell cycle checkpoints to prevent the transmission of mutations in 
the DNA (Fig. 1.8) (Zilfou and Lowe 2009). p53 has been shown to regulate the 
activation of the G1/S (Deng, Zhang et al. 1995) and G2/M  checkpoints (Hermeking, 
Lengauer et al. 1997) (Zilfou and Lowe 2009). It has also been documented that the 
enhanced activation of p53 can result in cell cycle arrest in the absence of DNA 
damage (Agarwal, Agarwal et al. 1995). Yet another well studied checkpoint is the 
spindle assembly checkpoint (SAC) which occurs in mitosis to constrain the transition 
from metaphase to anaphase until all sister chromatids are properly attached to the 
mitotic spindle and aligned at the metaphase plate (Huang, Chang et al. 2009). 
Although the direct regulation of SAC by p53 has yet to be shown, p53 has been 
shown to regulate BubR1, a key component of the mitotic spindle checkpoint 
machinery (Oikawa, Okuda et al. 2005). In this study, p53-/- cells have reduced levels 
of BubR1, resulting in a compromised spindle checkpoint that allows error-prone 
anaphase progression (Oikawa, Okuda et al. 2005). These lines of evidence reinforce 
the role of p53 as a critical regulator of the cell cycle checkpoints to maintain genome 
integrity.  
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The interplay of p53 in the regulation of the immune response has been established 
in animal models of inflammation and autoimmunity. p53-null mice exhibited an 
exacerbated inflammatory response and tissue destruction in mouse  models of 
collagen-induced arthritis (a model of rheumatoid arthritis) (Yamanishi, Boyle et al. 
2002) and experimental autoimmune encephalomyelitis (EAE) (Okuda, Okuda et al. 
2003). Furthermore, p53 has been indicated to inhibit the transactivation activity of 
NFκB, which promotes the activation of major inflammatory regulators such as IL-6 
(Santhanam, Ray et al. 1991). This implies that p53 negatively regulates the 
production of inflammatory cytokines. Apart from that, p53-/- macrophages which were 
treated with the inflammatory agents, lipopolysacharride (LPS) and interferon 
gamma produced more proinﬂammatory cytokines and exhibited higher levels of 
total and phosphorylated signal transducer and activator of transcription (STAT)-1, a 
transcription factor important for immunity and inflammation compared to wild-type 
macrophages (Zheng, Lamhamedi-Cherradi et al. 2005). This indicates that p53 also 
modulates innate immunity in addition to inflammation and autoimmunity. 
 
Dendritic cells (DCs) that are transduced with wild-type p53 have been demonstrated 
to induce a CD8+ T cell response to mediate the specific killing of tumour cells that 
are overexpressing p53 (Tokunaga, Murakami et al. 2005). The involvement of DCs 
and T cells in this context suggests that p53 is involved in the regulation of the 
adaptive immune response as well. This is consistent with the finding that p53 
induces the transporter associated with antigen processing (TAP) 1 to enhance the 
transport of MHC class I peptides and the activation of the MHC class I pathway. In 
fact, the targeted deletion of p53 in T cells predisposes to spontaneous autoimmunity, 
due to enhanced Th17 T cells responses (Zhang, Zheng et al. 2011). These lines of 
evidence imply that not only does p53 regulates innate and adaptive immunity, but it 
also bridges these two forms of immune responses.  
 
In a nutshell, p53 coordinates a wide range of cellular processes in response to 
various forms of stress signals to maintain cellular integrity. Mutations or loss of p53 
functions could provide many facets for tumourigenesis.  
 
 
36 
1.8 An overview of DRAM 
1.8.1 Functions of DRAM-1 beyond autophagy 
Damage Regulated Autophagy Modulator (DRAM), now known as DRAM-1, is a 
direct p53 target gene and was initially identified by Crighton et. al (2006) in the p53-
null human osteosarcoma cell line, Saos-2. Human DRAM-1 consists of 238 amino 
acids, and domain prediction analysis suggested that it contains an ER targeting 
signal and six hydrophobic transmembrane regions, as illustrated in Fig. 1.9 
(Crighton, Wilkinson et al. 2006). DRAM-1 is found primarily in lysosomes, although 
its presence in other secretory compartments have been documented (Park, Kim et 
al. 2009) (Mah, O'Prey et al. 2012). DRAM-1 is highly conserved across species 
(Crighton, Wilkinson et al. 2006), thus suggesting that it must have a very important 
function since it does not mutate very often.  
 
 
 
 
Figure 1.9: Schematic representation of DRAM-1  
DRAM-1 is a six-transmembrane spanning protein that contains a putative ER-
targeting signal. 
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DRAM-1 modulates autophagy and enhances p53-dependent cell death by mediating 
autophagosome accumulation and cytochrome c release, respectively (Crighton, 
Wilkinson et al. 2006). This suggests that the apoptotic and autophagic functions of 
DRAM act in parallel, and seemingly converge, in a p53-dependent manner. The 
participation of key regulators of cellular viability in the p53 and DRAM-1 dependent 
apoptotic and autophagic pathways are slowly emerging. In line with this, 2-
methoxyestradiol (2-ME) has been demonstrated to induce autophagy and apoptosis 
in Ewings sarcoma cells via the activation of p53 and JNK (Lorin, Pierron et al. 2010). 
In this context, p53 regulates Jun N-terminal kinase (JNK), which in turn modulates 
autophagy through two distinct mechanisms, one of which is by up-regulating DRAM-
1, and DRAM-1 is critical for effective induction of autophagy and apoptosis (Lorin, 
Borges et al. 2009). Additionally, the nuclear factor κB (NFκB) inhibitor, SN50, also 
induces the expression of the pro-apoptotic proteins, p53 and PUMA, as well as 
DRAM-1 in gastric cancer cell lines which exhibit morphological features of autophagy 
and eventually succumb to apoptosis in a p53 dependent manner (Zhu, Xing et al. 
2011). This highlights the mechanism in which NFκB modulates apoptosis and 
autophagy via the p53 - DRAM-1 pathway. However, NFκB has been shown to 
promote both cell death and survival under different cellular conditions (Ryan, Ernst et 
al. 2000) (Griffiths, Grundl et al. 2011). Consistent with this, Wang et al (2009) 
showed that the overstimulation of NMDA receptors in rat striatum can induce NFκB -
dependent expression of p53 and DRAM-1, and proposed that p53 triggers 
autophagy and apoptosis, which eventually contribute to excitotoxic neuronal death 
(Wang, Dong et al. 2009). These lines of evidence imply that DRAM-1 is required for 
effective killing upon treatment with anti-tumoural compounds in many cancer cell 
lines. 
 
Apart from p53, DRAM-1 expression is also induced by p73, a protein that shares 
many functional similarities to p53 (Crighton, O'Prey et al. 2007). Like p53, p73 also 
promotes cell death and autophagy, but both of these cellular events are independent 
of DRAM-1 (Crighton, O'Prey et al. 2007). So far, the significance of p73-induced 
DRAM-1 expression has yet to be elucidated.  
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Another known regulator of DRAM-1 is E2F1, a member of the E2F family that is 
involved in modulating a variety of cellular functions, such as DNA repair, 
differentiation and development. Polager et al (2008) reported that in addition to 
mediating apoptosis, E2F1 also regulates autophagy at the transcriptional level by 
upregulating the expression of four autophagy genes—LC3, ATG1, ATG5 and 
DRAM-1, eluding to the fact that E2F1 modulates autophagy via the DRAM-1 
pathway (Polager, Ofir et al. 2008). 
 
 
Recently, DRAM-1 has been shown to regulate p53 levels (Valbuena, Castro-
Obregon et al. 2011). Upon genotoxic stress, p53 is stabilised via specific 
phosphorylation by VRK-1, and DRAM-1 is required for the lysosomal degradation of 
VRK-1 and the subsequent HDM2-mediated dephosphorylation and destabilisation of 
p53 (Valbuena, Castro-Obregon et al. 2011) This double regulatory loop is proposed 
to be required to modulate the block in cell cycle progression upon DNA damage 
(Valbuena, Castro-Obregon et al. 2011).   
 
Because DRAM-1 regulates apoptosis and autophagy, two critical cellular processes 
that are closely associated to tumourigenesis, DRAM-1 is hypothesised to be a 
tumour suppressor downstream of p53 (Crighton, Wilkinson et al. 2006). Indeed, 
DRAM-1 mRNA level is reduced in a panel of oral tumour cell lines and primary 
squamous tumours (Crighton, Wilkinson et al. 2006). Upon further analysis, it was 
found that the downregulation of DRAM-1 is mediated by the direct hypermethylation 
within the CpG island of the DRAM-1 promoter (Crighton, Wilkinson et al. 2006).  
However, DRAM levels remains unchanged in colorectal cancer (Chang, Tseng et al. 
2011). These lines of evidence imply that the changes in DRAM-1 expression is 
cancer-type specific. 
 
Recent microarray analysis on the breast adenocarcinoma MCF-7 cell line revealed 
that several autophagy-core machinery genes including DRAM, BECN1, 
and UVRAG were upregulated in TNF-resistant cells (Moussay, Kaoma et al. 2011). 
The upregulation of these panels of autophagy regulators is postulated to activate 
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autophagy to sustain viability upon challenge with chemotherapeutic agents, 
eventually leading to drug resistance (Moussay, Kaoma et al. 2011).   
 
In short, these studies suggest that the critical regulators of apoptosis, DNA repair, 
differentiation and development explicitly regulate autophagy and potentially cell cycle 
via the participation of DRAM-1, as illustrated in Fig. 1.10. This suggests that there 
are other functional roles of DRAM-1 beyond those that are discussed in this section, 
and are worth pursuing. DRAM-1 level is also altered in some cancer cells, and is 
suggested to be upregulated in cancer cells that are exposed to chemotherapeutic 
challenge to sustain cellular survival. These findings suggest that the modulation of 
DRAM-1 expression could be important for developing therapeutic strategies.   
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1.8.2 DRAM family proteins 
The evolutionary conservation and divergence of DRAM’s functional roles in human is 
reflected by the identification of four other proteins that show significant homology to 
DRAM-1 which are nominally named as DRAM-2, DRAM-3, DRAM-4, DRAM-5 
(which is comprises of two isoforms, DRAM-5a and DRAM-5b (O'Prey, Skommer et 
al. 2009). However, simpler organisms, such as drosophila, contains only one DRAM 
protein (O'Prey, Skommer et al. 2009). 
 
DRAM-2 colocalises with DRAM-1 and is found primarily in the lysosomes (Park, Kim 
et al. 2009). Although the individual expression of DRAM-1 or DRAM-2 does not 
induce cell death, the co-expression of both homologues significantly induced cell 
death (Park, Kim et al. 2009). Additionally, DRAM-2 also induces autophagy upon 
nutrient starvation, and the silencing of DRAM-2 abolishes this effect (Yoon, Her et al. 
2012). These lines of evidence reveal that DRAM-1 and DRAM-2 share a high degree 
of functional similarity, and both homologues could be responsible for induction of a 
balance between apoptosis and autophagy.  The functions of DRAM-3, -4, and -5 
remain to be elucidated.  
 
Moreover, DRAM-1 encodes not just one mRNA, but a series of splice variants in 
multiple human and mouse cell lines (which will be discussed in Chapter 3). Thus, it is 
tempting to believe that alternative splicing is also present in other DRAM family 
members, thus conferring functional versatility for a strong and powerful response 
upon activation.  
 
The recent discovery and characterisation of DRAM-1 and other DRAM family 
members is certainly an exciting aspect in cancer biology. It remains possible that the 
members of the DRAM family work in synergy to invoke multiple cellular responses, 
mainly apoptosis and autophagy. In light of this, the generation of conditional DRAM 
knockout mice and flies—would indeed be very rewarding and would yield information 
with respect to both the functional and evolutionary nature of DRAM function, which 
could be targeted for the strategic development of cancer therapeutics 
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1.9 Project Aims 
The aims of this project are: 
1. To investigate the role of human DRAM-1 isoforms in vitro with respect to 
autophagy and cell death.  
2. To characterise DRAM-1 conditional knockout mice with respect to: 
a. Ability to survive post birth/ longevity  
b. Spontaneous development of autophagy-related diseases and cancer 
c. Irradiation induced p53-dependent and –independent cell death 
d. p53-induced liver senescence 
e. Irradiation- and inflammation-induced tumourigenesis 
f. Acute colitis (in vivo DSS model) 
3. To determine if the p53 – DRAM-1 signalling pathway regulates adaptive 
immunity 
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Chapter 2: Materials and Methods 
2.1 Materials 
 
The commercial materials used for general cell culture are listed in this section. 
 
Table 2.1: General tissue culture reagents and their suppliers. 
Reagent Supplier 
2-Mercaptoethanol GIBCO 
Agarose Sigma 
Ampicillin Sigma 
Blasticidin Invitrogen 
Bovine Serum Albumin (BSA) Sigma 
CryoTubeTM  vials  Nunc 
Cys/Met free medium  GIBCO 
Dimethylsulphoxide (DMSO) Fisher Scientific 
DNase I Roche 
Doxycycline  Sigma 
Dulbecco's modified Eagle's medium (DMEM)  GIBCO 
Fetal Calf Serum (FCS) PAA 
Flt-3L R&D Systems 
Gentamycin GIBCO 
Hygromycin Roche 
Kanamycin Sigma 
L-Glutamine Invitrogen 
M-CSF Peprotech Ltd 
Opti-MEM® GIBCO 
Penicillin GIBCO 
Polybrene (hexadimethrine bromide)  Sigma 
Puromycin Sigma 
RBC Lysis Buffer Sigma 
RPMI-1640  GIBCO 
Streptomycin GIBCO 
Tet-On® Gene Expression Systems Clontech 
Trypsin GIBCO 
Virkon tablets DuPont 
Xfect polymer and reagent buffer Clontech 
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Table 2.2: Reagents used for molecular, biological, and biochemical analyses. 
Reagent Supplier 
35S Perkin Elmer 
30% (w/v) Acrylamide (bis-acrylamide ratio 
37:5:1) Severn Biotech Ltd  
5U Calf Intestine Alkaline Phosphatase  New England Biolabs (NEB) 
AdEasyTM Viral Titer Kit  Stratagene 
Adeno-XTM Maxi purification kit  Clontech 
Adriamycin Sigma 
Agarose Sigma 
BCA Sigma 
CFSE Molecular Probes 
DCFDA Molecular Probes 
DyNAmo™ Probe 2-Step qRT-PCR Kit Finnzymes 
Enhanced Chemiluminescence Reagent (ECL) Amersham Biosciences 
Enzymes used for restriction digest New England Biolabs (NEB) 
Etoposide Sigma 
Fluorescent Mounting Medium  Dako 
Giemsa Stain Sigma 
Lipopolysaccharide (LPS) Sigma 
Low Fat Milk Powder Marvel 
Nitrocellulose membrane Amersham Biosciences 
Nutlin-3 Sigma 
OVA peptide (257-264) Abgent 
OVA peptide (323-339) Abgent 
Ovalbumin Sigma 
Paraformaldehyde (PFA) 
Electron Microscopy 
Sciences 
Ponceau S Sigma 
ProofStartTM DNA polymerase Qiagen 
Propidium Iodide (PI) Sigma 
Rapid DNA Ligation Kit Roche 
RNase Sigma 
RNeasy® Mini Kit  Qiagen 
Tamoxifen Sigma 
TEMED Sigma 
Trichloroacetic acid (TCA) Fluka 
X-ray film Fuji 
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Table 2.3: Reagents used for in vivo experiments 
Reagent Source 
Puregene DNA extraction Kit Flowgen 
Proteinase K Roche 
Protein Precipitation Solution Flowgen  
GoTaq® Flexi DNA Polymerase Kit Promega 
β-napthoflavone Sigma 
4-Hydroxytamoxifen (4-OHT) (active Z-isomer 
>98%)   Sigma 
Autoclaved Sunfower Oil Sigma 
RNAlater Sigma 
Dextran Sodium Sulfate (DSS) MP Biochemicals 
Azoxymethane (AOM) Sigma 
Poly-L-lysine slides Sigma 
Citrate Buffer for Heat-Induced Epitope 
Retrieval (10X) Thermo Scientific 
Hydrogen Peroxide (30% w/v) Sigma 
X-Gal Gold Biotechnology 
Potassium ferricyanide(III) (K3Fe(CN)6) Sigma 
Potassium hexacyanoferrate(II) Trihydrate, 
(C6FeK4N6*3H2O) Fluka 
Dimethylformamide Sigma 
DAB complex  Thermo Scientific 
Goat Serum DAKO Ltd 
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Table 2.4: Composition of Buffers and Solutions 
Reagent Composition 
2 x Western Sample 
Buffer 
100mM Tris Base, pH 6.8; 2% (w/v) SDS; 5% 
(v/v) ß- mercaptoethanol; 15% (v/v) glycerol; 
bromophenol blue 
20x Potassium cyanide 
(KC) solution  
1 mM Potassium ferricyanide(III) (K3Fe(CN)6); 1 
mM Potassium hexacyanoferrate(II) Trihydrate 
(K4Fe(CN)6 · 3H2O); diluted in PBS 
4 x Western Sample 
Buffer 
60mM Tris-HCl,pH 6.8; 2% (w/v) SDS; 14.4mM 
ß-mercaptoethanol; 20% (v/v) glycerol; 0.1% 
(w/v) bromophenol blue 
5% BSA (in TBS-T) 
5% (w/v) BSA; 0.01% (v/v) Sodium Azide; diluted 
in TBS-T 
HBS  
50mM HEPES, 250mM NaCl, 1.5mM NaHP04 
pH 7.12) 
L-Broth (LB) 
1% (w/v) Bacto-tryptone, 86mM NaCl, 0.5% 
yeast extract 
LB Agar 
1% (w/v) Bacto-tryptone, 86mM NaCl, 0.5% 
yeast extract; 1.5% (w/v) Agar 
Phosphate Buffered 
Saline (PBS) 
170mM NaCl; 3.3mM KCl; 1.8mM Na2HPO4; 
10.6mM KH2PO4 
RIPA lysis buffer 
0.15M NaCl;1% (v/v) NP-40; 0.5% (v/v) Sodium 
deoxycholate (DOC); 0.1% (v/v) SDS; 0.05M Tris 
pH 8.0; 25nM DDT; Protease inhibitors 
(Complete; Roche); 1mM Vanadate 
SDS Running Buffer 
 0.1% (w/v) SDS; 192mM glycine; 25 mM Tris, 
pH 8.3 
Transfer Buffer 
192mM glycine; 25 mM Tris, 20% (v/v) methanol; 
0.01% (v/v) SDS 
Tris-acetate-EDTA (TAE) 
40mM Tris, 0.1% (v/v) glacial acetic acid, 1mM 
EDTA 
Tris-Buffered Saline (TBS) 25mM Tris-HCl, pH 7.4; 137mM NaCl; 5 mM KCl 
Tris-Buffered Saline + 
Tween 20 (TBS-T) 
25mM Tris-HCl, pH 7.4; 137mM NaCl; 5 mM KCl; 
0.1% (v/v) Tween-20 
Tris-EDTA (TE) 10mM Tris-HCl, pH 8.0; 1mM EDTA 
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Table 2.5: Primary and Secondary antibodies used. 
Antibody Source 
Application 
and working 
dilution 
Horseradish peroxide (HRP)-
conjugated secondary antibody  Cell Signaling WB; 1:3000 
Rabbit anti-Actin Sigma WB; 1:5000 
Rabbit anti-LC3B Abcam WB; 1:1000 
Mouse anti-Myc tag (4A6) Milipore 
WB; 1:1000; 
IF:1:200 
Rabbit anti-p42/ERK Cell Signaling WB; 1:3000 
Mouse anti-p53 BD Pharmingen WB, 1:5000 
Anti-mouse CD4-APC BioLegend FC; 1:200 
Anti-mouse CD8-APC BioLegend FC; 1:200 
Anti-mouse CD40-Alexa Fluor®488 BioLegend FC; 1:200 
Anti-mouse CD80-FITC BioLegend FC; 1:200 
Anti-mouse CD86-FITC BioLegend FC; 1:200 
Anti-mouse MHC class I-
PerCP/Cy5.5 BioLegend FC; 1:200 
Anti-mouse MHC class II-PerCP BioLegend FC; 1:500 
Anti-mouse CD11c-PE BioLegend FC; 1:200 
Mouse anti-Cathepsin D Milipore IF; 1:200 
Mouse anti-GM130 BD Transduction IF; 1:500 
Mouse anti-Rab5 BD Transduction IF; 1:100 
Mouse anti-CD63 BD Transduction IF; 1:200 
Rabbit anti-Calnexin BD Transduction IF; 1:200 
Rabbit anti-CoxIV Abcam IF; 1:201 
Mouse anti-Lamp-2 BD Transduction IF; 1:200 
Rabbit-anti TGN 46 Sigma IF; 1:200 
Mouse anti-EEA1 BD Transduction IF; 1:201 
Rabbit anti-GRP78 Bip Abcam IF; 1:200 
Rabbit anti-PMP70 Abcam IF; 1:200 
Anti-rabbit Tom 20 Santa Cruz IF; 1:400 
Rabbit anti-p53 CM-5  Vector Labs IHC; 1:250 
Alexa Fluor 488® anti-mouse IgG Molecular Probes IF; 1:400 
Alexa Fluor 488® anti-rabbit IgG Molecular Probes IF; 1:400 
Alexa Fluor 647® anti-mouse IgG Molecular Probes IF; 1:400 
Alexa Fluor 647® anti-rabbit IgG Molecular Probes IF; 1:400 
Rabit anti-P-Histone H3 Upstate IHC; 1:4000  
Rabbit anti-Caspase 3 (Asp-175)           Cell Signaling IHC; 1:50 
Mouse anti-Brdu BD Biosciences IHC; 1:200 
Rabbit anti-MPO DAKO IHC; 1:350  
Rat anti-F4/80 Abcam IHC; 1:150 
Rabbit anti-p4EBP-1 Cell Signaling IHC; 1:500 
Rabbit anti-pAkt (Ser473)  Cell Signaling IHC; 1:25 
Rabbit anti-phospho-mTOR Cell Signaling IHC; 1:100 
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(Ser2448)  
Rabbit anti-OLFM4 Abcam IHC; 1:200 
Rabbit Secondary antibody 
(Vectastain Elite ABC Rabbit kit) Vector Laboratories IHC; 1:200 
Rabbit secondary antibody solution  DAKO  IHC; Neat 
WB=Western Blot; FC=Flow cytometry; IHC = Immunohistochemistry 
 
 
Table 2.6: List of plasmids or fluorophores used for immunofluorescence studies. 
Reagent Source 
Adenoviral GFP-LC3  Tumor Cell Death Lab (BICR) 
Peroxisome GFP Molecular Probes 
Adenoviral mCherry LC3 Tumor Cell Death Lab (BICR) 
Rab7 plasmid J.Norman (BICR) 
DFCP1 plasmid N. Ktistakis (Babraham) 
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2.2 Methods 
2.2.1 Cell Culture 
2.2.1.1 Origin of cell lines 
All transformed parental human cell lines and Phoenix-Ampho retroviral packaging 
cells were generated at the Beatson Institute for Cancer Research by past and 
current members of the Tumor Cell Death Laboratory. Primary mouse embryonic 
fibroblasts (MEFs), lymphocytes, and bone marrow progenitors were isolated and 
cultured as described below.  
 
2.2.1.2 Isolation of MEFs 
Pregnant females were culled at day 13.5 to 14.5 post coitum by cervical 
dislocation.  The whole carcass was briefly dipped into a solution of distilled water 
containing virkon tablets to kill any bacteria/fungus present on the animal. The 
ventral side of animal was sprayed with 70% (v/v) ethanol and laperotomy 
performed to isolate the uterine horn containing the embryos. Incisions were made 
at the top of uterus where it joins the oviduct and at the cervix where the oviducts 
join. The membranes and blood vessels adjoining the oviduct were cut, while 
taking care not to puncture the oviduct membranes. The oviduct was removed and 
washed three times in PBS supplemented with gentamycin (33µg/ml). The oviduct 
membrane was then cut and the embryos dissected away from the placenta and 
surrounding membranes and placed in PBS/gentamycin. Embryos were 
decapitated and the internal organs teased out with fine forceps. Following three 
washes in PBS/gentamycin, embryos were minced as finely as possible and 
added to 10ml of 0.05% (v/v) trypsin supplemented with 100 µl DNase I and 
incubated for 45 minutes in a 370C water bath with occasional agitation (~ every 
10-15 mins). After 30 minutes of incubation, 500ul 2.5% (v/v) trypsin was added 
and the incubation allowed to proceed for another 15 minutes. DMEM medium 
(40ml) was then added and the tissue suspension from 4-5 embryos was pooled. 
The mixture was filtered through a 70μm cell strainer prior to being centrifuged at 
200 x g for 5 minutes. Cell pellets were re-suspended in 40ml of complete medium 
and the cells plated out into 15cm dish. The media was changed the next day to 
 50 
remove dead cells. MEFs were cultured until confluent and then passaged for use 
in experiments or frozen down and stored in liquid nitrogen. 
2.2.1.3 Isolation of T lymphocytes 
Mice aged 6 weeks or older were culled using schedule 1(CO2 asphyxiation).The 
spleens were removed, meshed with a syringe plunger and flushed through a 
40μm cell strainer with cold culture media. The cellular suspension was 
centrifuged at 200 x g for 5 minutes. The supernatant was aspirated and 4ml of 
red blood cell (RBC) lysis buffer added to the pellet. Following incubation at room 
temperature for 5-10 minutes, 20ml of cold medium was added and the 
suspension centrifuged. The cell pellet was re-suspended in RPMI-1640 
supplemented with 10% (v/v) heat inactivated FBS, 2mM L-glutamine, 50μM 2-
mercaptoethanol, 100μg/ml penicillin, and 100μg/ml streptomycin. The cells were 
plated at a density of 1x106 into 100mm dishes. 
2.2.1.4 Isolation of bone marrow progenitors 
Mice aged 6 weeks or older were culled using schedule 1 (CO2 asphyxiation). The 
femur and tibia were removed and the ends cut off. Bone marrow progenitor cells 
were flushed out with cold RPMI-1640 supplemented with 10% (v/v) heat 
inactivated FBS, 2mM L-glutamine, 100μg/ml penicillin, and 100μg/ml 
streptomycin using a 25G needle attached to a syringe. The resulting cell 
suspension was passed through a 70μm cell strainer and either used immediately 
for analysis (See below) or cultured with different growth factors.  
 
To induce differentiation into dendritic cells, the cell suspension was centrifuged at 
200 x g for 5 minutes, the medium removed and the cell pellet treated with 4ml of 
RBC lysis buffer for 5 minutes. Following the addition of 20ml of cold medium was 
added, cells were pelleted by centrifugation. The cell pellet was re-suspended in 
complete RPMI-1640 supplemented with 100ng/ml Flt-3L and plated at a density 
of1x106 in 100mm dishes. Bone marrow progenitor cells were incubated at 37oC in 
a humidified atmosphere containing 5% CO2 for seven days. 
 
To induce differentiation into macrophages, the bone marrow progenitor cells were 
cultured in RPMI-1640 supplemented with 10ng/ml M-CSF. Macrophages were 
plated at 3x107 in 100mm dishes and cultured at 37oC in a humidified atmosphere 
 51 
containing 5% CO2 for a total of 6 days. Macrophage cultures were rinsed and 
fresh media supplemented with M-CSF was added at day 3-4 in order to remove 
non-adherent cells. Adherent cells remaining at day 6 exhibited a homogeneous 
morphology. 
 
2.2.1.5 Maintenance of cell lines 
All cells were maintained at 37oC in a humidified atmosphere containing 5% CO2. 
Cell culture was performed in either biosafety Class 1 or 2 hoods, under sterile 
conditions.  
 
With the exception of primary lymphocytes and cells originated from the bone 
marrow, all other cell lines were cultured in complete Dulbecco's Modified Eagle's 
medium (DMEM) supplemented with 10% (v/v) fetal calf serum (FCS), 2mM L-
glutamine, 100μg/ml penicillin and 100μg/ml streptomycin.  
 
Cell lines were passaged when they reached approximately 80% confluency. 
Media was removed by aspiration, the monolayer rinsed with PBS, and then 2-4 
ml of 0.25% trypsin/TE added. Following incubation at 37°C for 5 minutes, 
dissociated cells were re-suspended in fresh media and transferred to a clean 
tissue culture flask at an appropriate ratio.  
 
For long-term storage, cells were trypsinised and pelleted by centrifugation at 200 
x g for three minutes. They were then re-suspended in 1ml of 10% (v/v) 
dimethylsulphoxide (DMSO) in FBS, transferred to CryoTubeTM vials, insulated by 
wrapping in cotton wool and slowly frozen at -80°C before storage in liquid 
nitrogen. 
 
To bring up from storage, cells were thawed quickly at 37oC after removal from 
liquid nitrogen, mixed with fresh media and centrifuged at 200 x g for three 
minutes. The supernatant was removed completely and the cell pellets re-
suspended in fresh culture media and plated out into a small tissue culture flask. 
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2.2.2 Molecular cloning 
2.2.2.1 Restriction digest 
Restriction digests were performed using a 5 to 10-fold unit excess of the 
appropriate enzyme with 2-10μg plasmid DNA for 1 hour at the temperature, as 
specified by the manufacturer. For sequential digests DNA was purified using 
Qiagen PCR purification kit following the first restriction digest and then re-
suspended in an appropriate reaction buffer for the second restriction digest. 
Linearized plasmid DNA was treated with 5U Calf Intestine Alkaline Phosphatase 
to remove 5’ phosphate groups, purified using Qiagen PCR purification kit and 
then re-suspended in an appropriate volume of TE. 
 
2.2.2.2  Ligation 
Restriction fragments for ligation were purified by gel electrophoresis followed by 
excision using a Qiagen Gel Band Purification Kit. Ligations were carried out using 
Rapid DNA Ligation Kit. An approximate 2-fold molar excess of the insert fragment 
over the vector fragment was combined in a final volume of 10μl DNA Dilution 
Buffer. 10μl T4 DNA Ligation buffer was then added along with 5U T4 DNA ligase. 
This was incubated at room temperature for 16 hours. 
 
2.2.2.3 Transformation of competent cells 
Super-competent E.Coli DH5α cells were thawed on ice and gently mixed with 10-
20ng of plasmid. The cells were incubated on ice for 30 minutes, heat shocked at 
42ºC for 30 seconds and then transferred to ice for a further 15 minutes. 250μl of 
pre-warmed LB broth was added before incubation for 1 hour on an orbital shaker 
(225-250 rpm). The transformation mix was then plated on LB agar plates 
containing 50μg/ml ampicillin or kanamycin and the plates were incubated at 37ºC 
overnight to allow growth and colony formation of the transformed cells. 
 
2.2.2.4 Screening of transformants 
Colonies obtained from transformation were grown in overnight cultures of LB with 
50μg ampicillin/kanamycin, and plasmid DNA isolated using QIAprep Spin 
Miniprep Kits. Analytical restriction digests were performed and resolved on 
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agarose gels to validate the correct orientation of the inserts. Inserts were always 
sequenced. Sequencing was performed by the Molecular Service unit at the 
Beatson Institute for Cancer Research. 
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2.2.2.5 Preparation of plasmid DNA 
For large-scale plasmid DNA preparation, a single bacterial colony was picked 
from a freshly streaked plate and used to inoculate 4 ml LB medium containing 
50μg/ml ampicillin or kanamycin. This was incubated at 37ºC with vigorous 
shaking for about 16 hours to form a mini culture and was subsequently used to 
inoculate 100 ml LB containing 50μg/ml ampicillin or kanamycin. Following an 
overnight incubation at 37ºC in an orbital shaker (300 rpm), cells were pelleted by 
centrifugation at 3000 x g for 20 minutes at 4ºC and plasmid DNA isolated using 
the Qiagen Plasmid Maxi Kit. Briefly, the bacterial pellet was re-suspended in 10 
ml of Buffer P1 (50mM Tris pH 8.0, 10mM EDTA, 100μg/ml RNase A) and then 
gently but thoroughly mixed with 10ml Buffer P2 (200mM NaOH, 1% SDS) to 
initiate an alkaline lysis reaction. This reaction was allowed to proceed for 5 
minutes at room temperature before the addition of 10 ml chilled buffer P3 (3M 
potassium acetate, pH 5.5) to allow neutralization and the formation of a 
precipitate of dodecyl sulphate. The SDS-denatured proteins and chromosomal 
DNA were co-precipitated with the detergent whilst the plasmid DNA remained in 
solution due to a lack of close protein associations. Precipitation was enhanced by 
20 minute incubation on ice and the precipitate was then pelleted by centrifugation 
at 4000 x g for 30 minutes at 4ºC. The supernatant containing plasmid DNA was 
promptly removed and applied to a QIAGEN-tip 500 pre-equilibrated with 10 ml of 
Buffer QBT (750mM NaCl, 50mM MOPS pH 7.0, 15% Isopropanol, 0.15% TritonX-
100). Gravity flow allowed the supernatant to pass through the anion exchange 
resin that bound the plasmid DNA. The resin was the washed twice with 30 ml of 
buffer QC (1M NaCl, 50 mM MOPS pH 7.0, 15% Isopropanol) and the purified 
plasmid DNA was subsequently eluted with 15 ml Buffer QF (1.25M NaCl, 50mM 
Tris pH 8.5, 15% isopropanol) and precipitated with 10.5 ml (0.7 volume) of room 
temperature isopropanol. The eluent was immediately centrifuged at 4000 x g 
centrifugation at 4ºC for 30 minutes. The plasmid DNA pellet was then washed 
with 70% (v/v) ethanol, dried at room temperature for 5-10 minutes and re-
suspended in an appropriate volume of sterile TE buffer. 
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2.2.2.6  Agarose gel electrophoresis 
Agarose was melted by heating in 1xTAE. Prior to solidification, ethidium bromide 
was added to a final concentration of 0.5μg/ml,. Agarose was allowed to solidify in 
gel trays. Samples for electrophoresis were diluted with 10x gel loading buffer 
(30% (v/v) glycerol, bromophenol blue) and loaded onto the gel alongside a 
suitable DNA ladder. Electrophoresis was carried out at 100V in 1xTAE gel 
running buffer. DNA was visualised using a UV transilluminator. 
 
2.2.3 Genetic Manipulation 
Ectopic over expression of proteins were achieved by calcium phosphate 
transfection, Xfect transfection, adenovirus infection, retrovirus infection or by 
inducing stable Saos-2 cell lines which were generated using the Tet-On® Gene 
Expression Systems with 1μg/ml Doxycycline for protein expression.  
 
Ablation of DRAM-1 isoforms in human cells is achieved by siRNA transfection. 
DRAM-1fl/fl MEFs were infected with an empty retrovirus (pBabe puro) or retrovirus 
vector carrying a Cre-recombinase construct.  
 
2.2.3.1 Calcium phosphate transfection 
1x106 cells were seeded into 10cm dishes one day prior to transfection. 15µg of 
plasmid DNA in 440 µl distilled water was mixed with 500µl HBS (50mM HEPES, 
250mM Nacl, 1.5mM pH 7.12), prior to vigorous mixing with 60 µl 2M CaCl2. 
Reactants were vortexed and incubated at 37oC for 25 minutes to allow for the 
formation of DNA-calcium phosphate precipitate, and then added drop-wise to 
cells. The precipitate was removed after 16 hours by three washes in DMEM 
before 10%DMEM was added.  
 
2.2.3.2 Xfect transfection (Rab-7 and DFCP-1 constructs) 
Saos-2 cells were plated in 35 mm wells 24 hours before transfection at a density 
of 1.5 x 105 cells per well. 5μg of plasmid DNA was added to Xfect reaction buffer 
to a final volume of 100μl. In another tube 1.5μl Xfect polymer was added to 98.5μl 
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Xfect. Both tubes were vortexed briefly. The polymer solution was added to the 
DNA solution and vortexed well at medium speed for 10 sec. Both samples were 
incubated for 10 min at room temperature to allow nanoparticle complexes to form. 
The 200μl of nanoparticle complexes were added drop-wise to the cells, and 
incubated for 4 hours at 37°C. The complexes were removed and replaced with 
fresh medium. After 48 hours, cells were harvested for immunofluorescence 
staining. 
 
2.2.3.3 Adenovirus amplification, purification, titration and 
infection 
The recombinant adenoviruses used in this thesis are replication defective human 
adenovirus serotype 5, and were amplified in HEK-293 cells. 24 hours prior to 
infection, 4x106 HEK-293 cells were seeded in 10cm dishes. Cells were infected 
with the appropriate titre of adenovirus. When the cytopathic effect took place, 
cells were detached, centrifuged at 200 x g for five minutes and the pellet re-
suspended in DMEM without antibiotics. Adenovirus was recovered by performing 
four freeze-thaw cycles in dry ice/ethanol and a 37oC water bath.  
 
Adenovirus was purified using the Adeno-XTM Maxi purification kit according to 
manufacturer’s instruction and a titration performed using the AdEasyTM Viral Titer 
Kit. 
 
To infect target cells, 1x106 cells were plated in either 100mm dishes or 6 well 
plates. Adenovirus was added accordingly to cultures and media is replaced after 
16 hours.   
 
2.2.3.4 Retrovirus infection 
Retroviral infections of mouse embryonic fibroblasts (MEFs) and Saos-2 cells 
carrying an Eco-receptor were performed using retrovirus produced by Phoenix-
Eco retroviral packaging cells. Phoenix-Eco cells were plated at 2x106 cells in a 10 
cm dish. The next day cells were transfected with 15μg retroviral vector DNA for 
16hours as described in section 2.3.1 Three harvests of retrovirus supernatant 
were collected in DMEM containing 20% (v/v) FBS at 12 hour intervals.  
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24 hours prior to infection, MEFs and Saos-2 cells were seeded at 0.8 x106 and 1 
x106 cells per 10cm dish respectively. Retroviral supernatants were passed 
through a 0.45μm filter to remove any contaminating cells, and then added to the 
target cells together with polybrene at a final concentration of 5μg/ml. Three 
rounds of infection were undertaken at 12 hour intervals. Cells were allowed to 
recover for 24 hours in DMEM supplemented with 10% (v/v) FBS prior to selection 
with either 2.5μg/ml puromycin, 100μg/ml hygromycin or 10μg/ml blasticidin.   
 
2.2.4 RNA/cDNA techniques  
2.2.4.1  RNA preparation 
RNA was extracted and purified using the RNeasy® Mini Kit according to 
manufacturer’s instructions. Briefly, media was removed from cells and washed 
once with PBS.  Adherent cells were harvested by scraping in 200μl of RLT buffer 
per well (6-well plate) or 500μl per 10cm plate and transferred to a sterile 
eppendorf tub, whereas non-adherent cells were re-suspended in 200μl of RLT 
buffer after the PBS wash. Both cell and tissue lysates were homogenized by 
repeated passing through a 20G (0.9 mm) needle attached to a sterile plastic 
syringe. 1 volume of 70% (v/v) ethanol was added to the homogenized lysate, and 
mixed well by pipetting.  All the contents in the tube were then transferred to the 
RNeasy spin column placed in a 2 ml collection tube and centrifuged at 8000 x g 
for 15 seconds. After discarding the flow-through, the spin column was 
sequentially washed with 700μl Buffer RW1 followed by 2 washes of 500μl of 
RPE, discarding the flow-through each time. The RNeasy spin column was placed 
in a new 2 ml collection tube and centrifuged at full speed for 1 min to remove 
residual ethanol. RNA was eluted by adding 30–50μl RNase-free water directly to 
the spin column membrane, followed by centrifugation for 1 min at 8000 x ginto a 
new collection tube. The concentration of RNA samples was determined by 
measuring the absorbance at 260 nm using a Biophotometer plus 
spectrophotometer (Eppendorf). The ratio of the absorbance readings at 260 nm 
and 280 nm (A260/A280) gave an indication of the purity of each RNA sample. 
2.2.4.2  Reverse transcription (cDNA synthesis)  
cDNA was synthesised using the DyNAmo SYBR Green 2-step qRT-PCR kit 
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according to manufacturer’s instructions on a Peltier Thermal Cycler (MJ 
Research). Briefly, 1-2µg of RNA was mixed with 20µl of 20x RT buffer (containing 
dNTP mix and 10 mM MgCl2), 2µl of Random Hexamers (300ng/μl) and 4µl M-
MuLV RNase H reverse transcriptase to a final volume of 40 µl. Samples were 
incubated at 25°C for 10 mins to allow primer annealing and extension, then 37°C 
for 30 mins to allow cDNA synthesis. The reaction was terminated by heating at 
85°C for 5 mins and then cooled to 4°C.  
 
2.2.4.3  Quantitative Polymerase Chain Reaction (qPCR) 
Quantitative PCRs were carried out using the DyNAmo SYBR Green 2-step qRT-
PCR kit (Finzymes) according to manufacturer’s instructions in a Peltier Thermal 
Cycler (MJ research, Helena Bioscience). Briefly, 1μl of cDNA (See Section 2.4.2) 
was added to 10μl 2x qPCR master mix (contains modified hot start Tbr DNA 
polymerase, SYBR Green I, optimized PCR Buffer, 5mM MgCl2 and dNTP), 7μl 
H2O and 2μl custom designed primers or validated QuantiTect Primer sets 
(Qiagen) for the gene of interest. Reactions were pipetted into 96 well optical plate 
(BioRad) and sealed using optically clear flat cap strips (BioRad). Reactions were 
carried out in triplicate for each sample. Cycling parameters used were 95°C -15 
mins (initial denaturation); [94°C - 10 s (denaturation); 55°C - 30 s (annealing); 
72°C - 30 s (extension); plate read (data acquisition)] 40 cycles; 72°C - 10 mins 
(final extension); melting curve 70-90°C; Read 0.3°C; hold 1 s; 72°C - 10 mins 
(reannealing); then 15°C hold. Data collection was carried out using a Chromo4 
real-time PCR detector (BioRad) and MJ Opticon Monitor software. Gene 
expression was normalized relative to 18S rRNA levels.  
 
Primers used for qPCR are listed below: 
18s Fwd   : 5’-GTAACCCGTTGAACCCCATT-3’ 
18s Rev   : 5’-CCATCCAATCGGTAGTAGCG-3’ 
Hs DRAM-1 Fwd  : 5’-GTACAGAAGCAAAATCAAACCTGC -3’ 
Hs DRAM-1 Rev  : 5’-TCAAATATCACCATTGATTTCTGTGCA -3’ 
Hs MAP1LC3-B  : Quantitect® Primers (Qiagen; QT01673007) 
Mm DRAM-1 Fwd  : 5’-CAGCCTTCATCATCTCCTACG-3’ 
Mm DRAM-1 Rev  : 5’-ATGCAGAGAAGTTTATCATG-3’ 
Mm DRAM-2   : Quantitect® Primers (Qiagen; QT00158515) 
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Mm DRAM-3 /TMEM150b : Quantitect® Primers (Qiagen; QT01163470) 
Mm DRAM-4 /TMEM150c : Quantitect® Primers (Qiagen; QT00131901) 
Mm DRAM-5 /TMEM150a : Quantitect® Primers (Qiagen; QT00135632) 
 
2.2.4.4 Polymerase Chain Reaction 
Amplifications were undertaken using ProofStartTM DNA polymerase (Qiagen) on a 
PTC-200 PCR machine.Cycling parameters used to amplify human and mouse 
DRAM-1 splice variants were 95°C 4 min (94°C - 30 s; 52°C - 30 s; 72°C -1 min) 
for 35 cycles (DRAM-1) or 20 cycles (18S rRNA); 72°C 10 min; hold 4°C. Gene 
expression was normalized relative to 18S rRNA levels.  
 
Primers were custom designed and synthesized by Dharmacon. A list of primers 
are listed below: 
 
18S Fwd   : 5'-GTAACCCGTTGAACCCCATT-3' 
18S Rev   : 5'-CCATCCAATCGGTAGTAGCG-3’ 
Fwd Hs DRAM-1 exon 1 : 5'-ATGCTGTGCTTCCTGAGGGGAATG-3' 
Rev Hs DRAM-1 exon 7 : 5'-CACAGAAATCAATGGTGATATTTGA-3' 
Fwd Mm DRAM-1 exon 1  : 5'-TTCCTCCTGGTGACTTGGTC-3' 
Rev Mm DRAM-1 exon 7 : 5’ AGT CGT CAT TGA TTT CTG TGG A -3’ 
 
PCR products were resolved on a 3% (w/v) agarose gel and bands visualised 
using a UV transilluminator as described above. 
 
2.2.5 Protein analysis 
2.2.5.1 Protein extraction  
Media was removed from cells and washed once with PBS.  Adherent cells were 
harvested by scraping in 200μl of RIPA buffer per well or 500μl per 100 mm plate 
and transferred to a sterile eppendorf tube, whereas non-adherent cells were re-
suspended in 200μl of RIPA buffer after one PBS wash. Insoluble material was 
pelleted by centrifugation at 14000 x g at 4°C for 15mins and supernatants 
removed to a clean eppendorf tube. Protein lysates were either processed 
immediately or stored at -20°C.  
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2.2.5.2 BCA assay  
Bicinchoninic acid (BCA) solution was mixed with CuSO4 solution in a 50:1 ratio. 
200µl of this mixture was added to 10µl standards (containing 80, 100, 200, 400, 
1000 or 2000μg/ml BSA diluted in distilled water); or 2µl of protein samples diluted 
in 48µl of distilled water, in a 96 well plate. The samples were incubated at 37oC 
for 30-60 minutes. Optical density was read at 562nm and the concentration of 
protein calculated from the BSA standard curve. 
 
2.2.5.3 Separation of proteins by polyacrylamide gel 
electrophoresis (SDS-PAGE)  
Proteins were resolved according to molecular weight by electrophoresis on 
denaturing polyacrylamide gels in Amersham Biosciences SE400 standard format 
vertical unit tanks. Samples were mixed with 2x sample buffer, boiled for 10 
minutes, briefly centrifuged to collect the sample, and then loaded onto a 
polyacrylamide gel. Electrophoresis was carried out in 1x SDS Running buffer 
(See Table 2.4 for composition)at 55V overnight or 200V for three hours until the 
dye front had reached the bottom of the gel. SDS-PAGE gels consisted of a 
separating gel overlaid by a stacking gel. Depending on the molecular weight of 
the protein of interest, the separating gel was between 6% and 15% acrylamide 
(from 30% stock solution (37.5:1 acrylamide:bis acrylamide) and otherwise 
constituted 375mM Tris-HCl, pH8.8, 0.1% SDS, polymerised with 0.05% 
ammonium persulphate, 0.1% TEMED. Stacking gel was 4% acrylamide and 
otherwise constituted 125mM Tris-HCl, pH 6.8, 0.1% SDS, polymerized with 
0.05% ammonium persulphate, 0.1% TEMED. 
 
2.2.5.4 Western Blotting 
Proteins resolved by SDS-PAGE were transferred to nitrocellulose membrane in 
1x Transfer Buffer (See Table 2.4 for composition) at 0.5A for 4 hours using 
Hoefer TE 42 Protein Transfer apparatus. Following transfer, the membrane was 
stained with Ponceau S to check for loading and the fidelity of transfer. 
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2.2.5.5 Probing 
Following transfer, the membrane was blocked in TBS-T containing 5% (w/v) dried 
skimmed milk for 1 hour at room temperature. Membranes were incubated with 
primary antibodies (typically a 1:1000 dilution in 5% (w/v) BSA in TBS-T) for 2 hour 
at room temperature or overnight at 4°C. Excess primary antibody was removed 
from the membrane by washing 3 times in TBS-T for 10 minutes before incubating 
for 1 hour at room temperature with the appropriate horseradish peroxidase-
conjugated secondary antibody at a dilution of 1:3000. To ensure the removal of 
excess secondary antibody, the membrane was washed 3 times for 30 minutes in 
TBS-T. Proteins bound to the membrane were visualized by chemiluminescence 
using ECL Western Blotting Substrate and autoradiography. 
 
2.2.6 Cell death assays 
2.2.6.1 Clonogenic assay 
Saos-2 cells were plated on 10cm dishes and transfected the following day with 
10μg of either: DRAM-1 SV1, SV4 or SV5, p53 (positive control) or an empty 
plasmid pcDNA3-Myc/His (Invitrogen) (negative control), as described in section 
4.2.1. Two days after transfection, cells were detached and counted. 
Approximately 0.6 x106 cells were cultured in 15cm dishes with 600μg/ml G418 to 
select for transformed cells. Cells were cultured for two weeks, and fresh medium 
containing the selection antibiotic replenished every three days. On the day of 
harvest, the medium was removed, and the cells were washed with PBS prior to 
staining with 8 ml of Giemsa for 10 minutes at room temperature. Plates were then 
washed with 10% (v/v) methanol (diluted in distilled water) and left to dry 
overnight, prior to analysis.  
 
2.2.6.2 Sub-G1 content  
After treatment for the indicated times the total populations of cells (both floating 
and adherent cells) were processed for flow cytometric analysis (FACScan, 
Becton Dickinson). Adherent cells grown in 6-well plates were harvested by 
collection of media in 15ml falcon tube. The cells were then washed in 0.5 ml PBS 
that was also collected into the 15 ml falcon tube and 0.5ml of TE plus 0.25% (v/v) 
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trypsin was added to remove adherent cells, and subsequently transferred to the 
falcon tube. The samples were then centrifuged for 5 minutes at 1000 x g and the 
supernatants removed. Cells were re-suspended in 500μl PBS and then 5 ml ice-
cold methanol added slowly while vortexing to avoid clumping. Cells were 
incubated at 4°C for a minimum of 3 hours. Directly before FACS analysis the cells 
were collected by centrifugation and re-suspended in 400μl PBS, 20μl of 1mg/ml 
Propidium Iodide (PI) and 0.2μl RNaseA (100 mg/ml) and incubated for 30 
minutes at room temperature then sorted for and analysed for DNA content using 
a FACSCalibur flow cytometer (Becton Dickinson) and CellQuest software. The 
percentage of cells with sub-G1 DNA content was taken as a measure of the 
number of apoptotic cells in the total cell population. 
 
2.2.6.3 PI exclusion assay  
To assay for apoptosis, floating and adherent cells harvested from 6-well plates 
were collected as described in 2.6.2 and centrifuged at 200 x g after the 
treatments and times indicated. The pellet was immediately stained with 5μg/ml PI 
in 200μl of media for 5 minutes, in the dark at room temperature. The cells were 
then analysed using a FACSCalibur flow cytometer (Becton Dickinson) and 
CellQuest software. .  
 
2.2.7 Autophagy assays 
2.2.7.1 Autophagosome formation (LC3 punctation) 
Cells infected with DRAM-1 isoforms or ‘empty virus’ as control, and GFP-LC3 
adenovirus (Bampton, Goemans et al. 2005). After 48 hours cells were fixed in 4% 
(v/v) PFA and imaged on Zeiss Axioplan 2 / ISIS. Cell images were analyzed 
visually and cells with 8 or more GFP-LC3 puncta were scored as positive for cells 
with accumulated autophagosomes. At least 200 cells were analyzed for each 
condition.  
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2.2.7.2 LC3 immunoblotting 
LC3-I to LC3-II conversion was measured by western blotting following infection 
with either adenoviruses expressing DRAM-1 isoforms or control ‘empty’ 
adenovirus that contains no transgene. LC3 levels were analysed as described in 
section 4.5 and probed with antibodies against LC3B. 
 
2.2.7.3 Long-lived protein degradation 
Saos-2 cells and MEFs were plated at a density of 0.2 x 106 and 0.1 x 106 per 
60mm dishes (6-well plate), respectively. The next day, the medium was removed 
and cells were labeled 5μCi L-[35S] cysteine/methionine in met/cys free medium 
(Invitrogen) supplemented with 10% (v/v) FCS, 2mM glutamine, 100μg/ml 
penicillin and 100μg/ml streptomycin for 8 hours. Cells were then washed 3 times 
with PBS and incubated overnight in met/cys free medium supplemented with 
2mM cold cys/met, 10%FCS, 2mM glutamine, 100μg/ml penicillin and 100μg/ml 
streptomycin at 37oC. Following the appropriate treatment, 200ul aliquots of media 
were removed, trichloroacetic acid (TCA) added to give a final concentration of 
10% and incubated at 4oC overnight. Meanwhile, the cells were fixed by adding 
1ml 10% (v/v) TCA for 15minutes. The cells were then washed with 10% (v/v) TCA 
and then dissolved with 200μl 0.2M NaOH per well while shaking at 4oC overnight. 
The next day, the medium was centrifuged at 12000 x g for 10 mins. The pellet 
was discarded and the supernatant added to 3ml scintillation fluid to determine the 
amount of acid-soluble radioactivity. Similarly, 3ml of scintillation fluid was also 
added to the cells to determine the amount of acid-precipitable radioactivity. The 
rate of protein degradation was determined as follows: 
 
% protein degradation =   acid-soluble radioactivity in culture medium 
      (acid-soluble + acid-precipitable radioactivities) 
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2.2.7.3 RFP-GFP LC3 assays 
Tet-On DRAM-1 Saos-2 cells were retro-infected with pBabe puro mRFP-GFP 
LC3 construct as described in section 2.3.4. The cells were then treated with 
1μg/ml Doxycycline to induce expression of full length DRAM-1 protein, and/or 
infected with adenoviruses expressing DRAM-1 isoforms 4 and 5, or an empty 
vector. Cells were harvested for immunoflourescence staining as described in 
section 2.7.5.1. 
 
2.2.7.4 Reactive Oxygen Species (ROS) production assay  
Saos-2 cells and MEFs were plated at a density of 0.2 x 106 and 0.1 x 106 per 
60mm dishes (6-well plate), respectively. The next day, cells were treated as 
indicated. At the end point of the experiment, the medium was removed and the 
cells were washed 3 times with PBS. Cells were stained with 5μM DCFDA in 
phenol-red free OPTIMEM supplemented with 10% (v/v) FCS for 20minutes, at 
37oC in the dark.  Cells were washed 3 times with PBS, detached with trypsin as 
described in section 2.1.5, and re-suspended in phenol-red free OPTIMEM 
supplemented with 10% (v/v) FCS. Samples were kept on ice, while being 
analysed by flow cytometry. 
 
2.2.7.5  Immunofluorescence 
Cells seeded on 16mm and 19mm coverslips were washed with PBS, fixed in 4% 
(v/v) Paraformaldehyde/PBS for 20 minutes and washed 3 times in PBS. Cells 
were then permeabilised with 0.3% (v/v) Triton-X-100 in PBS for 10 minutes. 
Following 3 more washes in PBS, non-specific binding sites were blocked with a 
solution containing 0.3% (w/v) Avid BSA, 10% (v/v) FCS, 5% (w/v) Milk, 0.3% (v/v) 
Triton-X-100 in PBS for 30 minutes. Primary antibodies diluted in blocking solution 
(without milk) were applied for 1 hour in 37oC. Coverslips were washed 3 times 
with 0.1% (v/v) Triton in PBS, stained with the secondary antibody diluted in 
blocking solution (without milk) for 30 minutes in 37oC. Following 3 washes with 
PBS, coverslips were incubated with 4% (v/v) paraformaldehyde/PBS at room 
temperature for 15 minutes, washed with PBS plus a final wash in water, then 
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mounted in 8μl of Fluorescent Mounting Medium. The antibodies used for 
immunofluorescence are listed in table 2.7. 
 
Table 2.7: Markers used for validation of DRAM-1 localisation in cellular 
organelles. 
Organelle Marker 1 Marker 2 
Lysosome Lamp-2 Cathepsin D 
Golgi apparatus TGN GM130 
Early Endosomes EEA1 Rab5 
Late Endosomes Rab7 CD63 
Autophagosome mCherry LC3 DFCP1 
Endoplasmic 
reticulum Bip Calnexin 
Peroxisome PMP70 Peroxisome GFP 
Mitocondria Tom 20 CoxiV 
 
 
Cells were imaged on Zeiss Axioplan 2/ISIS for autophagosome formation and 
Leica Confocal 2 for DRAM-1 isoform co-localisation studies. Images were 
processed using Leica and Image J software.  
 
2.2.8 T cell activation assay 
2.2.8.1 Upregulation of T cell activation signals on APCs upon 
stimulation 
Differentiated bone marrow dendritic cells from section 2.1.4 were plated in ‘U 
bottom’ 96 well plates (Nunc) at a density of 1x106 cells/ml and incubated with 
1µg/ml LPS for 16 hours. Cells were centrifuged at 200 x g and the media 
removed. Pellets were re-suspended in the appropriate antibodies listed in Table 
2.5 in complete RPMI-1640, and incubated for 20 minutes on ice, in the dark. Cells 
were washed twice by repeated centrifugation at 200 x g and re-suspended in 
200µl of complete RPMI-1640. Samples were kept on ice and surface marker 
expression levels were analysed by flow cytometry immediately. 
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2.2.8.2 Pulsing of APCs with antigen/ antigenic peptide  
The antigen presenting cells (APCs) used to stimulate T cells were dendritic cells 
and macrophages (isolated and cultured as described in section 2.1.4.).Dendritic 
cells and macrophages were plated in ‘U bottom’ 96 well plates (Nunc) at a density 
of 1x106 cells/ml and incubated with 10µM of Nutlin for 16 hours.  The cells were 
centrifuged at 200 x g, and the medium removed. The cells were then pulsed with 
the T cell specific peptide, ovalbumin (OVA) for four hours at 37°C.  In addition, 
dendritic cells were also incubated with MHC class I processed OVA peptides 257-
264, or MHC class II processed OVA peptides 323 -329 under identical conditions. 
At the end-point of the incubation period, the cells were centrifuged and the 
medium removed as before, prior to the addition of CFSE-labeled CD8+ or CD4+ 
T cells from transgenic OT-1 or OT-2 mice respectively. These transgenic mice 
were obtained from Dr. Simon Milling (Institute of Infection, Immunity and 
Inflammation, University of Glasgow).  
 
2.2.8.3 T cell proliferation assay 
T cells were isolated as described in section 2.1.3 and used immediately. To track 
T cell proliferation, T cells were stained with 50μM CFSE for 5 minutes at 37°C. 
The cells were washed twice with PBS, and re-suspended at 1x106 cells/ml in 
complete RPMI-1640. These cells were then mixed with dendritic cells at a ratio of 
10:1 (T cells: dendritic cells), or macrophages at a ratio of 2:1 (T 
cells:macrophages). The T cell/dendritic cell and T cell/macrophage co-culture 
was incubated at 37°C for three and four days respectively to allow for T cell 
activation and proliferation. At the end point of the experiment, the medium was 
removed as before, and the cell pellet stained with anti-CD8 (APC) or anti-CD4 
(APC) antibodies diluted in complete RPMI-1640 to identify T cells subsets. Cells 
were immediately analysed by flow cytometry. T cell activation is associated with 
proliferation, which was monitored by CFSE intensity.  
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2.3 Characterisation of DRAM-1 conditional knockout mice 
All Experiments were performed under the UK Home Office guidelines (project 
license 60/4183 and personal license 12265). All mice were of the mixed 
background and maintained under non-barrier conditions and given a standard 
diet (Harlan) and water ad libitum. At least 3 mice of each genotype were used for 
each experimental cohort. The alleles used in this thesis were Cre, AhCre, CAGG-
Cre ER, DRAM-1+, DRAM-1-, DRAM fl and Mdm2 f/fl. 
 
2.3.1 Generation of DRAM-1 fl/+ mice 
DRAM-1 fl/+ mice (mixed background - 50% 129S6 and 50% C57BL/6J) were 
generated by Model Animal Research Centre, Nanjing University. Briefly, exon 2 
was replaced with the DRAM-1 Flox targeting vector (Fig. 2.1). Upon 
recombination mediated by Cre recombinase, exon 2 of the DRAM-1 is excised, 
leading to frame shift in the exons behind exon 2 and subsequently the production 
of a truncated, non-functional DRAM-1 protein, as illustrated in Fig. 2.2. The 
DRAM-1 Flox targeting vector was transfected into 129S6/SvEvTac-derived W4 
embryonic stem (ES) cells. Clones expressing this targeting vector were 
microinjected into C57BL/6 pseudo-pregnant females to generate chimeras. The 
chimeras born were crossed with C57BL/6 mice to obtain heterozygotes.  
 
2.3.2 Generation of DRAM-1-/-  null mice 
DRAM-1 fl/+ heterozygotes were back-crossed with each other to obtain DRAM-
1 fl/fl  homozygotes. DRAM-1 fl/fl homozygotes were then bred with a Cre Deleter, 
which harbours the Cre+ allele(s) from a C57BL/6 background (developed by 
Artemis Pharmaceuticals/Taconic). Offspring which are heterozygous for DRAM-1-
/+ were back-crossed to each other to obtain DRAM-1-null mice, as well as the 
wild-type and heterozygous littermate controls.  
 
 68 
 69 
 
 70 
2.3.3 Genotyping of mice 
The initial results to confirm the presence of DRAM-1+, DRAM-1fl and DRAM-1- 
alleles were validated by in-house genomic Polymerase Chain Reaction (PCR) 
(2.3.6) from DNA extracted from tails (2.3.5). Subsequent genotyping were 
conducted by Transnetyx, Inc (Cordova, TN). 
 
2.3.4 DNA extraction from tails 
DNA was extracted from mice tails using the Puregene DNA Extraction kit. Tails 
were lysed in eppendorf tubes with 500μl of cell lysis solution (Flowgen) and 10μl 
of proteinase K (from 20mg/ml stock), and incubated at 37ºC in shaking incubator 
(70rpm) for 16 hours. Tails were left to cool at room temperature prior to the 
addition of 200μl of protein precipitation solution (Flowgen) to each tube. Tubes 
were vortexed and centrifuged at maximum speed for 5 minutes in a microfuge. 
The supernatant was removed into a clean tube containing 500μl of isopropanol, 
vortexed and centrifuged at maximum speed for 5 minutes. The supernatant was 
carefully removed and the DNA pellet was left to dry overnight. DNA was re-
suspended in 250µl of nuclease free water. 
 
 2.3.5 PCR conditions for DRAM-1+  DRAM-1+, DRAMfl and DRAM – 
alleles 
All PCR reactions were carried out in 50μl volumes with 3.5μl of the genomic DNA 
preparation using the GoTaq® Flexi DNA Polymerase Kit (Promega). The amount 
of reagents used per sample is as follows: 
Reagent Volume 
Nuclease free water 30.5μl 
5x Colourless GoTaq Flexi Buffer 10μl 
MgCl2 (25μM) 5μl 
dNTP (10mM) 2μl 
GoTaq® Flexi DNA Polymerase (5U/μl) 0.5μl 
F Primer (5’) (100μM) 1μl 
R Primer -1 (3’) (100μM) 0.5μl 
R Primer -2 (3’) (100μM) 0.5μl 
 
Add 1μl genomic DNA.  
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Primers: 
F Primer (5’)   : 5’ GTT GAG CCC AGC TAT GAA GG 3’ 
R Primer -1 (3’)  : 5’ TGCATCCAGTCAACTGCTTC 3’ 
R Primer -2 (3’)  : 5’ GAA GTG CTT CCT GGA CAA GC 3’ 
 
PCR Program:  
95°C- 3min (95°C - 30s; 55°C - 30s; 72°C -1min) 36 cycles, then 72°C - 5min, then 
4°C - hold. 
 
PCR products were resolved on a 3% agarose gel. The size of the bands 
corresponding to DRAM-1+, DRAM-1+, DRAM fl and DRAM – alleles are depicted 
in Fig. 2.3.  
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2.3.6 Long term aging cohort 
To assess the role of DRAM-1 in regulating development and life-span, wild-type, 
heterozygotes and DRAM-1-null mice were aged for up to 650days. Mice were 
checked routinely to observe for phenotypic differences and disease development. 
Whole body autopsy was performed on mice that reached the end point of the 
experiment. The dissection and analysis of the animals in this cohort were 
performed hand in hand with Dr. Ayala King (Pathologist, The Beatson Institute for 
Cancer Research).  
 
2.3.7 Blood profiling/ Haematology smear test 
Blood profiling was performed by the Veterinary Diagnostic Services, Glasgow 
University. Mice were culled with rising concentrations of carbon dioxide (CO2). 
Peripheral blood was isolated from the vena cavae into plastic whole blood tube 
spray coated with K2EDTA. Blood samples incubated on ice were sent 
immediately to the clinical pathology laboratory for processing. The parameters 
assessed are summarised in Table 2.8. 
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Table 2.8: Parameters that were assessed in the haematology smear test of wild 
type and DRAM-1 null mice at the age of 3 months.  
 
Parameters Indication 
Red Blood Cell (RBC) Number of red blood cells per volume of blood. 
Hematocrit (Hct) Percentage of red blood cells in a given volume of whole 
blood. 
Haemoglobin (Hb) Amount of oxygen-carrying protein in the blood. 
Mean corpuscular 
volume (MCV) 
Average size of RBCs. 
Mean corpuscular 
hemoglobin (MCH)  
Average amount of oxygen-carrying hemoglobin inside a 
red blood cell. 
Mean corpuscular 
hemoglobin 
concentration (MCHC) 
Average concentration of hemoglobin inside a red cell. 
Red cell distribution 
width (RDW) 
Calculation of the variation in the size of your RBCs. 
White Blood Cell (WBC) Number of white blood cells per volume of blood. 
WBC differential count Number of different types of white blood cells 
(Neutrophils lymphocytes, monocytes, eosinophils, 
basophils) per volume of blood.  
Platelet count Number of platelets in a given volume of blood 
Mean platelet volume 
(MPV) 
Average size of circulating platelets (Platelet size 
corresponds to platelet production in the bone marrow 
as newly-formed platelets are larger). 
Plateletcrit (PCT) Total circulating platelet mass. 
Platelet component 
composition distribution 
width (PDW) 
Variability in platelet density (The value decreases with 
platelet activation). 
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2.3.8 Radiation-induced lymphomagenesis 
To investigate whether DRAM-1 deletion could accelerate the development of 
radiation-induced tumourigenesis wild-type, heterozygous and DRAM-1 null mice 
were treated with 4 Gy and aged for up to 650 days. Mice were checked routinely 
to observe for phenotypic differences and disease development. Whole body 
autopsy was performed on mice, which reached the end point of the experiment.  
 
2.3.9 p53-dependent cell death in the small intestine  
2.3.9.1 Irradiation 
To investigate if DRAM-1 deletion affects the DNA damage response to ionizing 
radiation, wild-type and DRAM-1 knock-out mice were irradiated with 14 Gy 
irradiation using a Cs137 source delivered at a dose rate of 0.423 Gy/min. Mice 
were harvested at 6, 24, 48 and 72 hour time points following irradiation. At least 5 
mice were used for each time point.  
 
2.3.9.2 Inducible activation of p53 in the gastrointestinal tract and 
liver 
For Cre induction, AhCre+ DRAM-1+/+ Mdm2fl/fl and AhCre+ DRAM-
1fl/fl Mdm2fl/fl were given 3 intraperitoneal (i.p.) injections of 80mg/kg β-
naphthoflavone in a single day, yielding almost 100% constitutive recombination in 
the crypts of the small intestine, including the stem cells (Muncan et al., 2006b). 
To induce recombination in the liver, mice were given one i.p. injection of 80mg/kg 
β-naphthoflavone in one single day and monitored for between two and six days. 
 
2.3.9.3  Tamoxifen preparation for intraperitoneal injection 
To facilitate its formulation in sunflower oil, 5mg of 4-hydroxytamoxifen (4-OHT) 
(>98% active Z-isomer) was first dissolved in 500μL of absolute ethanol. This was 
then further diluted further with 4500μL of sunflower oil.  
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2.3.10 Acute colitis and inflammation-driven tumourigenesis 
 
Mice were provided ad libitum with 2% (w/v) DSS (MP Biomedicals) for 5 days, 
after which drinking water was given. The subjects were monitored daily for 
changes in weight and clinical symptoms of disease were scored as previously 
described (Bordon, Hansell et al. 2009). The colons of the subjects were 
harvested at day 2, 5 and 7 post treatment.    
 
To induce colitis-associated cancer, mice were subjected to a single i.p. injection 
of Azoxymethane (AOM) (12.5mg/kg body weight).  Three days later, mice were 
subjected to three cycles of 2% Dextran Sodium Sulfate (DSS) for 5 days, and 
normal drinking water for 16 days. Animals were sacrificed at 70 days post AOM 
treatment and the colon harvested. The schematic diagrams that illustrate the 
mode of treatment used are shown in Fig. 2.4.   
 
 77 
 
 78 
2.3.11 Tissue isolation 
All organs and tumours isolated (See sections 2.3.6 and 2.3.8) were fixed in 10% 
(v/v) formalin for 16 hours. Small intestine and colon were flushed with water and 
rolled into ‘swiss rolls’ prior to further sectioning and fixation.  
 
For experiment in chapter 2.3.9.1, the proximal length of the small intestine was 
cut into 10 '1cm' sections, stacked and secured with surgical tape. This 'gut parcel' 
was then fixed overnight in 10% (v/v) formalin. 
For experiments in section 2.3.9.2, the small intestine was were dissected as 
follows:  
• The proximal 5cm was mounted ‘en face’ and fixed overnight in methacarn 
(methanol, chloroform and acetic acid; 4:2:1).  
• The following 3cm was divided into 1cm lengths, bundled using surgical tape 
and then fixed in 10% (v/v) formalin. 
• The next 1cm was stored in RNAlater (Sigma) for subsequent RNA 
extraction.  
• The remaining section was fixed in methacarn overnight. 
 
Additionally, the liver was isolated as follows:  
• 3 pieces of 2mm x 2mm and stored in RNA later. 
• For SA-β-gal (or senescence associated beta-gal), 1cm x 1cm of the liver 
was placed onto a cork disk and covered in the embedding medium-OCT 
before being placed in dry ice. 
• The remainder was fixed in 10% (v/v) formalin for 16 hours. 
 
For experiment in section 2.8.10, the colon was flushed with water and fixed in 
methacarn for 16hours. For acute colitis, the colon was also fixed in 10% formalin 
for 16 hours. The colon was then wound into ‘swiss rolls’ and transferred to 10% 
(v/v) formalin and subsequently stored in 70% (v/v) ethanol. 
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2.3.12 Immunohistochemistry (IHC) 
Immunohistochemical stainings of formalin-fixed, paraffin embedded tissue for 
hematoxylin & eosin (H&E), BrdU, Caspase 3, myeloperoxidase (MPO), p53 and 
F480 were performed by Colin Nixon of Histology Services (Beatson Institute).  
 
IHC staining for mTOR activity and the stem cell marker OFLM-4 was performed 
as follows. In brief, formalin-fixed paraffin embedded tissue sections (10μm) on 
Poly-L-lysine slides were de-waxed in xylene for 20 minutes and then rehydrated 
through graded ethanol solutions (100% alcohol for 10 minutes, 70 % (v/v) ethanol 
for 5minutes) and finally into water. Antigen retrieval was performed in 1x Citrate 
buffer diluted in dH2O in 95oC for 30 minutes. 
Endogenous peroxidase was blocked using 3% (v/v) H2O2 (Sigma) in water for 10 
minutes at room temperature. Sections were washed for 5 minutes in TBS-T and 
blocked for 30 minutes with 5% (v/v) normal goat serum (NGS) in TBS-T for 30 
minutes at room temperature (45 minutes for anti-mTOR Ser2448).  Sections were 
incubated with the following primary antibody solutions at 4°C for 16 hours.  
 
• p4E-BP1; 1:500 in 5% (v/v) NGS in TBS-T 
• pAktSer473; 1:25 in 5% (v/v) NGS in TBS-T 
• mTOR Ser2448 ; 1:100 in 10% NGS in TBS-T 
 
Following a 10 minute wash in TBS-T, sections were incubated with secondary 
antibody with biotinylated secondary antibody (Rabbit ABC kit, Vector 
Laboratories) for 30 mins at room temperature. Sections were then washed for 10 
minutes in TBST and incubated with pre-mixed ABC complex (Vectastain Elite 
ABC Rabbit kit; Vector Laboratories) for 30 mins at room temperature. Staining 
was visualised by incubation with DAB complex for 5-15 minutes at room 
temperature.  After reaction termination by immersion in distilled water, sections 
counterstained with hematoxylin. Sections were dehydrated by washing in 
increasing concentrations of alcohol (70% (v/v) ethanol for 5 minutes, 100% 
ethanol for 10 minutes), treated with xylene for 15 minutes and then mounted 
using DPX mounting medium.  
 
 80 
IHC staining for the stem cell marker OFLM-4 was performed as in 2.3.12 with the 
following exceptions. Sections were incubated with the primary antibody to OFLM-
4 at 1:200 in 5% (v/v) normal goat serum in PBS for 16 hours at 4°C. Incubation 
with the secondary rabbit antibody solution (DAKO)  was for 1 hour.  
 
2.3.13 Assaying live crypts, apoptosis and regeneration in vivo 
Intestinal crypts containing at least 5 consecutive epithelial cells were considered 
to be live crypts and used as an indicator of crypt survival or regeneration, 
depending on the experimental time point.   
 
Colonic crypts were identified as straight and narrow crypts that are aligned 
parallel to the crypt bases. The number of polyps (small benign growths protruding 
from the colon or rectum) were scored along the whole length of the colon and 
confirmed by H&E staining.  
  
To quantify for apoptosis, caspase-3 IHC was performed. The number of caspase-
3 positive cells in 25 full crypts was noted and compared within each genotype. 
Additionally, H&E stained sections were analysed under the microscope for cell 
shrinkage, chromatin condensation, formation of apoptotic bodies, appearance of 
red ‘halo’ around the dying cells, and nuclei demonstrating increased ‘red’ staining 
(Kerr et al., 1972, Wyllie et al., 1980). Proliferation and mitotic division was 
determined by performing IHC staining for BrdU (to identify cells in the S-phase of 
the cell cycle) and phospho-histone H3 respectively. For BrdU assay, mice were 
injected intraperitoneally with 2.5mg BrdU. For quantification of mitosis in the small 
intestine, the number of Ki67 or BrdU positive cells in 25 full crypts was noted and 
compared within each genotype.  
 
2.3.14 SA-β-gal (senescence associated beta-gal) staining 
Frozen liver sections (10μm thick) on poly-L-lysine slides were fixed for 15 minutes 
in a solution of 2% (v/v) paraformaldehyde/ 0.25% (w/v) glutaraldehyde diluted in 
PBS. Sections were washed 3 times with 1mM MgCl2 diluted in PBS (pH5.5) and 
then stained with a solution of 1mM MgCl2/PBS (pH5.5) containing 1x potassium 
cyanide (KC) solution and 20mg/ml X-Gal solution in a wet chamber at 37oC for 16 
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hours. Following three washes in PBS sections were mounted with DPX mounting 
medium.  
 
2.3.15 Statistics 
Statistical analysis for the qPCR data shown in Fig. 4.4 and Fig. 4.26 was 
generated using the Relative Expression Software Tool (REST) 2009 
(http://www.genequantification.com/).  All other statistical analyses were performed 
using SPSS software. Statistical analyses for results in chapter 3 were undertaken 
via a univariate general linear model followed by correction using Tukey HSD, 
except where indicated. Statistical analyses for results in chapter 4 and 5 were 
undertaken via Mann Whitney U test.  
 
Graphs (with the exception of Fig. 4.4 and Fig. 4.26 which was generated using 
Prism 5 software) were generated using Microsoft Excel. The error bars were 
calculated and represented in terms of mean ± SD. The boxplots for Chapter 5 
were generated using SPSS.  
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Chapter 3: Characterisation of DRAM-1 isoforms 
 
3.1 Introduction  
The proteome of humans and higher eukaryotes is greatly expanded from the 
genome by various post -transcriptional and -translational modification events. Of 
these events, alternative splicing of nascent mRNA, in which exons in a common 
transcript are ligated in various combinations to generate distinct splice variants, 
has been regarded as the primary contributor for this diversification of the human 
genome (Shankarling and Lynch 2010) (Wang, Sandberg et al. 2008). In fact, 
elegant microarray profiling and EST-cDNA sequence data analysis suggested 
that almost 70% of human genes are estimated to contain at least one 
alternatively spliced exon (Johnson, Castle et al. 2003). The protein isoforms that 
are translated from these splice variants may have similar, different or even 
antagonizing functions (Hernandez, Moreno et al. 2010) (Boise, Gonzalez-Garcia 
et al. 1993; Echard, Opdam et al. 2000).  
 
The DRAM-1 protein is encoded by the DRAM-1 transcript that contains 7 exons. 
(Crighton, Wilkinson et al. 2006). In this study, eight other splice variants of 
DRAM-1 have been identified in human. These transcripts contain exons 1 and 7, 
but lack different combinations of exons 2-6. Three of these splice variants, 
nominally termed Splice Variant (SV)1, SV4 and SV5 which code for DRAM-1 
isoforms 1, 4 and 5 respectively, were further characterised with respect to their 
ability to regulate autophagy. In line with this, autophagy was monitored by 
assessing the changes in two of the well characterised autophagic markers, the 
conversion of the microtubule-associated protein 1 light chain 1, LC3-I to LC3-II 
and the degradation of long – lived proteins (Klionsky, Abeliovich et al. 2008). 
 
Mammalian paralogues of Atg8 are categorized into two subgroups based on their 
amino acid sequence homology - the LC3 subfamily consisting of LC3A, LC3B and 
LC3C and the GABARAP/GATE 16 subfamily comprising of the GABARAPL1, 
GATE-16/ GABARAPL2, and GABARAP-L3 (Weidberg, Shvets et al. 2010). LC3B, 
or more commonly known as LC3, is most commonly used as a marker for 
autophagy induction, and has been demonstrated to associate with 
autophagosomes and recruit other autophagic factors such as p62 and NBR1 
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(Kirkin, Lamark et al. 2009) (Weidberg, Shvets et al. 2010). LC3B exists in three 
forms, the pre-cursor pro-LC3, LC3-I and the lipidated LC3-II (Klionsky, Abeliovich 
et al. 2008).  Pro-LC3 is processed into the cytosolic LC3-I, which is then cleaved 
by ATG4 and modified into LC3-II by its conjugation to phosphatidylethanolamine 
(PE) (Klionsky, Abeliovich et al. 2008). The lipidated LC3-II, which can be 
visualized as puncta when conjugated to fluorochromes like GFP or mRFP, is 
present on isolation membranes, autophagosomes and much less on 
autolysosome, thus making it a reliable marker for autophagy induction 
(Mizushima and Yoshimori 2007). In light with this, the development of assays to 
monitor LC3 turn over, such as the tandem mRFP GFP fluorescent-tagged LC3 
reporter protein has greatly facilitated the study of autophagic flux.  The dynamics 
of autophagy comprises of the formation of autophagosomes and the subsequent 
fusion with lysosomes, forming autolysosomes to create an acidic environment for 
cargo digestion (Klionsky and Emr 2000). Since GFP fluorescence is quenched 
under acidic conditions whereas mRFP remains stable, the colocalisation of both 
signals indicates LC3-containing components that are not fused to the lysosomes 
such as the isolation membrane and immature autophagosomes (Klionsky, 
Abeliovich et al. 2008). On one hand, when fusion occurs, the GFP signal is 
quenched, leaving only the mRFP signal – corresponding to amphisomes and 
autophagosomes (Kimura, Noda et al. 2007). The stepwise visualisation of green 
and red signals that correspond to autophagosome formation and maturation is 
illustrated in Fig. 3.1.  As such, this assay is able to successfully determine the flux 
of autophagosomes and autolysosomes.  
 
 84 
 85 
Long-lived protein is also a well-known autophagic substrate and the rate of long-
live protein degradation is a well-established method to measure autophagic flux 
and enables good quantification (Klionsky, Abeliovich et al. 2008). In this context, 
proteins are usually labelled with a radio-isotope by incorporation of a radioactive 
amino-acid, followed by a long cold-chase to allow for the degradation of short-
lived proteins, and the subsequent release of the acid-soluble radioactivity, which 
is quantified to reflect autophagic activity (Klionsky, Abeliovich et al. 2008) (Furuta, 
Hidaka et al. 2004; Mizushima, Yoshimori et al. 2010). Upon autophagy induction, 
the degradation of long-lived proteins is accelerated, resulting in a mark increase 
in the release of the radioisotope from intact cells into the medium. 
 
Elevated ROS levels well above the basal level have been demonstrated to induce 
autophagy (Rouschop, Ramaekers et al. 2009). Furthermore, p53 target genes 
like TIGAR and PUMA have been demonstrated to modulate ROS levels. In this 
context, TIGAR supresses ROS formation and the subsequent inhibition of 
autophagy in a p53-independent manner, with no clear effects on the mTOR 
pathway when deprived of nutrient or subjected to metabolic stress (Bensaad, 
Cheung et al. 2009). This discovery adds yet another level of complication to 
autophagy regulation by p53. Furthermore, the regulation of ROS by TIGAR is 
also essential to modulate apoptosis (Bensaad, Tsuruta et al. 2006). Enhanced 
expression of PUMA is also reported to induce ROS formation that contributes to 
apoptosis in colorectal cancer cells (Liu, Lu et al. 2005). Since DRAM-1 is also a 
p53 target gene, which is involved in autophagy and apoptosis, we wanted to 
know if the overexpression and deletion of DRAM-1 can modulate ROS levels with 
respect to its ability to induce autophagy and apoptosis.   
 
Following the role of the previously characterised DRAM-1 in facilitating p53-
mediated apoptosis (Crighton, Wilkinson et al. 2006), the ability of DRAM-1 
isoforms 4 and 5 to induce cell death in a p53-independent and -dependent 
manner was also assessed. Given that autophagy activation is largely perceived 
as a cytoprotective mechanism when nutrients are scarce, and that DRAM-1 
promotes autophagy, the role of DRAM-1 in modulating cell death in nutrient 
limiting conditions was also assayed.   
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3.2 Results 
3.2.1 DRAM-1 encodes multiple splice variants that are induced 
by p53 
The previously characterised p53 tetracycline-inducible (TetOn-p53) Saos-2 
osteosarcoma cell line (Ryan, Ernst et al. 2000) were used to determine if DRAM-
1 encodes for other splice variants beyond the one that has been characterised 
(Crighton, Wilkinson et al. 2006), and if so, whether they are also induced by p53. 
RNA was isolated from TetOn-p53 cells without or with 24h Doxycycline (Dox) 
treatment and was subjected to semi-quantitative PCR using primers from exon 1 
at the extreme 5' of the DRAM-1 open reading frame and exon 7 at the extreme 3'. 
These primers were able to detect eight other mRNA species, nominally named 
SV 2, 3, 4, 5, 6, 7, 8 and 9 - several of which were upregulated when p53 was 
activated with Doxycycline (Fig. 3.2). These transcripts were cloned and 
sequencing confirmed that they harbour different internal deletions of exons 2-6, 
while retaining exons 1 and 7 (Fig. 3.3) (Analysis by Jim O’Prey, Tumour Cell 
Death Laboratory). Sequencing also confirmed that only SV4 and SV5 results in 
mRNA species that continue in-frame to the same stop codon as SV1 at the end of 
exon 7, and thus it is postulated that they also have mature 3’ ends to maintain 
mRNA stability. These 3 isoforms also retained the highly conserved ‘PYISD’ motif 
as described by Crighton et al (2006) (Fig. 3.4). The ‘PYISD’ domain is required 
for the efficacy of DRAM-1 to modulate autophagy, as a mutation of the amino 
acid from Serine (suspected to be the phosphorylation site) to Alanine diminished 
the formation of GFP-LC3 puncta (Fig. 3.5). Having said that, only DRAM-1 
isoform 1 harbours a putative canonical LC3 Interacting Region (LIR) which 
consists of the WxxL, (Fig. 3.4) that enables the recognition of autophagy 
receptors by autophagy effectors (Kirkin, Lamark et al. 2009; Rozenknop, Rogov 
et al. 2011). 
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The presence of DRAM-1 isoforms was also confirmed in other cells and tissues 
by performing PCR amplification using the same primers from various cell lines of 
different origin. The levels of expression of these splice variants is variable across 
the different cell lines that were tested (Fig. 3.6). The splicing of DRAM-1 is not 
restricted to human, as several DRAM-1 transcripts were also found to be 
expressed mouse embryonic fibroblasts (MEFs), and are also upregulated when 
induced with the p53-inducing agent, Nutlin-3A (Fig. 3.7).  
 
 92 
 93 
 
 94 
3.2.2 DRAM-1 isoforms are localised and degraded in distinct 
cellular compartments 
DRAM-1 isoform 1 is localised to lysosomes (Crighton, Wilkinson et al. 2006). To 
determine the cellular distribution of isoforms 4 and 5, DRAM-1 isoforms were over 
expressed from adenoviruses in Saos-2 cells and stained with at least two 
markers for each cellular component that were analysed, as listed in Table 3.1.  In 
addition to the lysosome (Fig. 3.8), DRAM-1 isoform 1 was also found to be 
present in golgi apparatus, (Fig. 3.9), early and late endosomes (Fig. 3.10 and 
3.11), but neither isoforms 4 nor 5 showed convincing colocalisation in these 
compartments (Fig. 3.8-3.11). Further colocalisation studies were carried out with 
markers of mitochondria, peroxisomes and the endoplasmic reticulum.  DRAM-1 
isoform 4 was partially localised to the endoplasmic reticulum and peroxisomes 
(Fig. 3.12 and 3.13), whereas isoform 5 was partially found in the endoplasmic 
reticulum (Fig. 3.12). None of the DRAM-1 isoforms were found in the 
mitochondria (Fig. 3.14). DRAM-1 isoforms were also tested to determine if they 
colocalise with other autophagy markers, in this case, the previously discussed 
LC3B and also DFCP1, a novel autophagy regulator which is normally distributed 
in Golgi and endoplasmic reticulum, but colocalises with LC3B upon autophagy 
induction (Ridley, Ktistakis et al. 2001). DRAM-1 isoforms 1 and 5 colocalised with 
the autophagosome marker, LC3, but not isoform 4 (Fig. 3.15). In light of this 
result, all the DRAM-1 isoforms partially colocalised with DFCP1 (Fig. 3.16). 
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Table 3.1: Markers used for determination of DRAM-1 localisation in cellular 
organelles 
 
Organelles 
Marker 1 Marker 2 
Name Details Name Details 
Lysosome Lamp-2 
Lysosomal 
integral 
membrane 
protien Cathepsin D 
Lysosomal aspartyl 
protease 
 
Golgi apparatus TGN-46 
Trans-golgi 
network protein GM130 Golgi matrix protein  
Early Endosomes EEA1 
A hydrophillic 
peripheral 
membrane 
protein which  
colocalizes to 
early endosomes  Rab5 
GTP-binding protein 
that is associated 
with early endosome 
and plasma 
membranes 
Late Endosomes Rab7 
GTP-binding 
protein which is 
associated with 
late endosomes. CD63 
A highly glycosylated 
type-III lysosomal 
(integral) glycoprotein 
 
Autophagosome mCherry LC3 
Autophagsome 
marker (refer to 
section 1.2) DFCP1 
An autophagy 
regulator normally 
distributed in Golgi 
and endoplasmic 
reticulum, but 
colocalises with 
LC3B upon 
autophagy induction  
ER BiP 
GRP78 BiP is 
localised to the 
endoplasmic 
reticulum Calnexin 
An integral 
membrane protein 
located primarily in 
the ER 
Peroxisome PMP70 
Peroxisomal 
Membrane 
Marker 
of 70kDa Peroxisome GFP 
A modified 
baculovirus 
expressing a fusion 
construct of 
a peroxisomal marker 
and green 
fluorescent protein 
Mitocondria Tom 20 
The mitochondrial 
preprotein 
translocases of 
the outer 
membrane which 
is located in the 
mitochondria Cox IV 
This protein is one of 
the nuclear-coded 
polypeptide chains of 
cytochrome c 
oxidase, the terminal 
oxidase in 
mitochondrial 
electron transport 
Details of all commercial antibodies and reagents were obtained from the data 
sheet enclosed. Details of Rab 7 and DFCP1 contructs were obtained from Jim 
Norman (The Beatson Institute for Cancer Research; personal communication) 
and (Ridley, Ktistakis et al. 2001)
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It was also found that DRAM-1 isoform 1 turnover occurs at the lysosome, as 
evident in the increase of the protein level upon lysosomal inhibition with the 
vacuolar-type H(+)- ATPase inhibitor, Bafilomycin-A1. In the contrary, the protein 
expression of isoform 4 decreases slightly whereas the protein level of isoform 5 
remains the same, upon lysosomal inhibition (Fig. 3.17A). Rather, isoforms 4 and 
5 are degraded in the proteasome, as shown by the significant increase in protein 
levels when the proteasomal function is blocked with the potent and reversible 
proteasome inhibitor, MG132 whereas isoform 1 protein levels decreases slightly 
(Fig. 3.17B). 
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3.2.3 DRAM-1 isoforms and the regulation of autophagy 
To test if DRAM-1 isoforms 4 and 5 were also autophagy regulators, Saos-2 cells 
were simultaneously infected with adenoviruses expressing isoforms 1, 4 and 5, or 
empty adenoviral vector as control, together with an adenovirus expressing GFP-
LC3 (Kabeya, Mizushima et al. 2000; Bampton, Goemans et al. 2005). Consistent 
with previous findings, cells expressing isoform 1 displayed marked increase in 
GFP-LC3 punctation, which corresponds to autophagosome formation compared 
with cells infected with empty viral control (p = 0.001) (Fig. 3.18). Significant 
accumulation of autophagosomes was also observed in cells infected with 
isoforms 4 and isoform 5 (p < 0.05) albeit to a lower extent compared to isoform 1 
(Fig. 3.18). This implies that DRAM-1 isoforms 4 and 5 are also autophagy 
modulators.   
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To test if DRAM-1 isoforms promote autophagy, autophagic flux was assessed by 
monitoring the change in ratio of LC3-I to LC3-II by western blot following infection 
with each of the DRAM-1 isoforms, in the presence or absence of lysosomal 
degradation. Lysosomal degradation was prevented by treatment with Bafilomycin-
A1 – an inhibitor of vacuolar H(+)-ATPase which increases the lysosomal pH to 
prevent the fusion of autophagosomes and lysosomes (Oda, Nishimura et al. 
1991). Autophagy promoters are expected to cause a further increase in LC3-II 
accumulation upon the inhibition of this final stage of the autophagy machinery 
(Mizushima and Yoshimori 2007; Klionsky, Abeliovich et al. 2008).  Consistent with 
the previous observation (Fig. 3.18), all the DRAM-1 isoforms increase the ratio of 
LC3-II to LC3-I, and the change with isoform 1 was greater than that observed with 
isoform 4 or isoform 5 (Fig. 3.19). Further accumulation in LC3-II levels was 
observed in all the cells when treated with the lysosome inhibitor, Bafilomycin-A1 
compared to conditions when the lysosome function was not perturbed (Fig. 3.19). 
Additionally, cells that were overexpressing DRAM-1 isoforms 1 and 4 reflected a 
greater accumulation of LC3-II compared to those infected with the empty vector 
when the lysosomal function was inhibited, as reflected by the changes in the ratio 
of LC3-II to the actin control.  This implies that both isoforms 1 and 4 promote 
autophagy. However, there is a slight decrease in the ratio of LC3-II to actin in the 
cells that were overexpressing the DRAM-1 isoform 5 control compared to those 
infected with the empty vector upon Bafilomycin-A1 treatment. This suggests that 
DRAM-1 isoform 5 could possibly repress autophagy. 
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Thus, it remains plausible that the coexpression of DRAM-1 isoforms 1, 4 and 5 
can either cause a synergistic or additive increase in LC3-II levels. To test this, 
TetOn-DRAM-1 cells (Saos-2 cells which contain a tetracycline inducible DRAM-1 
transgene) were infected with adenoviruses expressing either DRAM-1 isoform 4, 
5 or an empty vector as control. DRAM-1 expression was achieved by incubating 
the cells with Doxycycline. It turned out that the total levels of LC3-1 and LC3-II did 
not increase upon coexpression of either DRAM-1 isoforms 1 and 4 or isoforms 1 
and 5, compared to the individual overexpression of DRAM-1 isoform 1 alone (Fig. 
3.20). Despite previous speculations that DRAM-1 isoform 5 could potentially 
repress autophagy, this experiment suggests that the enhanced expression of 
DRAM-1 Isoforms 1 and Isoforms 4 or 5 does not cause a synergistic and additive 
increase in LC3 lipidation. 
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Having seen this effect, we sought to determine if the coexpression of DRAM-1 
isoforms not only promotes autophagosome biogenesis, but also fusion with 
lysosomes. To monitor autophagosome turn over, DRAM-1 isoforms were 
ectopically overexpressed in cells that were stably expressing the tandem 
monomeric RFP-GFP tagged LC3 to determine the autophagsomes and 
autolysosomes flux. As discussed in section 3.1, the presence of GFP puncta 
indicates immature autophagosomes. The presence of mRFP signal (red puncta) 
indicates mature autophagosomes and amphosomes, and is normally observed 
when cells are cultured in nutrient-limiting conditions, such as EBSS, which is a 
potent and well-characterised stimulus for autophagy induction and completion 
(Fig. 3.21B). At basal levels, both autophagosomes and autolysosomes are 
present at steady state levels, thus the formation of GFP and RFP puncta is very 
low (Fig. 3.20A). The colocalisation of both signals (yellow puncta) indicates LC3 II 
containing autophagosomes that are not fused to the lysosome, and is normally 
observed when the later stages of autophagy are inhibited with agents that block 
lysosomal function, such as the vacuolar ATPase inhibitor Bafilomycin-A1 (Fig. 
3.21C). Ectopic overexpression of DRAM-1 isoforms 1 (Fig. 3.21D), 4 (Fig. 3.21E) 
and 5 (Fig. 3.21F) alone increases both mRFP and GFP puncta. Despite the 
increase in autophagic flux when DRAM-1 isoforms 1 and 5 were coexpressed 
together, the simultaneous overexpression of neither isoforms 1 and 4 (Fig. 3.20G) 
nor isoforms 1 and 5 together (Fig. 3.21H) was able to accelerate the fusion of 
autophagosomes and autolysosomes. Since all DRAM-1 isoforms promote 
autophagy, as evident with the further increase in LC3 lipidation upon lysosomal 
inhibition and enhanced autophagic flux, it seems reasonable to imply that DRAM-
1 isoforms are potent inducers of autophagosome biogenesis, and that the rate of 
formation exceeds the rate of fusion with lysosomes.  
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DRAM-1 is required for p53-mediated long-lived protein degradation (Crighton, 
Wilkinson et al. 2006). In line with this, long-lived protein degradation assay was 
performed in conditions where DRAM-1 isoforms were ectopically overexpressed. 
Cellular proteins were labelled with the radioisotope 35S by incorporation of the 
radioactive amino acids methionine and cysteine for 8 hours. Cells were subjected 
to an overnight cold chase and the rate of protein degradation was determined as 
follows: 
 
% protein degradation =   Acid-soluble radioactivity in culture medium 
       (Acid-soluble + acid precipitable radioactivity) 
 
Despite their autophagic roles, long-lived protein turnover was not increased upon 
the ectopic overexpression of DRAM-1 isoforms (Fig. 3.22). This implies that 
ectopic overexpression of DRAM-1 isoforms does not modulate long-live protein 
turn over, in a p53-independent context.    
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Following from the above, the role of DRAM-1 isoforms 1, 4 and 5 in the regulation 
of reactive oxygen species (ROS) – one of the many signalling molecules involved 
in the autophagy cascade, was also studied. DRAM-1 inducible Saos-2 cells were 
treated with the Tetracycline analogue, Doxycycline (1μg/ml) for 48 hours to 
induce the expression of DRAM-1 isoforms 1, 4 and 5 (Fig. 3.23A). When 
expression of DRAM-1 isoforms were validated, these cells were incubated with 
2’,7’ - dichloro-dihydroﬂuorescein diacetate  (H2-DCFDA), which was metabolised 
by non-speciﬁc esterases to the non-ﬂuorescence product, 2’,7’ dihydroﬂuorescein 
(Bensaad, Cheung et al. 2009). 2’,7’ dihydroﬂuorescein is then subsequently 
oxidised to the ﬂuorescent product, DCF, by ROS (Bensaad, Cheung et al. 2009). 
Ectopic overexpression of neither isoforms 1, 4 or 5 modulates basal and 
enhanced ROS levels upon treatment with hydrogen peroxide (H2O2) (Fig. 3.23B). 
These results indicate that ectopic expression of DRAM-1 isoforms does not 
modulate intracellular ROS levels.   
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3.2.4 Validation of DRAM-1 effects in mouse cells 
We were also interested to know if the genetic ablation of DRAM-1 affects the 
above characterised autophagy readouts associated with ectopic overexpression 
of DRAM-1 isoforms 1, 4 and 5. DRAM-1 deletion was achieved by infecting 
DRAM-1fl/fl MEFs with a retrovirus expressing Cre recombinase (Fig. 3.24), and the 
similar autophagy assays were conducted.  
 
Following the convincing LC3-I to –II conversion following forced expression of 
DRAM-1 isoforms, wild-type (DRAM-1fl/fl) and DRAM-1-null (DRAM-1-/-) MEFs 
were deprived of essential amino acids by culturing them in EBSS for four hours. 
Surprisingly, DRAM-1 deletion does not impair the conversion of LC3-I to LC3-II 
when the cells were cultured in amino acid in limiting conditions (Fig. 3.25). This 
suggests that DRAM-1 is either functionally redundant, or that the loss of DRAM-1 
can be compensated, perhaps by other members of the DRAM-1 family or 
autophagy regulators. 
 
To validate that DRAM-1 does not play a role in long-live protein turnover, wild-
type and DRAM-1-null MEFs were incubated with 35S and subjected to a cold 
chase prior culture in EBSS. Acute DRAM-1 deletion in DRAM-1fl/fl MEFs does not 
affect the basal levels of long-lived protein turnover, nor does it affect the ability of 
cells to degrade long-lived proteins upon amino acid starvation (Fig. 3.26), 
consistent with the above. This confirms that long-lived protein is not a substrate 
for DRAM-1 mediated autophagy, or that DRAM-1 is not required for long-lived 
protein degradation under amino acid limiting conditions. 
 
Next in line, we were interested to determine if DRAM-1 deletion affects basal or 
modulate elevated ROS levels, a well known signalling molecule for autophagy 
induction (Section 3.1).  Wild–type and DRAM-1-null MEFs were incubated with 
hydrogen peroxide (H2O2) and H2-DCFDA. Basal ROS levels were not affected by 
DRAM-1 status, and DRAM-1 deletion does not affect H2O2 enhanced intracellular 
ROS levels (Fig. 3.27). 
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3.2.5 DRAM-1 isoforms do not induce programmed cell death 
The overexpression of DRAM-1 isoform 1 (encoded by SV1) alone does not 
induce cell death (Crighton, Wilkinson et al. 2006). To investigate if isoforms 4 and 
5 (encoded by SV 4 and 5 respectively) are functionally similar, isoforms 1, 4 and 
5 were overexpressed alongside p53 at similar levels (Fig. 3.28A) for 48 hours, 
and assessed for the presence of cells with sub-G1 content – a marker for 
apoptosis. Although p53 causes significant cell death (p<0.001), neither of the 
DRAM-1 isoforms was able to induce cell death in this short-term assay (Fig. 
3.28B). I also investigated if the overexpression of isoforms 1, 4 and 5 affected the 
long-term viability by monitoring their effects on clonogenic survival. Consistent 
with the short-term cell death data, neither of the DRAM-1 isoforms affected the 
clonogenic potential of the cells (Fig. 3.29). 
 
 125 
 126 
 127 
DRAM-1 isoform 1 expression is required for the enhancement of p53-induced 
apoptosis, as siRNA ablation of all DRAM-1 transcripts impeded the extent of cell 
death (Crighton, Wilkinson et al. 2006). p53 is activated by various forms of 
genotoxic stress (refer to section 1.7). Thus it is of no surprise that various DNA 
damaging agents share a common effect in the induction of p53 (Attardi, de Vries 
et al. 2004). Consistent with this, DRAM-1 message levels were upregulated in 
various human cell lines – MDA-MB-231 (breast cancer carcinoma) (p<0.05), 
Saos-2 (p53-null osteosarcoma) (p<0.10) and U2OS (osteosarcoma) (p<0.05) that 
were treated with etoposide, a Topoisoerase II inhibitor which causes DNA 
damage and consequently apoptosis (Karpinich, Tafani et al. 2002) (Fig. 3.30).  
 
To identify if any of these three isoforms play an individual role in p53-dependent 
cell death, DRAM-1fl/fl fibroblasts (MEFs) were infected with a retrovirus expressing 
the E1a oncogene fused to a portion of the estrogen receptor (E1aER). E1aER  is 
bound and inactivated by hsp90 under basal conditions (Helgason, O'Prey et al. 
2010). Upon treatment with 4-hydoxytamoxifen, hsp90 binding is abrogated, and 
E1a is active, sensitising the cells to death induced by the chemotherapeutic drug, 
doxorubicin (adriamycin) in a p53-dependent manner (Helgason, O'Prey et al. 
2010). These E1aER-expressing cells were then sequentially infected with either 
DRAM-1 isoform 1, 4 and 5, or empty vector as control (Fig. 3.31A) and retrovirus 
expressing Cre recombinase to ablate all endogenous DRAM-1 expression, or 
empty retroviral vector as control (Fig. 3.31B). This panel of cells was treated with 
4-hydoxytamoxifen and doxorubicin. Activation of E1a sensitised the control cells 
to doxorubicin and this effect was significantly reduced in cells where endogenous 
DRAM-1 expression was loss following recombination when infected with Cre 
(p=0.001) (Fig. 3.31C). Rescue of this effect was not achieved by individual 
expression of either DRAM-1 isoforms 1, 4 or 5 (Fig. 3.31C), implying that neither 
of these isoforms, when expressed alone can reconstitute the role of DRAM-1 in 
p53-mediated programmed cell death.  
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3.2.6 DRAM-1 is required to sustain survival under nutrient-
limiting conditions 
Since DRAM-1 isoforms has been demonstrated to positively regulate autophagy, 
it would be interesting to know if DRAM-1 plays a pro-apoptotic or pro-survival role 
under nutrient stress. When cells were starved in amino-acid and glucose free 
medium, human DRAM-1 transcripts were upregulated in a time dependent 
manner (Mann-Whitney U test; p<0.05) (Fig. 3.32).    
 
To elucidate whether DRAM-1 is required for cell death or survival in this context, 
DRAM-1fl/fl fibroblasts (MEFs) were infected with an empty vector, or a retrovirus 
expressing the Cre recombinase to delete endogenous DRAM-1. Wild-type 
(DRAM-1fl/fl) and DRAM-1-/- MEFs were subjected to amino-acid and glucose 
starvation for 24h and 48h. Cells were then stained with the vital DNA intercalating 
dye - propidium iodide, which is taken up by dead cells that have lost their 
membrane permeability (Galluzzi, Aaronson et al. 2009). Live and dead cells were 
then quantified by flow cytometry.  DRAM-1-/- MEFs were highly sensitised to both 
amino acid and glucose withdrawal (Fig. 3.33), suggesting that DRAM-1 is 
required for survival under nutrient limiting conditions.   
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Figure 3.32: DRAM-1 mRNA levels is upregulated in Saos-2 cells upon 
nutrient starvation  
Saos-2 cells were cultured in complete DMEM (Basal) glucose- and amino-acid-
limiting (-AA) conditions for 24 and 48 hours. Cells were harvested and relative 
expression of DRAM-1 was validated by RT-PCR. 
 
 
 
 
 
 
 
 
Figure 3.33: DRAM-1 deletion in MEFs sensitises them to cell death upon 
nutrient starvation  
Wild-type and DRAM-1-null MEFs were cultured in glucose and amino acid-limiting 
conditions for 24 and 48 hours. Cells were harvested, and analysed for cell death 
using PI exclusion assay, as described in the previous section. 
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3.3 Discussion  
DRAM-1 encodes a series of splice variants. In addition to the previously 
characterised autophagy modulator SV1, (Crighton, Wilkinson et al. 2006) we 
have identified eight other p53-inducible splice variants, all containing exons 1 and 
7 but lacking different combinations of exons 2-6. These mRNA species are 
expressed at varying levels in multiple human cell lines, suggesting that the 
expression of DRAM-1 splice variants is widespread and that the relative 
importance of these isoforms is cell-type dependent. DRAM-1 splice variants are 
also present in mouse embryonic fibroblasts (MEFs) and are induced by p53, 
implying that the alternative splicing of DRAM-1 is also present in higher 
eukaryotes. Of these 9 mRNA species, we have confirmed that only SV 1, 4 and 5 
do not contain a pre-mature stop codon, and thus, were hypothesised to code for a 
functional protein. DRAM-1 isoforms 1, 4 and 5 contain the PYISD domain, which 
is critical for the induction of autophagy.  
 
DRAM-1 isoforms were found to localise to different cellular compartments – 
isoform 1 in the golgi apparatus, endosomes, lysosomes and autophagosomes; 
isoform 4 partially in the ER and peroxisomes, and isoform 5 partially in the ER 
and autophagosomes. Both isoforms 4 and 5 are also partially diffused in the 
cytoplasm. Occasionally, isoform 4 is observed to form puncta in the cells. The 
conditions that result in the punctate staining pattern remains to be elucidated. 
Although all DRAM-1 isoforms are predicted to contain a cleavable ER-targeting 
signal, colocalisation studies revealed that only isoforms 4 and 5 were partially 
localised in the ER. This implies that only isoforms 4 and 5, but not isoform 1, are 
retained in the ER upon synthesis. A plausible explanation for this could be that 
the posttranslational modification of isoform 1 could be different to that of isoforms 
4 and 5. As a consequence, the ER-signal peptide might be lost prior to complete 
protein translation. Further biochemical studies should be conducted to confirm 
this. Colocalisation studies also revealed that DRAM-1 isoforms 1 and 5, but not 
isoform 4, might potentially interact with the autophagy marker LC3B. This is 
consistent with the presence of the canonical WxxL LIR motif on isoform 1. The 
co-compartmentalisation of isoform 5 and LC3B suggests that Isoform 5 may 
potentially harbour a non-canonical LIR domain. In the future, the interaction 
between DRAM-1 isoforms and LC3B should be confirmed by performing 
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immunoprecipitation assays. Subsequently, the functional significance of this 
interaction is worth pursuing. The distribution of DRAM-1 isoforms in multiple 
cellular organelles suggests that autophagy and possibly other cellular effects 
brought upon by DRAM-1 activation is widespread and occurs in various 
organelles of the cell. These effects may be mediated by different DRAM-1 
isoforms in their respective cellular compartments.  
 
DRAM-1 isoform 1 turnover occurs in lysosomes as evident in the accumulation of 
protein levels when the lysosomal function is inhibited with Bafilomycin-A1. 
Bafilomycin-A1 is a vacuolar-H(+)-ATPase inhibitor which increases lysosomal pH 
and subsequently inactivates the majority of the pH-sensitive lysosomal enzymes, 
thus leading to a loss of lysosomal activity (Oda, Nishimura et al. 1991). On the 
other hand, DRAM-1 isoforms 4 and 5 are degraded in the proteasomes, as 
reflected in the massive accumulation of protein levels when the cells were treated 
with specific concentrations of cell permeable, reversible proteasomal inhibitor, 
MG132 (Tsubuki, Saito et al. 1996). Given that lysosomes degrade long-lived 
protein, whereas proteasomes primarily degrade ubiquitin-tagged short-lived 
proteins (Qiao and Zhang 2009), (Korolchuk, Mansilla et al. 2009) (Tsuchihara, 
Fujii et al. 2008), these findings indicate that DRAM-1 isoform 1 is relatively more 
stable, possibly with a longer half-life compared to isoforms 4 and 5. The 
proteasomal and lysosomal degradation pathways have been shown to cross-talk 
to each other to maintain protein homeostasis (Qiao and Zhang 2009). 
Additionally, pharmacological inhibition of proteasomal activities has been shown 
to upregulate the levels of lysosomal enzymes that may affect lysosomal transport 
of selected membrane-bound proteins (Qiao and Zhang 2009) (van Kerkhof, Alves 
dos Santos et al. 2001). Consistent with the compensatory upregulation of 
lysosomal activity when the proteasome is inhibited, the turnover of DRAM-1 
isoform 1 is slightly enhanced, as evidenced by the subtle decrease in protein 
levels upon proteasomal inhibition.  
 
Despite lacking the putative WxxL LIR domain (Kirkin, Lamark et al. 2009), DRAM-
1 isoforms are functionally similar in terms of autophagy modulation. DRAM-1 
isoforms 1, 4 and 5 promote the initial stage of autophagy by inducing 
autophagosome biogenesis, as reflected by the formation of GFP-LC3 puncta and 
LC3-I to -II conversion, with isoform 1 evoking a stronger effect compared to 
isoforms 4 and 5. As such, there could be other non-canonical LIR domains 
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present on DRAM-1 isoforms 4 and 5, which enables weaker interactions with 
LC3. This could explain the weaker LC3 lipidation by isoforms 4 and 5. The 
accumulation of LC3-II may simply imply an enhanced autophagic activity, 
indicated by an increase in autophagosome formation, or autophagy inhibition 
when the fusion of autophagosomes to lysosomes is blocked, thus preventing LC3 
turnover. Hence, it is crucial to measure autophagic flux by comparing LC3-II 
levels in the presence and absence of lysosomal protease inhibitors (Mizushima 
and Yoshimori 2007). As expected of autophagy promoters, LC3-II levels are 
further enhanced upon lysosomal inhibition in cells overexpressing DRAM-1 
isoforms 1, 4 and 5.  
 
The simultaneous overexpression of DRAM-1 isoforms does not promote further 
accumulation of LC3–II compared to individual overexpression of isoform 1. This 
suggests that DRAM-1 isoforms 1, 4 and 5 may work independently of one 
another to promote autophagy.  
 
DRAM-1 isoforms 1, 4 and 5, whether expressed individually or simultaneously, 
only increase the amount of autophagosomes, but not autolysosomes. This 
implies that DRAM-1 only modulates the earlier stages of autophagy comprising 
autophagosome formation, but not fusion with lysosomes. DRAM-1 isoforms are 
likely potent inducers of autophagosome biogenesis, and the rate of formation is 
so rapid that it exceeds the fusion with lysosomes.  
 
Despite the fact that DRAM-1 plays an important role in mediating p53-induced 
autophagy (Crighton, Wilkinson et al. 2006), genetic ablation of DRAM-1 in MEFs 
does not affect basal autophagy or starvation-induced autophagy. Wild-type and 
DRAM-1-null MEFs were able to promote LC3-I to LC3-II conversion when 
cultured under amino-acid limiting conditions (EBSS). This indicates that DRAM-1, 
like another autophagy modulator, Head Involution Defective (HID) (Juhasz and 
Sass 2005), and possibly other autophagy regulators that are yet to be identified, 
can induce but is not required for autophagy activation. This can be attributed to 
the fact that loss of DRAM-1 can be compensated for by the other DRAM family 
members, namely DRAM-3, DRAM-4 and DRAM-5 (O'Prey, Skommer et al. 2009). 
 
Having seen the encouraging effects on LC3, the ectopic overexpression of 
DRAM-1 isoforms does not enhance long-lived protein degradation. Consistent 
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with this, acute DRAM-1 deletion in mouse embryonic fibroblast (MEFs) does not 
affect long-lived protein turnover under basal and nutrient limiting conditions. This 
suggests that the substrate(s) for DRAM-1-mediated autophagy may differ from 
those degraded in the canonical starvation-induced autophagy. Alternatively, the 
cargoes for DRAM-1 might be highly specific, and thus the ectopic overexpression 
of DRAM-1 may only affect the autophagy adapter protein, LC3. Forced 
expression of DRAM-1 does not appear to modulate basal or enhanced ROS 
levels. Likewise, ectopic expression and acute loss of DRAM-1 in these cells do 
not affect ROS levels under similar conditions. This implies that the mechanism by 
which DRAM-1 induces autophagy is ROS-independent. Considering these, it 
seems that DRAM-1 is a highly specific autophagy modulator, which responds or 
signals to a narrow range of stimuli and signalling molecules, and affects only a 
very limited range of substrates, one of them being LC3. Recently, p62 has also 
been demonstrate to be yet another substrate for DRAM-1 in the execution of 
autophagy. Galavotti et al. (2012) showed that DRAM-1 is critical for the 
localisation of p62 to autophagosomes to evoke autophagy. Additionally, the acute 
silencing of either of these two autophagy modulators in glioblastoma stem cells 
(GSCs) decreased cellular ATP levels and impaired the invasive and metastatic 
potentials of these cells (Galavotti, Bartesaghi et al. 2012). Following on from this, 
it is worthwhile to identify other DRAM-1 interactors, effectors and the autophagic 
substrates. 
 
DRAM-1 is pro-apoptotic under several conditions. The simultaneous 
overexpression of DRAM-1 and DRAM-2 induces cell death in a range of human 
tumour cell lines (Park, Kim et al. 2009).   Furthermore, DRAM-1 is required for 
effective p53-dependent apoptosis by mediating the release of cytochrome c from 
the mitochondria (see section 1.8.1) (Crighton, Wilkinson et al. 2006). We have 
shown that the role of DRAM-1 in enhancing p53-mediated cell death is 
conserved, at least, across higher eukaryotes. The acute deletion of DRAM-1 in 
mouse embryonic fibroblasts (MEFs) caused a marked reduction in cell death 
when endogenous p53 levels were upregulated upon treatment with the DNA 
damaging agent adriamycin (doxorubicin). Doxorubicin is a chemotherapeutic drug 
that is often used in combination with radiotherapy to treat cancer patients. (Kim 
and Leeper 1987). However, the ectopic expression of neither DRAM-1 isoforms 
1, 4 or 5 alone was able to restore optimum cell death. This suggests that more 
than one isoform of DRAM-1 is required for effective p53 killing.   
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Consequently, the mechanism by which DRAM-1 contributes to cytochrome c 
release and cell death downstream of p53 remains to be elucidated. Elegant in 
vivo studies in mice by Mihara et. al (2003) have shown that the translocation of 
p53 to mitochondria is sufficient to induce apoptosis in the thymus upon exposure 
to ionising gamma irradiation. They also showed that p53 can directly provoke the 
permeabilisation of the outer mitochondrial membrane by co-complexing with the 
anti-apoptotic Bcl-XL and Bcl-2 proteins to facilitate cytochrome c release (Mihara, 
Erster et al. 2003). In line with this, it might be interesting to investigate if DRAM-1 
mediates the translocation of p53 to the mitochondria to bring about cell death, 
and the subsequent effects on Bcl-XL and Bcl-2 proteins. Additionally, the mode of 
action in which DRAM-1 induces p53-dependent cell death is independent of 
caspases (Crighton et. al, 2006). Caspase-independent cell death (CICD) may be 
triggered by several stimuli, such as mitochondrial outer membrane 
permeabilisation, which results in the release of cytochrome c from the 
mitochondrial intermembrane space (IMS) (Tait and Green 2008). Besides 
cytochrome c, numerous IMS proteins such as Smac/Diablo, HtrA2/Omi, 
Endonuclease G (Endo G) and apoptosis-inducing factor (AIF) are also released, 
and these proteins have also been proposed to actively induce CICD, as reviewed 
by Tait and Green (2008). Thus, it seems worthwhile to investigate whether 
DRAM-1 might mediate the release of these factors, in addition to cytochrome c in 
order to characterise the pathways downstream of these factors in evoking p53-
dependent apoptosis. Yet another possibility by which DRAM-1 mediates cell 
death is by inducing autophagy, which may subsequently facilitate p53-dependent 
apoptosis. Since the simultaneous silencing of DRAM-1 and Atg5 does not cause 
a greater reduction in death than the individual knockdown of DRAM-1 (Crighton 
et. al, 2006), it remains possible that DRAM-1 may act upstream of ATG5 to evoke 
autophagy and subsequently cell death. The interplay of other autophagy 
regulators that are involved in the autophagic machinery upstream of ATG5 such 
as Beclin 1 and ATG 101 (see section 1.2) merits further investigation.  
 
DRAM-1 message level was upregulated when cells were subjected to nutrient 
stress. In this context, DRAM-1 deletion in MEFs sensitised the cells to death upon 
amino acid and glucose withdrawal. Given that DRAM-1-null MEFs were able to 
induce LC3 lipidation upon amino-acid starvation (Fig. 3.25 and Fig. 3.26), the 
requirement for DRAM-1 to promote survival under nutrient-limiting conditions is 
likely to be independent of autophagy. This implies that there are potentially other 
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cellular mechanism(s) that are disrupted upon the loss of DRAM-1, which sensitise 
cells to die under nutrient stress. For instance, serum-starvation has been reported 
to induce the cleavage of poly (ADP-ribose) polymerase (PARP), the full-length 
procaspase-3 and procaspase-9, as well as causing decreased expression of 
endogenous Bid, a BH-3-only proapoptotic protein of the Bcl-2 family (Goyeneche, 
Harmon et al. 2006). Although the involvement of autophagy in this context is not 
reported, the role of DRAM-1 in response to nutrient starvation in the regulation of 
intrinsic, as well as extrinsic apoptosis and other forms of cell death such as 
necrosis is worth investigating. 
 
In conclusion, results from this section suggest that DRAM-1 transcripts encode 
for specific regulators of autophagy, which also participate in p53-mediated cell 
killing. Given that DRAM-1 SV1, SV4 an SV5 were identified by primers spanning 
the first and the last exon (exon 7) of the transcript, it remains plausible that there 
could be other splice variants of DRAM-1 which do not contain either of the exons 
1 and 7, which still might regulate autophagy, cell death or other functions which 
are yet to be elucidated. Additionally, the cellular effects driven by DRAM-1 
expression is hypothesised to require the participation of multiple isoforms of 
DRAM-1. Since the overexpression of DRAM-1 induces autophagosome 
formation, it remains highly plausible that DRAM-1 might regulate other autophagy 
effectors, such as mTOR and the panel of ATG proteins which are involved in the 
earlier stages of autophagy preceding autophagosome maturation, and is worth 
investigating.  
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Chapter 4: Characterisation of conditional DRAM-1 
knockout mice  
4.1 Introduction 
 
The use of the bacterial- (Cre/loxP) and yeast-derived (FLP/frt) site-specific DNA 
recombination systems has facilitated the development of conditional knockout 
mice models (Vooijs, Jonkers et al. 2001). For instance, the development of the 
Cre Deleter strain that is driven by the CMV promoter, enables the ubiquitous 
deletion of a gene flanked by loxP sites (Artemis Pharmaceuticals/Taconic). 
However, this strategy is not ideal, as the onset of Cre expression may occur at an 
early developmental period in which the gene is required, thus leading to the 
accumulation of phenotypic aberrations which may complicate the analysis of later 
developmental stages, and occasionally may lead to death (Vooijs, Jonkers et al. 
2001).  
 
This has prompted the development of spatial and temporal control of Cre-
mediated recombination models (Vooijs, Jonkers et al. 2001). For instance, 
intestinal and liver inducible Cre can be driven using the Cyp1A1 (cytochrome 
p450 subfamily A1) (Ireland et al., 2004). The Cyp1A1 promoter which is usually 
transcriptionally inactive, is upregulated upon exposure to lipophilic xenobiotics, 
such as β- naphthoflavone and binds to the cytoplasmic Aryl Hydrocarbon receptor 
(hence termed AhCre), allowing it to translocate to the nucleus where it form 
complexes with other factors to facilitate DNA binding and subsequently 
transcription (Ireland, Kemp et al. 2004). Alongside this, many mouse models of 
diseases have been developed to unravel the signalling pathways that are altered 
in human diseases. 
 
To complement our in vitro findings, we have extended our studies of DRAM-1 in 
vivo. In this context, we were interested to determine if the ubiquitous deletion of 
DRAM-1 is embryonically lethal, and if DRAM-1 is required for normal organ 
development. In line with this, DRAM-1 flox-flox mice were crossed to CMV Cre 
Deleter to delete DRAM-1 in the whole body.  Subsequent to this, we wanted to 
determine if DRAM-1-null mice are predisposed to diseases that arose from 
autophagy deficiency. Given that DRAM-1 has been shown to enhance p53-
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dependent apoptosis in vitro, we were also interested to determine if the deletion 
of DRAM-1 can modulate p53-dependent and –independent cell death in vivo. To 
address this, wild-type and DRAM-1-null mice were exposed to 14 Gy of gamma-
irradiation and the small intestines were harvested from these mice after 6h and 
24h to assess for apoptosis; and 48h and 72h to assess for regeneration. 
Additionally, since DRAM-1 mRNA levels were down regulated in various forms of 
human cancer (Crighton, Wilkinson et al. 2006), we were also interested to 
determine if the ubiquitous loss of DRAM-1 predisposes to the development of 
cancer upon exposure to low dose of gamma-irradiation. Finally, since human 
DRAM-1 is upregulated by various cytokines (refer to section 5.2.1), we were 
interested to determine if the whole-body deletion of DRAM-1 in mice can 
modulate the inflammatory response in the colon, as well as inflammation-driven 
tumourigenesis.  
 
In addition, we wanted to investigate if DRAM-1 is required for p53-mediated 
senescence in the liver. In this context, MDM2 flox/flox mice harbouring either both 
copies of the wild type (DRAM-1+/+) and DRAM-1 flox/flox alleles were crossed to 
the AhCre Deleter to drive specific excision of DRAM-1 and MDM2 primarily in the 
small intestine and liver. The deletion of MDM2 would result in an increase in p53 
levels in the small intestine and the liver, which will enable us to study apoptosis 
and senescence both in the presence and absence of DRAM-1 (see sections 4.2.2 
and 4.2.4 for detailed explanation).  
 
4.1.1 The intestinal crypt as a model to examine apoptosis in vivo 
The intestinal tract is composed of three tissue layers – the smooth muscles which 
enable peristalsis, the stromal muscles and the mucosa layers which comprise of 
epithelial cells for nutrient absorption (Sancho, Batlle et al. 2004). The epithelium 
is further characterised by the presence of numerous finger-like protrusions, 
termed villi, and crypts of Lierberkuhn (Sancho, Batlle et al. 2004). The base of the 
intestinal crypts constitutes of columnar and antimicrobial peptide and enzyme-
secreting paneth cells (Porter, Bevins et al. 2002). Intestinal stem cells, which 
differentiate into daughter progenitor cells, are found directly above the paneth 
cells (Hocker and Wiedenmann 1998).  
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Actively cycling murine intestinal stem cells are identified by leucine-rich repeats 
containing G-protein coupled receptor 5 (Lgr5), Achaete scute-like 2 (Ascl2) and 
olfactomedin 4 (Olfm4) expression; whereas slowly cycling stem cells are marked 
by B cell-specific Moloney murine leukemia virus integration site 1 (Bmi1) and 
Telomerase Reverse Transcriptase (mTert) (Dehmer, Garrison et al. 2011). Lgr5 
was most exclusively expressed in cells intermingled with paneth cells, whereas 
OLFM4, which display a membranous-staining pattern, is enriched at the bottom of 
crypts and is expressed to varying degrees above the paneth cell compartment 
(Munoz, Stange et al. 2012).  
 
These progenitor cells differentiate to form three distinct cell lineages that populate 
the villus - the enterocytes, which produce hyrdrolases and absorb nutrients; 
goblet cells which secrete a protective mucous lining, and the enteroendocrine 
cells which secrete hormones (Hocker and Wiedenmann 1998). It was later 
revealed that the crypt progenitor cells divide every 12-16 hours to form 200 cells 
per crypt daily (Sancho, Batlle et al. 2004).  
 
The small intestine is a well characterised model to study DNA damage response 
in vivo. It is highly sensitive to DNA damage-induced apoptosis, and has a high 
regenerative capacity, which is attributed to the presence of a population of 
intestinal stem cells (Potten 1998). Upon the deletion of these stem cells, there 
exists another population of 30-40 clonogenic cells that can repopulate the 
intestinal crypt in a hierarchical manner, with increasing numbers of new cells 
being recruited after 1, 8 and 15 Gy of gamma-irradiation (Roberts and Potten 
1994). The recruitment and clonogenic repopulation of the crypt is characterised 
by a marked burst of proliferation within the crypt, thus leading to transient crypt 
enlargement (Ijiri and Potten 1986). Various cytotoxic agents such as gamma-
irradiation (8 Gy and higher) induce apoptosis in the intestinal crypts, with a peak 
induction at 6-12 hours following DNA damage, and this early wave of apoptosis is 
mediated by the activation of p53 (Sansom and Clarke 2000) (Potten, Merritt et al. 
1994). There is also a second wave of apoptosis at 24 hours following DNA 
damage (Merritt, Allen et al. 1997). This form of cell death is independent of p53 
and is proposed to be attributed to aberrant mitosis post gamma-irradiation 
(Merritt, Allen et al. 1997).   
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4.1.2 The colon as a model to examine inflammation in vivo 
The colon epithelium contains crypts and Lgr5 positive stem cells at the bottom of 
the crypts, but has a flat surface rather than protruding villi (Sancho, Batlle et al. 
2004) (Barker, van Es et al. 2007). The epithelium comprises two main 
differentiated cell types - the absorptive colonocytes and the goblet cells (Sancho, 
Batlle et al. 2004) 
 
Animal models of intestinal inflammation have greatly facilitated our understanding 
of the pathogenesis of Crohn’s disease and ulcerative colitis, two of the most 
common form of inflammatory bowel disease (IBD) in human (Wirtz, Neufert et al. 
2007).One of the most established models of inflammation is the dextran sulfate 
sodium (DSS) colitis model, in which mice are fed with the DSS polymer to 
stimulate the development of acute colitis characterized by bloody diarrhoea, 
ulcerations and infiltrations of immune cells (Okayasu, Hatakeyama et al. 1990). 
DSS is proposed to be toxic to gut epithelial cells of the basal crypts and disrupts 
the integrity of the mucosal barrier (Wirtz, Neufert et al. 2007). When the integrity 
of this layer is compromised, pathogens can easily can access into the inflamed 
niche, resulting in colon inflammation (Wirtz, Neufert et al. 2007). Myeloperoxidase 
(MPO) is an enzyme that is found in the lysosomes of neutrophil, and is often used 
as a marker for neutrophil infiltration (Roncucci, Mora et al. 2008). MPO activity 
has been described to be upregulated in mouse models of colon inflammation 
(Yamada, Marshall et al. 1992), and is now used as an established marker to 
monitor intestinal inflammation (Galvez, Garrido et al. 2000). 
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4.1.3 Mouse models of radiation- and inflammation-induced 
tumorigenesis 
The oncogenic effects of radiation in humans and mice have been extensively 
studied. The loss of p53 greatly accelerate the development of lymphoma and 
other forms of cancer upon exposure to ionising radiation (Kemp, Wheldon et al. 
1994). Apoptosis elicited by p53 upon DNA damage mediates the removal of cells 
that potentially carry mutation(s) to prevent tumourigenesis (Michalak, Jansen et 
al. 2009). However, regeneration normally follows apoptosis, and the repeated 
deletion and regeneration of tissues can lead to tumour promotion (Labi, Erlacher 
et al. 2010). This phenomenon also enhances the propagation of treatment-
resistant cancer cells during anti-cancer therapy (Allan and Travis 2005).  
 
Inflammation and tumourigenesis are inherently linked. The infiltration of 
lymphocytes and the secretion of chemokines have been proposed to be a driving 
factor for tumour maintenance and progression (Mantovani, Allavena et al. 2008).  
In line with this, patients with inflammatory bowel disease (IBD) have an increased 
risk of developing colorectal cancer (Clapper, Cooper et al. 2007). Following from 
the previous section, DSS in combination with carcinogens such as azoxymethane 
(AOM) have been demonstrated to enhance tumour incidence, multiplicity and 
lesion progression in mice, and is a well characterised model for inflammation-
driven tumourigenesis (De Robertis, Massi et al. 2011). The major mechanism in 
the AOM-induced colon carcinogenesis model is the aberrant activation of Wnt 
signaling which is caused by accumulation of beta-catenin. Apart from beta-
catenin, k-ras is also frequently mutated in this model (Takahashi and 
Wakabayashi 2004).   
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4.2 Results 
4.2.1 Characterisation of DRAM-1 knockout mice 
Wild-type, heterozygotes and whole body DRAM-1 knockout mice were generated 
from a starting cross between DRAM-1 flox/flox (DRAM-1fl/fl) and Cre Deleter 
(Cre+) mice (refer to section 2.3.1). Accordingly, four independent DRAM-1+/- 
intercrosses yielded DRAM-1-/- mice in the expected Mendelian ratio [6 DRAM-1+/+: 
14 DRAM-1+/-: 9 DRAM-1-/-; Chi-square value = 0.655, p = 0.9] (For calculations, 
refer to Fig. 4.1). There was also no difference in the number of DRAM-1+/+, 
DRAM-1+/-, DRAM-1-/- female and male pups that were born. Thus, DRAM-1 is 
deletion is not embryonic lethal, and does not affect neonatal survival. DRAM-1-
null mice are viable, fertile, and appeared normal, with no obvious phenotypic 
defects compared to wild-type and heterozygote controls up to 650 day of age 
(Analysis were verified by Dr. Ayala King, in-house veterinarian, The Beatson 
Institute for Cancer Research). 
 
DRAM-1 mRNA level has been shown to be downregulated in preleukemic 
hematopoietic stem cells knocked down for the transcription factor PU.1 (Steidl, 
Rosenbauer et al. 2006) PU.1 is a transcription factor which is required for 
myelomonocytic differentiation during normal haematopoiesis (Steidl, Rosenbauer 
et al. 2006). This suggests that DRAM-1 could be required for haematopoiesis. To 
investigate this, DRAM-1+/+ and DRAM-1-/- mice at the age of 3 months old were 
culled, and circulating blood from these mice was harvested and subjected to 
peripheral blood smear analysis. The number of circulating lymphocytes and 
platelet per volume of blood is significantly lower in DRAM-1-null mice (Fig. 4.2A 
and 4.2B). However, the number of circulating red blood cells, and the remaining 
white blood cells - neutrophils, monocytes and eosinophils is indistinguishable 
between wild-type and DRAM-1-null mice (Fig. 4.2C - 4.2F).  
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To determine if DRAM-1 deletion affects the lifespan or predisposes to 
spontaneous tumour development, wild-type, heterozygous and DRAM-1-null mice 
were aged under normal conditions and monitored for up to 650 days. Whole body 
autopsy which was performed at the end point of the experiment, revealed no 
phenotypic differences between wild-type, heterozygous or DRAM-1-null mice 
(collaboration Dr. Ayala King, in-house veterinarian at the Beatson Institute for 
Cancer Research). Overall, the loss of DRAM-1 does not affect the life span of the 
animals (Fig. 4.3A). Likewise, wild-type and DRAM-1-null mice display a similar 
propensity to develop spontaneous tumourigenesis (Table 4.1 and Fig. 4.3B). 
However, the % of heterozygous mice which developed spontaneous tumours 
were higher compared to the wild-type and DRAM-1-/- animals (Table 4.1 and Fig. 
4.3B). This could be attributed to the smaller number of animals in this group 
(N=9) compared to wild-type (N=16) and DRAM-1-null mice (N=20). 
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4.2.2 The role of DRAM-1 in p53-dependent and -independent 
apoptosis in vivo 
 
Human DRAM-1 mRNA expression has been shown to be upregulated upon 
treatment with DNA damaging agents (Fig. 3.24).  In line with this, DRAM-1 is also 
required for effective p53-dependent cell death in vitro. We were interested to 
determine if murine DRAM-1 mRNA expression is upregulated upon DNA damage 
and if DRAM-1 is required to mediate both p53-dependent and -independent cell 
death in the small intestine. Wild-type C57BL/6 mice were subjected to 14 Gy of 
whole body gamma-irradiation at the age of 6-8 weeks. mRNA from epithelial cells 
of the small intestine was harvested at 6 hours (early time point) and 48 hours  
(late time point) post irradiation. At least three mice were used for each condition. 
DRAM-1 mRNA expression is significantly upregulated 48 hours post irradiation 
(REST analysis; p = 0.016) (Fig. 4.4).      
 
To determine if DRAM-1 deletion affects apoptosis in vivo, wild-type, and  
DRAM-1-/- knockout mice were subjected to 14 Gy of gamma-irradiation at the age 
of 6-8 weeks. The small intestines were harvested 6 and 24 hours post irradiation 
to assess for p53-dependent and –independent apoptosis respectively.  
 
p53 is activated upon DNA damage at 6 hours post irradiation, and the extent of 
nuclear p53 activation is similar in both wild-type and DRAM-1-/- mice (Fig. 4.5).  
The loss of DRAM-1 is not required for the enhancement of radiation-induced p53-
dependent apoptosis, as revealed by caspase 3 scoring of apoptotic cells in the 
intestinal crypts (Fig. 4.6 A).   
 
Additionally, the loss of DRAM-1 does not modulate p53-independent apoptosis, 
as reflected by the indistinguishable number of caspase 3 positive cells per 25 
crypts during the later wave of p53-independent apoptosis (Fig. 4.6B).  
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To rule out the involvement of murine DRAM-1 in p53-dependent cell death in the 
small intestine, an independent model was used. The AhCre+ mouse (refer to 
section 4.1) was crossed with Mdm2fl/fl mice (Grier, Yan et al. 2002) and either 
DRAM-1+/+ or DRAM-1fl/fl mice. Since MDM2 is responsible for directing the 
proteasomal turnover of p53 (refer to section 1.8), MDM2 deletion in the small 
intestine was validated by p53 staining. As demonstrated by others, in the wild-
type intestines, high p53 levels were observed in highly proliferative cells of the 
intervillus pockets and in terminally differentiated cells in the villus region, leading 
to apoptosis in crypts (Valentin-Vega, Okano et al. 2008) (Fig. 4.7). The intense 
p53 staining in the nucleus is associated with DRAM-1 deletion. The nuclear 
activation of p53 in these areas is independent of DRAM-1 status (Fig. 4.7). 
Consistent with previous observation, the loss of DRAM-1 does not modulate p53-
dependent apoptosis in the small intestine, as validated by the number of caspase 
3 positive cells per crypt (Fig. 4.8).  
 
From these in vivo studies, DRAM-1 deletion does not rescue p53-dependent 
apoptosis in the small intestine. Additionally, DRAM-1 is also not a regulator of 
radiation-induced apoptosis in the small intestine.  
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4.2.3 DRAM-1 is required for regeneration post radiation-induced 
injury in the small intestine  
Albeit DRAM-1 deletion does not impair p53-dependent cell death, we were 
interested to determine if DRAM-1 mediates regeneration. To investigate this, 
DRAM-1+/+ and DRAM-1-/- mice were subjected to 14 Gy of whole body gamma-
irradiation at the age of 6-8 weeks and harvested at 48 and 72 hours later. The 
first proximal 10cm of the small intestine was harvested and analysed for p53 
activation, live crypts, mitosis, proliferation and regeneration. 
 
DRAM-1 deficiency reduced the number of surviving crypts at 48 hours (Mann-
Whitney U test; p = 0.021) (Fig. 4.9A) and 72 hours (Mann-Whitney U test; p  = 
0.018) (Fig. 4.9 B) post irradiation. Consistent with this, the crypt size is 
significantly reduced in DRAM-1-/- animals compared to the wild-type controls at 72 
hours (Mann-Whitney U test; p = 0.021) (Fig. 4.9C). The difference in crypt size 
between wild-type and DRAM-1-/- animals is illustrated in Fig. 4.9D.  
 
To confirm the role of DRAM-1 in regulating crypt regeneration, the small 
intestines harvested at 72 hours post irradiation were stained with the mitotic 
marker (phospho-Histone H3) and the proliferation marker (BrdU). DRAM-1-
deficient intestines show a reduced capacity to undergo mitosis as reflected by a 
reduction in phospho-Histone H3 positive cells per crypt (Mann-Whitney U test; p = 
0.043) (Fig. 4.10A). Likewise, proliferation is also compromised in DRAM-1-/- 
intestines, as reflected by the significant decrease in BrdU positive cells per crypt 
compared to the wild-type intestines (Mann-Whitney U test; p = 0.009) (Fig. 
4.10B).  
 
The defect in crypt regeneration can be attributed to a decrease in the stem cell 
pool of the small intestine. To determine if DRAM-1 deletion modulates the stem 
cell pool, small intestines harvested at 72 hours post radiation was stained with the 
well established human and murine intestinal stem cell marker, OLFM4. (van der 
Flier, Haegebarth et al. 2009) (Begus-Nahrmann, Lechel et al. 2009). The 
population of stem cells remains indistinguishable in wild-type and DRAM-1-null 
intestinal crypts (Fig. 4.11).  This suggests that the fast-cycling stem cell pool 
within regenerating intestinal crypts is not affected upon DRAM-1 deletion.  
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Yet another regulator of cellular growth and regeneration is the mammalian Target 
of Rapamycin (mTOR) (Fu, Kim et al. 2009).  In line with this, Akt/mTOR signaling 
has been shown to be required for intestinal regeneration (Ashton, Morton et al. 
2010). mTOR activity has been previously demonstrated to be downregulated 
when the Intestinal cell kinase (ICK), a downstream target of mTOR, is inhibited, 
leading to a decreased proliferation and differentiation of intestinal epithelial cells 
(Fu, Kim et al. 2009). Although DRAM-1 has yet to be identified as a downstream 
target of mTOR, we were interested to determine if the reduced proliferation, 
mitosis and regeneration in DRAM-1-/- small intestine upon injury is attributed to 
decreased mTOR activity. Wild-type and DRAM-1-null small intestine harvested 72 
hours post radiation were stained with anti-phospho-AKT, a kinase which 
phosphorylates and activates mTOR at Ser-2448 (Fu, Kim et al. 2009), and this 
event is validated by further staining with anti-phospho-mTOR Ser 2448.  
Additionally, the small intestine was also stained with the downstream target of 
mTOR, anti-phospho-4EBP1 (Zou, Smith et al. 2009). mTOR activity, as reflected 
by the levels of phospho-AKT (Fig. 4.12A), phospho-mTOR Ser 2448 (Fig. 4.12B) 
and phospho-4EBP1 (Fig. 4.12C) is indistinguishable in wild-type and DRAM-1-
null crypts of the small intestine. This suggests that mTOR activity is not affected 
in DRAM-1-/- cells within regenerating crypts of the small intestine.  
 
To briefly summarise this part, DRAM-1 is required for efficient regeneration of the 
small intestine post injury by facilitating mitosis and cell proliferation. Additionally, 
the loss of DRAM-1 does not modulate mTOR activity and does not affect the 
subpopulation of OLFM4 positive fast-cycling stem cells. 
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4.2.4 DRAM-1 deletion does not modulate p53-induced 
senescence, but increases the frequency of apoptosis and 
mitosis in the liver 
Reactivation of endogenous p53 in p53-deficient liver carcinoma cell lines has 
been shown to promote tumour regression, and the primary response of p53 in 
this context is to induce cellular senescence instead of apoptosis (Xue, Zender et 
al. 2007). Along the same lines, autophagy has been documented to mediate the 
acquisition of the senescence phenotype that was associated with differentiation 
and the upregulation of inflammatory cytokines (Young, Narita et al. 2009). Given 
that the interplay of p53, autophagy and senescence is emerging into the limelight, 
we were interested to determine if DRAM-1 is required for the induction of p53-
dependent senescence in vivo. 
 
To test this, the livers of AhCre+ Mdm2fl/fl DRAM-1+/+ (‘wild-type’) and AhCre+ 
Mdm2fl/fl DRAM-1fl/fl (DRAM-1-null after Cre-mediated excision) mice (refer to 
section 4.2.2) were either fixed in formalin or preserved with OCT 6 days after 
induction. Similar to section 4.2.2, Mdm2 and DRAM-1 recombination events were 
validated by p53 staining (Fig. 4.13). The frozen liver sections were stained with 
SA-β-gal (senescence associated beta-gal).  From this, the intensity of SA-β-
gal staining between ‘wild-type’ and DRAM-1-/- liver is indistinguishable (Fig. 4.14). 
Since senescent cells do not undergo proliferation, senescence event in livers of 
‘wild-type’ and DRAM-1-/-mice was quantified by the comparing the number of 
proliferating hepatocytes. The number of BrdU positive hepatocytes in ‘wild-type’ 
and DRAM-1-/- liver is indistinguishable (Fig. 4.15). This suggests that DRAM-1 
deletion does not affect cellular senescence upon p53 activation in the liver.  
 
Albeit this, the appearance of a ‘condensed chromatin’ phenotype in hepatocytes 
was more frequent in DRAM-1-/- liver compared to ‘wild-type’ upon analysis of H&E 
stained livers (data not shown). To determine if this morphology is attributed to 
increased apoptotic or mitotic events, the liver sections were stained with the 
apoptotic marker- caspase 3 and mitotic marker- phospho-Histone H3. Histone H3 
is specifically phosphorylated during mitosis and the phosphorylation event is most 
pronounced in metaphase (Hans and Dimitrov 2001). In this case, DRAM-1 
deletion increases the rate of apoptosis and mitosis in the liver, as evident by an 
increase in caspase 3 positive (Mann-Whitney U test; p = 0.013) (Fig. 4.16) and 
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phospho-Histone H3 positive (Mann-Whitney U test; p = 0.05) (Fig. 4.17) 
hepatocytes respectively. p21 activity remains indistinguishable in wild-type and 
DRAM-1-null livers (Fig. 4.18).  
 
To sum up this part of the experiment, DRAM-1 deletion in the liver does not 
enhance p53-mediated cellular senescence. However, DRAM-1 deletion results in 
an increased rate of apoptosis and mitosis, in conditions when p53 levels are 
upregulated.  
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4.2.5 DRAM-1 deletion does not predispose to radiation-induced 
tumourigenesis 
Human DRAM-1 is downregulated in various forms of cancer (refer to Section 1.7). 
Furthermore, since the loss of p53 greatly enhances the development of cancer 
upon exposure to ionizing radiation (Kemp, Wheldon et al. 1994) and that DRAM-1 
is a p53 target gene, we sought to investigate if DRAM-1 deletion accelerates 
tumourigenesis upon exposure to gamma-irradiation. 
 
In this context, wild-type, heterozygous and DRAM-1-null mice aged 6-8 weeks 
were exposed to 4 Gy of gamma irradiation and aged under normal conditions for 
up to 650 days. The mice were monitored frequently for the development of 
tumours. From this experiment, the loss of DRAM-1 does not predispose to 
radiation-induced tumourigenesis, as indicated by the tumour-free Kaplan Meier 
survival curves (Fig. 4.19A). The types of tumours, if any, developed by the 
subjects in this cohort are listed in table 4.2 and the percentage of mice which 
developed tumours is summarised in Fig. 4.19B. 
 
Table 4.2: Cause of death of wild-type, heterozygotes and DRAM-1-/- mice aged up 
to 650 days post 4 Gy of a mma  irra dia tion 
Genotype DRAM-1+/+ DRAM-1+/- DRAM-1-/- 
Lymphoma 50.0 58.3 31.6 
Sarcoma 0.0 0.0 10.5 
Lung tumour 0.0 0.0 0.0 
Liver Tumour 7.1 8.3 15.8 
Unexplained 14.3 0.0 0.0 
Infection 7.1 0.0 0.0 
Old Age 7.1 16.7 26.3 
Healthy 14.3 16.7 15.8 
 
 
In summary, DRAM-1 deletion does not accelerate radiation-induced 
tumourigenesis upon exposure to 4 Gy of a mma  irra dia tion. 
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4.2.6 DRAM-1 is required for colon regeneration post 
inflammation  
 
We were also interested to determine if DRAM-1 deletion predisposes to 
inflammation-driven tumourigenesis. 11 wild-type and 7 DRAM-1-/- mice were 
subjected to intraperitoneal injection of the carcinogen azoxymethane (AOM), and 
three cycles of 2% DSS. This model reproduces a state of chronic inflammation, 
which is postulated to be a driving force in tumour progression in colitis associated 
colorectal carcinoma (De Robertis, Massi et al. 2011).  
 
DRAM-1-/- mice were highly sensitised to the DSS treatment, as 4 out of the 7 mice 
(57.1%) had lost 20% of their body weight (which is the threshold indicated in our 
home office personal license) and developed severe clinical symptoms 
(hunched/moribound), thus leading to a significant decreased lifespan (Fig. 4.20). 
Healthy wild-type mice were harvested along the same time as the ‘sick’ DRAM-1-
null mice as time-point control. Although the length of treatment was too short for 
polyps formation, the colons of DRAM-1-/- mice showed massive epithelial erosion 
(Fig. 4.21). Upon further analysis, the number of live crypts in the colons of DRAM-
1-/- mice was significantly lower that the wild-type controls (Mann-Whitney U test; 
p=0.05) (Fig. 4.22). However, both wild-type and DRAM-1-/- mice exhibited a 
similar degree of neutrophil infiltration, as validated by MPO staining (refer to 
section 4.1.2) (Fig. 4.23).  
 
The remaining 3 DRAM-1-/- mice were able to survive after 3 cycles of DSS 
treatment, although only one was ‘healthy’ enough to be kept until the end point of 
the experiment (70 days). Upon detailed analysis, both wild-type and DRAM-1-/- 
mice developed dysplastic crypts, polyps and lymphocyte infiltration in the colon to 
a similar extent (Fig. 4.24A and Fig.4.24B).  Since the majority of DRAM-1-/- mice 
were unable to complete the course of the treatment, we were unable to determine 
if the loss of DRAM-1 predispose to inflammation-driven tumourigenesis. 
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Given that a majority of DRAM-1-/- mice suffered severe epithelial erosion and 
crypt loss upon exposure to 2% DSS, we were interested to investigate if DRAM-1 
is involved in the modulation of the mediation of the immune responses, or the 
regeneration capabilities post inflammation-induced injuries, or both.  
 
Firstly, we were interested to determine if murine DRAM-1 mRNA expression in 
the colon is upregulated upon DSS treatment.  At least three wild-type C57BL/6 
mice were subjected to a 5-day 2% DSS treatment for 2, 5 and 7 days. DRAM-1 
mRNA expression is significantly upregulated 7 days post irradiation (REST 
analysis; p = 0.016) (Fig. 4.25).      
 
Following from this, DRAM-1+/+ and DRAM-1-/- mice were fed with 2% DSS 
drinking water for 5 days (refer to section 4.1.2) and monitored for up to seven 
days. At least three mice each from each genotype were dissected at day 2 to 
score for early stages of inflammation, day 5 for late stages of inflammation and 
day 7 for recovery upon inflammation-induced injury.  
 
2 days post treatment, the physiological and clinical symptoms between wild-type 
and DRAM-1-/- mice remain indistinguishable (data not shown). At this point of 
treatment, the epithelium, crypts (Fig. 4.26) and goblet cells (Fig. 4.27) are still 
intact. The infiltration of neutrophils and (4.28) and macrophages (4.29) is 
indistinguishable between wild-type and DRAM-1-/- mice. 
 
However, DRAM-1-/- mice exhibited a greater degree of weight loss compared to 
DRAM-1+/+ animals) (Mann-Whitney U test; p=0.05) 5 days post treatment, 
although the clinical symptoms between these two groups were not significantly 
different (Fig. 4.30A & Fig.4.30B). Similar to previous observations, the colons of 
DRAM-1-/- mice showed more severe tissue destruction, and exhibited a 
significantly lower amount of live crypts (Mann-Whitney U test analysis (p=0.05) 
(Fig. 4.31). The loss of DRAM-1-/- also reduced the number of goblet cells (Fig. 
4.32). Both wild-type and DRAM-1-/- mice exhibited a similar degree of neutrophil 
(Fig. 4.33) and macrophage (Fig. 4.34) infiltration. 
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Despite the preliminary studies in section 4.2.6, whereby the loss of DRAM-1 
exacerbates epithelial erosion 2 days after the completion of the 5-day 2% DSS 
treatment (7 days in total after exposure to DSS), the colons of both DRAM-
1+/+ and DRAM-1-/- animals were almost completely ‘denuded’ at this time point. 
H&E staining revealed massive epithelial erosion and crypt damage (data not 
shown).  However, the number of goblet cells revealed by Alcian blue staining) 
(Fig. 4.35) is more abundant in wild type, compared to DRAM-1-/- animals. Both 
wild-type and DRAM-1-/- mice exhibited a similar degree of neutrophil (Fig. 4.36) 
and macrophage (Fig. 4.37) infiltration. 
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From this study, the loss of DRAM-1 does not cause epithelial erosion or 
aggravate neutrophil and macrophage infiltration in the early stages of 
inflammation (2 days post treatment). However, the deletion of DRAM-1 
exacerbates the loss of epithelium integrity, as revealed by a reduced number of 
live goblet cells and crypts in the later stages of inflammation (5 days post 
treatment), with no difference between neutrophil and macrophage infiltration. The 
exacerbated colon damage observed in DRAM-1-/- mice could be attributed to an 
intensified immune response mediated by other immune cells such as plasma 
cells, B cells, T cells and monocytes. Alternatively, this can also be caused by a 
reduced regeneration capacity post inflammation-induced injury. Albeit preliminary 
results shown earlier in this section imply that the loss of DRAM-1 exacerbates 
inflammation, the colons of both DRAM-1+/+ and DRAM-1-/- animals were almost 
completely ‘denuded’ at day 7. As before, neutrophil and macrophage infiltration 
remained indistinguishable between wild-type and DRAM-1-/- mice. However, wild-
type colons appear to retain more live goblet cells compared to DRAM-1 deficient 
mice. 
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4.3 Discussion 
DRAM-1+/- intercrosses yielded DRAM-1-/- mice in the expected Mendelian ratio. 
There was also no difference in the number of DRAM-1+/+, DRAM-1+/-, DRAM-1-/-
 female and male pups that were born. DRAM-1 deletion is not embryonic lethal as 
DRAM-1-/- mice are viable, fertile, and appeared normal, with no obvious 
phenotypic defects compared to wild-type and heterozygote controls.  
Furthermore, DRAM-1-/- mice do not show an increased propensity to the 
spontaneous development of cancer or autophagy disorders. Given that there are 
other DRAM family members identified (O'Prey, Skommer et al. 2009), it remains 
plausible that the loss of DRAM-1 can be compensated by these proteins, implying 
the need to generate multiple DRAMs conditional knockout mouse models. In 
relation to this, DRAM-1 is highly conserved in a number of species including 
mouse, zebraﬁsh, Drosophila, and C. elegans, as demonstrated by sequence 
alignment studies performed by Crighton et. al (2006). This suggests that DRAM-1 
must have a very important function since the protein sequence does evolve 
drastically from lower organisms to higher eukaryotes. Alternatively, DRAM-1 
could form part of a huge regulatory complex in which the subunits comprising the 
complex have structural roles. The evolution of one subunit would also require the 
co-evolution of other subunits. The conservation of DRAM-1 may also allow for a 
flexibility to be involved in the regulation of a variety of cellular pathways, which 
could explain the diverse roles of DRAM-1 in the regulation of autophagy and cell 
death (discussed in chapter 3); mitosis, proliferation, regeneration and 
inflammation/innate immunity (discussed in chapter 4) and potentially adaptive 
immunity (discussed in chapter 5). 
 
Due to the high degree of similarity the involvement of other DRAM family 
members can also be confirmed by deleting DRAM in simpler metazoans like 
C.elegans and zebrafish, or organisms which only encode one copy of DRAM, 
such as Drosophila (O'Prey, Skommer et al. 2009). If the deletion of DRAM is 
lethal, this would suggest that the DRAM family members in higher eukaryotes 
may have evolved to share functional similarities with DRAM-1.  
 
DRAM-1-/- mice have a reduced number of circulating lymphocytes and platelets. 
Since DRAM-1 is modulates autophagsome formation, it would be plausible to 
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investigate if DRAM-1-null lymphocytes are still capable of undergoing autophagy, 
using methods described by Phadwal et. al (2012). Additionally, given that 
autophagy has been implicated in the clearance of mitonchondria (Pua, Guo et al. 
2009), the regulation of endoplasmic reticulum homeostasis and calcium 
mobilization in T lymphocytes (Jia, Pua et al. 2011), it seem plausible to 
investigate if these processes can still take place normally in  DRAM-1-null T 
lymphocytes.  
 
Furthermore, DRAM-1 mRNA expression is downregulated in PU.1 knockdown 
cells (Steidl, Rosenbauer et al. 2006). Thus, it remains plausible that DRAM-1 is 
involved in haematopoiesis, and that this defect does not progress due to the 
compensatory effects by other members of the DRAM family. Following from this, 
it would be interesting to determine which population of circulating lymphocytes 
(i.e. T cells, B cells, and/or natural killer (NK) cells that are affected upon DRAM-1 
deletion. Additionally, It is also crucial to investigate if DRAM-1 deletion affects the 
population of myeloid and lymphoid bone marrow progenitors, as well the activity 
of haematopoietic stem/progenitor cell (HSPC) by performing colony-forming cell 
assay (CFC) and in vivo repopulation assays (Mortensen, Soilleux et al. 2011) 
using bone marrow cells isolated from wild type and DRAM-1-/- mice.  
 
Although DRAM-1 is required to enhance p53-dependent apoptosis in vitro 
(Crighton, Wilkinson et al. 2006), DRAM-1 does not modulate p53-dependent 
apoptosis and radiation-induced apoptosis in vivo. Given that the previous in vitro 
assays were conducted in Saos-2 osteosarcoma cells and MEFs, this suggests 
that the involvement of DRAM-1 in p53-dependent apoptosis is maybe specific to 
certain cell(s) or tissue(s).  
 
However, DRAM-1 is required for the intestinal crypt regeneration upon radiation-
induced injury by modulating cellular proliferation and mitosis. Consistent with this, 
crypt size is significantly reduced in DRAM-1-/- mice compared to the wild-type 
control. Given this, DRAM-1 deletion does not affect the population of OLFM4 
positive fast cycling intestinal stem cells in regenerating crypts. Nonetheless, the 
stem cell pool in regenerating crypts of wild-type and DRAM-1-/- mice should be 
confirmed with other stem cell markers, such as Lgr5, Bmi1 and Musashi (Barker, 
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van Es et al. 2007). This can be ascertain by further IHC validation or by crossing 
DRAM-1-/- and Lgr5-GFP+ mice (Barker, van Es et al. 2007).  
 
While Akt/mTOR signaling is required for intestinal regeneration (Ashton, Morton 
et al. 2010), Akt and mTOR activity is not affected upon DRAM-1 deletion in 
regenerating crypts. Thus, the defect in crypt regeneration is most likely not 
attributed to a block in the Akt/mTOR signaling pathway.  
 
Autophagy activity has been shown to be upregulated in the small intestine paneth 
cells upon exposure to ionising radiation and this process is partly mediated by the 
iNOS signalling mechanism (Gorbunov and Kiang 2009). Similarly, high autophagy 
activity is also associated with the intestinal proliferative and undifferentiated 
progenitor cell populations (Groulx, Khalfaoui et al. 2012). Thus, it might be worth 
while to investigate if autophagic activity in the paneth cells, stem cells or other 
cells that reside in the small intestine is disrupted upon the loss of DRAM-1 when 
exposed to gamma irradiation. This can be confirmed by monitoring LC3-ll puncta 
by immunohistochemistry, as described by Rosenfeldt et. al (2012).   
 
Following from the above, the link between paneth cells and the maintenance of 
intestinal stem cells is well established both in vitro and in vivo. Genetic removal of 
paneth cells in vivo by mutating Gfi1, transgenic expression of diphtheria toxin A 
under the paneth-cell-specific cryptdin 2 promoter (CR2-tox176), and conditional 
deletion of Sox9, results in the concomitant loss of Lgr5 stem cells (Sato, van Es 
et al. 2011).  In addition, Paneth cells have been reported to express EGF, TGF-α, 
Wnt3 and the Notch ligand Dll4, all essential signals for stem-cell maintenance in 
culture (Sato, van Es et al. 2011). It is thus concluded that paneth cells provide a 
niche for intestinal stem cells, which drives clonogenic repopulation of the 
intestinal crypt (see section 4.1). Given that the loss of DRAM-1 is proposed to 
decrease the clonogenic repopulation of intestinal crypts upon irradiation, it would 
be interesting to establish if this is a DRAM-1 is required for paneth cell function, 
and subsequently stem cell maintenance. This can be tested by conditionally 
deleting DRAM-1 in the paneth cells using the cryptdin 2 promoter (CR2-tox176) 
(Garabedian, Roberts et al. 1997) , followed by assessing paneth cell function and 
number by staining for markers of the paneth cells - lysozyme 1 and 2 and 
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defensins (Wang, Peregrina et al. 2011). Lysozymes and defensins are anti-
microbial that are produced by the paneth cells (Sato, van Es et al. 2011). 
 
DRAM-1 mRNA expression level is downregulated in oncogene-induced 
senescent cells. However, DRAM-1 deletion does not modulate p53-induced 
senescence in the liver, quantified by the indistinguishable proliferative events in 
DRAM-1+/+ and DRAM1-/-.  However, the role of DRAM-1 in oncogene-induced 
senescence in vitro and in vivo has yet to be elucidated and is certainly worth 
pursuing.  
 
Although the in vivo model of moderate p53 activation in the liver does not induce 
apoptosis, a significant population of DRAM-1-/- hepatocytes exhibited an elevated 
level of histone H3 phosphorylation. The increase in mitosis does not contribute to 
increased proliferation (indistinguishable BrdU incorporation), but rather, DRAM-1-
null hepatocytes display a greater propensity to cell death, as revealed by caspase 
3 staining. Given that the phosphorylation of histone H3 is initiated in late 
G2/interphase and dephosphorylated takes place upon anaphase, (Hendzel, Wei 
et al. 1997), it is very likely that the DRAM-1-/- hepatocytes are arrested in the 
metaphase stage, at spindle assembly checkpoint (SAC) (refer to section 1.8.2). 
This could be attributed to a defect in the formation of the mitotic spindle, which 
disables the attachment of the chromosomes to the mitotic spindle, or the 
alignment at equatorial plane (Zhou, Yao et al. 2002). In this case, DRAM-1-/-
 hepatocytes may eventually exit mitosis without proper sister chromatid 
segregation and cell division, and then undergo apoptosis by p53-dependent 
tetraploidy checkpoint activation (Huang, Chang et al. 2009). To ascertain this, it 
would be useful to determine if the loss of DRAM-1 affects centrosomes and 
spindle formation, as well as the attachment of sister chromatids on the spindles 
and the alignment of the metaphase plate. Additionally, it would be interesting to 
determine if the loss of DRAM-1 modulates the expression of BubR1, a key 
component of the mitotic spindle checkpoint machinery, which is also regulated by 
p53 (refer to section 1.8.2).  In any case, it may also be interesting to establish the 
role of DRAM-1 in in vivo models of liver cancer, ranging from carcinogen- and 
virus-induced to genetically engineered mouse model for HCC (Leenders, Nijkamp 
et al. 2008). This would determine if the plausible defects in mitosis and increased 
apoptosis upon DRAM-1 deletion can result in tumourigenesis.  
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DRAM-1 deletion does not predispose to radiation-induced tumourigenesis, as the 
onset of tumourigenesis is indistinguishable between DRAM-1+/+, DRAM-1+/- and 
DRAM-1-/- mice. It remains plausible that the tumour suppressive roles of DRAM-1 
can be compensated by other members of the DRAM family, which explains why 
the loss of DRAM-1 does not predispose to radiation-driven tumourigenesis. Thus, 
it would be of great interest to determine if the tumours arising from DRAM-1-/-
 mice displayed an increased expression of DRAM-2, DRAM-3, DRAM-4 or 
DRAM-5, or if the simultaneous deletion of DRAM-1 and other DRAM family 
members increases the risk of tumour development. Yet another explanation is 
that the tumour suppressive (or promoting) effects of DRAM-1 are highly specific 
to the carcinogenic stimuli or tissue type.  
 
In our efforts to investigate if the loss of DRAM-1 predisposes to inflammation-
driven colorectal carcinogenesis using the AOM/DSS model, we found that DRAM-
1-/- mice are susceptible to 2% DSS. This indicates that the loss of DRAM-1 
predisposes to inflammation, at least in the colon. To investigate this further, 
DRAM-1+/+ and DRAM-1-/- mice were subjected to the acute colitis model (2% 
DSS) and monitored for changes in physiological and clinical symptoms for 7 days 
as before, without the AOM injection.  
 
DRAM-1 deletion does not affect epithelium integrity, as well as the infiltration of 
neutrophils and macrophages in the early stage of inflammation.  
 
However, DRAM-1 deficiency exacerbates the loss of epithelium integrity, crypt 
damage and the loss of goblet cells in the later stages of inflammation (5 days 
post treatment). As before, the infiltration of neutrophils and macrophages at this 
stage remained indistinguishable between DRAM-1+/+ and DRAM-1-/- colons.  
 
Recapitulating the preliminary results in the beginning of section 4.2.6, the colons 
of DRAM-1-/- animals assessed at day 7 (after the 5 days 2% DSS treatment and 2 
days recovery period on normal drinking water) exhibited complete epithelial 
destruction. However, the colons of both DRAM-1+/+ and DRAM-1-/- animals were 
almost completely ‘denuded’ at the endpoint of the acute colitis experiment, 
although there were more live goblet cells in the wild-type compared to DRAM-1-/- 
colons. An explanation for the variation is possibly due to the different animal 
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density in the animal facility between the period of preliminary studies and the 
‘controlled’ DSS experiment. Furthermore, the strain of mice used in this 
experiment normally survive past 7 days of this regimen (Clapper, Cooper et al. 
2007). Again, this implies that the exacerbated inflammation and irreparable tissue 
damage in wild-type may be attributed to varying hygiene conditions between 
different animal facilities in different institutions. Thus, it would be critical to 
optimise and tailor the dosage of DSS treatment to the hygiene condition in order 
to reach a comparable end-point between the wild-type experimental controls and 
the published wild-type cohorts.  
 
The loss of the autophagy regulator, ATG16L1 has been shown to drastically 
disrupt the function of paneth cells of the small intestine, thus leading to an 
increase in the expression of a subset of inflammatory cytokines (Cadwell, Liu et 
al. 2008). In line with this, it seems plausible to investigate if the expression of the 
genes (by qPCR) encoding these subset of cytokines is different in the wild-type 
and DRAM-1-null small intestine when exposed to DSS. Additionally, the 
production of inflammatory cytokine may be exacerbated upon the loss of DRAM-1 
during inflammation, which could explain the sensitisation of DRAM-1-null mice to 
DSS. This could be determined by performing a cytokine array on blood samples, 
which would indicate the level of systemic cytokine production (personal 
communication, Dr. Simon Milling). In addition, regulators of the unfolded protein 
response (UPR) such as XBP1 and ORMDL3 have been shown to genetically 
associated with Crohn’s disease and ulcerative colitis (Fritz, Niederreiter et al. 
2011). Since the loss of DRAM-1 predisposes to DSS-induced colitis, it would be 
interesting to investigate if the functions of these regulators might be disrupted 
upon the loss of DRAM-1. Additionally, it might be interesting to investigate if other 
inflammatory markers, such as granulocyte marker proteins (GMP) are expressed 
differently in DRAM-1+/+ and DRAM-1-/- mice (Nysoeter, Erichsen et al. 2007).  
The normal colon has been reported to contain a diverse population of immune 
cells ranging from T cells, plasma cells, macrophages and class II antigen-
expressing cells (Banner, Savas et al. 1993). Although we have demonstrated that 
the loss of DRAM-1 does not modulate neutrophil and macrophage infiltration, it 
would be interesting to investigate if other immune cells such as the ones 
mentioned above, are involved in modulating the immune responses in the 
inflamed colon (Banner, Savas et al. 1993).  
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Perhaps the most interesting facet associated with this study is to determine 
whether the intensified damage in the colon upon DRAM-1 deletion is attributed to 
an exacerbated inflammation (which could lead to excessive tissue damage 
beyond repair), loss of epithelial integrity, a defect in the regenerative capacity of 
the colonic crypts post injury, or a combination of all the above.  To investigate 
this, it DRAM-1 can be conditionally deleted in the colon under the control of the 
Vil-Cre promoter, which deletes specifically in the gut epithelium (el Marjou, 
Janssen et al. 2004). If the loss of DRAM-1 in the gut causes colon destruction, 
this may imply that DRAM-1 is required to maintain the integrity of epithelial cells. 
Additionally, the regeneration capacity could also be affected, and this can be 
determined by assessing proliferative and mitotic indices, as well as stem cell 
activity, similar to methods as described in section 4.2.3.  
 
Likewise, to investigate if DRAM-1 is required to control the extent of the immune 
response upon pathogen attack, DRAM-1 deletion in the immune cells can be 
driven by the Vav-Cre promoted which deletes DRAM-1 in the hematopoietic cells 
thus giving rise to DRAM-1-/- immune cells (de Boer, Williams et al. 2003). If 
DRAM-1 deletion in this context causes colon destruction, this may imply that 
DRAM-1 is required to regulate the magnitude of immune response. As mentioned 
above, DRAM-1 may also regulate all these processes, and thus is an exciting 
area worth pursuing. 
 
Lastly, to determine if DRAM-1 is required to prevent the onset of colitis-
associated colorectal cancer, it would seem plausible to reduce the dosage of 
DSS in order to limit the extent of inflammation so that DRAM-1-null mice can 
recover and stay alive until a point where they are able to develop polyps for 
accurate comparison with wild-type mice. Additionally, it would be interesting to 
establish if the infiltration of immunes cells, such as neutrophils, mast cells, natural 
killer (NK) cells, dendritic cells (DC), and tumor-associated macrophages is 
modulated in DRAM-1-null tumours, as suggested by Terzic and colleagues 
(2010) (Terzic, Grivennikov et al. 2010). 
 
In conclusion, the loss of DRAM-1 maybe compensated by other DRAM family 
members, thus explaining the lack of diseased phenotypes upon DRAM-1 
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deletion. However, the role of DRAM-1 in the cell cycle, particularly in the 
maintenance of the spindle assembly checkpoint and the progression from 
metaphase and anaphase is worth investigating. Furthermore, DRAM-1 is also 
very likely to be involved in tissue regeneration, at lease in the gastrointestinal 
tract upon radiation-induced injuries. The loss of DRAM-1 does not predispose to 
radiation-induced tumourigenesis, but its role in modulating cancer development 
driven by inflammation remains unknown and is worth pursuing. DRAM-1 is also 
required to limit the extent of damage in the colon upon pathogen attack. The 
direct function of DRAM-1 in the colon, whether to control the magnitude of the 
immune response, maintain epithelium integrity or mediate crypt regeneration 
upon damage is yet to be elucidated and merits further investigations.  
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Chapter 5: The role of p53 and DRAM-1 in the regulation 
of antigen processing via the MHC pathway  
5.1 Introduction 
Dendritic cells (DCs) are potent antigen presenting cells (APCs) that capture 
antigens in peripheral tissues and migrate to lymphoid organs where the 
processed antigenic fragments are presented to T cells (Pierre, Turley et al. 1997; 
Vidalain, Azocar et al. 2000).  Immature DCs express low levels of MHC class I, 
MHC class II molecules, and T cell costimulatory molecules, and they are 
specialised to endocytose antigen (Banchereau and Steinman 1998).  Mature 
DCs, which have acquired antigens, have increased expression of MHC molecules 
and T cell costimulatory molecules (Banchereau and Steinman 1998).  Effective T 
cell activation by antigen presenting cells requires the interaction of the MHC 
molecules and T cell costimulatory molecules on APCs with the receptors on T 
cells (Fig. 5.1) (Rovere, Vallinoto et al. 1998) (Pierre, Turley et al. 1997) (Tripathi, 
Bruch et al. 2008).  In addition to DCs, macrophages have also been shown to 
process and present peptides on MHC molecules for the activation of T cells 
(Unanue 1984) (Ceddia and Woods 1999). MHC class II molecules and T cell 
costimulatory molecules have also shown to be upregulated on macrophages 
upon exposure to antigens (Damoiseaux, Yagita et al. 1998) (O'Keefe, Nguyen et 
al. 2002). 
 
Apart from antigens, the presence of a high number of apoptotic cells can also 
induce DC maturation and the presentation of intracellular antigen from these 
dying cells (Rovere, Vallinoto et al. 1998).  However, the acquisition of apoptotic 
and necrotic neutrophils causes an increase in CD83 and MHC class II but a 
decrease in the classical T cell costimulatory molecules, CD40, CD80 and CD86, 
hence a decrease in the ability to stimulate T cells (Clayton, Prue et al. 2003).  
 
The development of T cell receptor (TCR) transgenic mice has greatly facilitated 
the study of T cell response to a variety of different antigens (Barnden, Allison et 
al. 1998).  For instance, the MHC class I and II restricted TCR transgenic lines - 
OT1 and OT2 respectively, have been modified to respond to the highly 
manipulable antigen ovalbumin (OVA) (Ehst, Ingulli et al. 2003) (Hogquist, 
Jameson et al. 1994) (Barnden, Allison et al. 1998). Ovalbumin (OVA), the protein 
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of hen’s egg white, is universally used as the main allergen to induce asthma, food 
and dermal allergy in animal models (Sun, Elsayed et al. 2010). The allergenic 
epitopes of OVA are mainly determined by the primary structure and are 
dependent on a certain peptide chain length (Sun, Elsayed et al. 2010). OVA 323-
339 has been demonstrated to include the CD4+ T cell epitope and is widely used 
to study the nature of class II MHC-peptide binding and CD4+ T cell activation 
(Sun, Elsayed et al. 2010). Similarly, OVA 257-264 is mainly used to study class I 
MHC-peptide binding and the concomitant activation of CD8+ T cells (Svensson 
and Wick 1999). T cell activation and proliferation can be monitored by utilizing the 
well-established carboxyﬂuorescein diacetate succinimidyl ester (CFSE) tracking 
method (Quah, Warren et al. 2007). CFSE is a non-fluorescent dye that readily 
crosses intact cell membranes and is subsequently converted into the fluorescent 
carboxyfluorescein molecule by intracellular esterases (Last'ovicka, Budinsky et al. 
2009). The succinimidyl ester group reacts with amino groups and results in stable 
long-term intracellular retention (Last'ovicka, Budinsky et al. 2009). CFSE is 
inherited equally by daughter cells after division, thus cell division can be 
measured as successive halving of the fluorescent intensity of CFSE, which can 
be visualized as distinct peaks and can be used to track division when analysed by 
flow cytometry (Last'ovicka, Budinsky et al. 2009). 
 
p53 has been shown to participate in the regulation of adaptive immunity (refer to 
section 1.6). Given that DRAM-1 is a p53 target gene, and is primarily localised to 
the lysosomes, which are critical intermediate compartments involved in the 
regulation of immune responses (refer to section 1.6), we were interested to 
explore the potential of p53 and DRAM-1 as regulators of the MHC processing 
pathway in the professional antigen presenting cells DCs and macrophages.  
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5.2 Results 
5.2.1 DRAM-1 expression is coregulated with regulators of the antigen 
presenting pathway  
Network analysis is an approach that identifies a cluster of genes from the genetic 
architecture that are functionally related (Quigley, To et al. 2011) (Quigley, To et 
al. 2009). The identification of these sets of genes can be subsequently exploited 
to map the whole pathways that are involved in the progression of various 
processes and diseases, such as inflammation and cancer (Quigley, To et al. 
2011) (Quigley, To et al. 2009).   A preliminary network analysis of normal skin 
reveals that DRAM-1 is closely coregulated with Lymphocyte cytoplasmic protein-1 
(LCP-1). LCP-1 is an actin remodeling protein that facilitates antigen presentation 
and T cell activation (Wabnitz, Kocher et al. 2007).  Further analysis was 
conducted in a panel of 25 epithelial cell lines to build an expression network, and 
we found that DRAM-1 is highly coregulated with CD80.  CD80, also known as the 
B7 protein, is required for T cell activation and costimulation (Bhatia, Sun et al. 
2010). These results suggest that DRAM-1 may be involved in antigen 
presentation and T cell activation.  
Consistent with this, DRAM-1 mRNA levels were upregulated upon challenge with 
bacterial lipopolysacharride (LPS) in mouse splenocytes, bone marrow-derived 
dendritic cells and macrophages (Fig. 5.2A-C). DRAM-1 mRNA levels are also 
upregulated in human breast cancer cells (MDA-MB-231) and osteosarcoma cells 
(Saos-2) upon stimulation with the bacterial lipopolysacharride (LPS) and the 
inflammatory cytokines interferon-gamma (IFN-γ) and tumour-necrosis factor 
alpha (TNF-α) (Fig. 5.3).  Since Saos-2 cells do not express p53, the upregulation 
of DRAM-1 is independent of p53. 
Given that DRAM-1 expression is upregulated in response to elevated levels of 
inflammatory cytokines or upon exposure to pathogens, it seems plausible that 
DRAM-1 may be involved in the regulation of immune response.  
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5.2.2 DRAM-1 regulates MHC class I and CD40 expression in DCs 
 
To determine if DRAM-1 deletion modulates antigen processing and presentation 
in dendritic cells, bone marrow progenitors were isolated from ‘wild-type’ and 
DRAM-1-null (DRAM-1-/-) mice. These cells were cultured in 100ng/ml Flt-3L for 7 
days to induce differentiation into dendritic cells. The cells were subjected to 
incubation with LPS for 16 hours, and stained for CD11c, CD19 and CD3e. The 
population of cells expressing CD11C+, cD19- and CD3e- were categorized as 
DCs (Fig. 5 .4). DRAM-1 deletion does not affect the ex-vivo differentiation of bone 
marrow progenitors into dendritic cells, both at untreated and LPS-stimulated 
conditions (Fig. 5.5).  
The surface expression of MHC molecules, as well as the panel of T cell 
costimulatory molecules – CD40, CD80 and CD86 was analysed by flow 
cytometry. DRAM-1 deletion does not affect the ability of differentiated bone 
marrow-derived dendritic cells (BMDCs) to upregulate the surface expression 
MHC class II (Fig. 5.6 B), CD80 and CD86  (Fig. 5.7 A-B) upon treatment with 
LPS.  However, DRAM-1-/- DCs have a reduced capacity to upregulate MHC class 
I (Mann-Whitney U test; p = 0.05) (Fig. 5.6A) and CD40 (Mann-Whitney U test;     
p = 0.05) (Fig. 5.7 C) upon exposure to LPS, compared to the wild-type control.  
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5.2.3 The role of p53 and DRAM-1 in the regulation of T cell activation 
 
Since DRAM-1 deletion interferes with the optimal expression of MHC class I and 
CD40, we were interested to determine if DRAM-1-null DCs have a reduced 
capacity to activate CD4+ and CD8+ T cells upon exposure to pathogens. Since 
DRAM-1 is induced by p53, it could be plausible that the effect of DRAM-1 in 
antigen presentation is emphasized in conditions where p53 levels are present 
above basal levels. To address this, p53 level was stabilised in ‘wild-type’ and 
DRAM-1-/- DCs by incubating the cells with the Mdm2 antagonist, Nutlin-3A (refer 
to section 1.7.1). DCs were subsequently pulsed with Ovalbumin (OVA) for three 
hours and co-cultured with the CFSE labeled transgenic CD4+ and CD8+ T cells 
isolated from OT-2 and OT-1 mice respectively. The activation and proliferation of 
T cells is indicated by a dilution of the CFSE dye (Fig 5.8).   
CD4+ and CD8 T+ cell activation was not affected when DRAM-1 is deleted in 
bone marrow-derived DCs, irrespective of p53 status (Fig. 5.9 A-B). Rather, the 
stabilisation of p53 protein levels impedes the ability of DCs to activate CD4+ (Fig. 
4.9A) and CD8+ (Fig. 5.9B) T cells. p53 stabilisation by Nutlin-3A was validated by 
an increase in the mRNA expression of the p53 target gene, p21 (Fig. 5.9C). 
The decreased activation of T cells could be attributed to the pathways 
downstream of p53 such as apoptosis. To rule out this possibility, and also to 
confirm that T cell activation is not a result of off-target effects caused by Nutlin-
3A, bone marrow derived DCs isolated from ‘wild-type’ and p53-null mice were 
incubated with Nutlin-3A as before, and harvested for sub-G1 analysis. Nutlin-3A 
induces a low amount of apoptosis in both p53+/+ and p53-/- DCs to a similar 
extent, which can be rescued by the pan-caspase inhibitor, zVAD-fmk (Fig. 5.10). 
zVAD-fmk has been demonstrated to be able to diminish apoptosis in array of cell 
lines (Kim, Mohan et al. 2000) (Ilangovan, Marshall et al. 2003), including dendritic 
cells (You, Chang et al. 2008).This suggests that Nutlin-3A treatment could result 
in p53-independent apoptosis, and that the decreased ability to activate T cells is 
not a direct result of cell death.  
Alongside this, p53+/+ and p53-/- DCs were incubated with Nutlin-3A and pulsed 
with OVA, as before. Consistent with the previous finding, Nutlin-3A treated p53+/+ 
DCs were unable to stimulate both CD4+ and CD8+ proliferation (Figure 5.11A & 
Figure 5.11B). However, Nutlin-3A treated p53-/- DCs were able to induce both 
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CD4+ and CD8+ T cell proliferation (Figure 5.11 A & B) to similar levels as the 
DMSO treated p53-/- DCs. This suggests that the defect in T cell stimulation is not 
attributed to the off-target effects of Nutlin-3A, but is solely caused by the 
increased expression of p53. This is well reflected in the observation that DMSO 
and Nutlin-3A treated p53-/- DCs were able to induce a bigger magnitude of CD4+ 
and CD8+ T cell proliferation compared to the p53+/+ DCs (Figure 5.11 A & B).  
Given that macrophages are also professional antigen presenting cells, we were 
interested to investigate if p53 and DRAM-1 modulation in these cells would affect 
their ability to induce T cell activation upon exposure to antigen. Similarly, bone 
marrow progenitors were isolated from DRAM+/+ and DRAM-/- mice and cultured in 
10ng/ml M-CSF for 6 days to induce differentiation into macrophages. These bone 
marrow-derived macrophages were pulsed with OVA, and co-cultured with T cells 
from OT-2 and OT-1 mice as before. Consistent with the previous findings in 
dendritic cells, DRAM-1 deletion in macrophages does not affect their ability to 
stimulate T cell proliferation upon incubation with OVA (Fig. 5.12 A & B). However, 
macrophages that were pre-treated with Nutlin-3A prior to incubation with OVA 
have a decreased ability to activate both CD4+ (Fig. 5.13 A) and CD8 + T cells  
(Fig. 5.13 B).  
To summarise this part, DRAM-1 deletion does not impair the ability of DCs and 
macrophages to activate CD4+ and CD8+ T cells upon incubation with OVA. On 
the other hand, p53 stabilisation in DCs and macrophages inhibits the activation of 
T cells upon exposure to OVA, implying that p53-mediated inhibition of T cell 
stimulation is probably applicable to other antigen presenting cells upon pathogen 
attack.   
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Figure 5.9C: Nutlin-3A treatment induces p21 mRNA levels 
Bone marrow-derived dendritic cells were incubated with 8µM Nutlin-3A for 16 
hours. p53 stabilisation was validated by quantifying  p21 mRNA expression using 
RT-PCR. Results shown are representative of what was observed in at least three 
separate experiments 
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5.2.4 p53 modulates MHC peptide processing and presentation  
 
Having established that p53 inhibits the ability of DCs to activate T cells, we were 
interested to determine if this inhibition occurs because p53 inhibits the engulfment 
and processing of the antigen, or the presentation of the processed antigenic 
peptide/MHC complex on the cell surface. To address the second question, Nutlin-
3A treated DCs were pulsed with the processed OVA peptides - OVA 323-339 
which contains the epitope for CD4+ T cell, and OVA 257-264 which harbours the 
epitope for CD8+ T cell. DCs will engage these antigen fragments on the MHC 
molecules, thus bypassing the endocytosis and cytoplasmic processing of the 
antigen (S. Milling, personal communication, The University of Glasgow).  
 
If DCs that are peptide-pulsed and pre-treated with either PBS or Nutlin-3A can 
stimulate T cell proliferation equally, this would imply that p53 does not affect the 
presentation of the processed antigenic peptide.  Otherwise, if Nutlin-3A treated 
DCs were unable to induce T cell proliferation to the same extent as the mock 
control (PBS), this would imply that p53 inhibits the presentation of the processed 
peptide.  
 
Upon incubation with OVA 257-264, both PBS and Nutlin-3A treated DCs were 
able to stimulate CD8+ T cell proliferation to a similar extent (Fig. 5.14). This 
suggests that p53 inhibits the presentation of the MHC class I peptide complex, 
without affecting antigen engulfment and processing.  
 
Likewise, Nutlin-3A treated DCs also induced T cell proliferation, albeit to a lower 
extent compared to PBS treated DCs upon incubation with OVA 323-339 (Fig. 
5.15). This implies that p53 partially affects the presentation of processed MHC 
class II antigenic peptides.  
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In line with this, the role of p53 in the modulation of MHC class II molecules and 
the T cell costimulatory molecule, in this case, CD40 was also investigated. In this 
context, p53+/+ and p53-/- bone marrow-derived DCs were incubated with the pan-
caspase inhibitor, zVAD to prevent apoptosis (Fig. 4.16). Upon exposure to LPS, 
the surface expression of MHC class II and CD40 is upregulated in both p53+/+ and 
p53-/- DCs (Fig. 4.16). Albeit the mean fluorescent intensity (MFI) for both MHC 
class II and CD40 is slightly higher in p53-/- DCs, this difference is not statistically 
significant, implying that both of these T cell activation signals are not affected by 
p53. However, Nutlin-3A treatment impairs the ability of p53+/+ and p53-/- DCs to 
upregulate MHC class II and CD40 upon exposure to LPS. This suggests that 
Nutlin-3A causes a downregulation of T cell activation signals, independent of p53 
status. Alternatively, the downregulation of MHC class II and CD40 could be a 
direct result of Nutlin-3A induced p53-independent apoptosis, as discussed in 
section 4.1.2 (Fig. 5.10).  On a different note, the upregulation of MHC class II and 
CD40 upon stimulation with LPS was also abrogated when DCs were treated with 
the pan-caspase inhibitor, Z-VAD, irrespective of p53 status (Fig. 5.16). This was 
consistent with the study by Santambrogio et al. (2005) which demonstrates that 
caspase 3 is required for the localisation of the MHC class II invariant chain in 
activated (mature) DCs (Santambrogio, Potolicchio et al. 2005). Having said that, 
the mechanism that governs p53-mediated downregulation of CD40 has yet to be 
elucidated.  
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Figure 5.16 (A-B): Nutlin-3A and zVAD-fmk impairs the surface expression of 
MHC class II independent of p53 status 
Bone marrow-derived dendritic cells were treated with 8µM Nutlin-3A, 500µM  
zVAD-fmk, and or 1µg/ml LPS for 16 hours.  
The cells were stained with anti-CD11c+ and anti-MHC class I conjugated to 
PerCP/Cy5.5 or anti-MHC class II conjugated to PerCP-eFlour®710, and 
subjected to flow cytometry analysis. The surface expression of MHC class II (A) 
and CD40 (B) on CD11c+ DCs is quantified using the mean fluorescent intensity 
(MFI). Results shown are representative of what was observed in two separate 
experiments 
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 5.3 Discussion 
 
DRAM-1 mRNA expression is upregulated in human cells and mouse professional 
antigen presenting cells – dendritic cells and macrophages upon exposure to 
bacterial lipopolysacharride (LPS) and other inflammatory cytokines such as 
interferon gamma (IFN-γ) and tumour-necrosis factor alpha (TNF-α).  Additionally, 
DRAM-1 is closely coregulated with regulators of antigen presentation such as the 
Lymphocyte cytoplasmic protein-1 (LCP-1) and CD80 in an array of human 
epithelial cell lines. These observations suggest that DRAM-1 is a potential 
regulator of the immune response, particularly in mediating antigen presentation.  
However, loss of DRAM-1 in dendritic cells does not affect the upregulation of  
the T cell activating signals like MHC class II, as well as the T cell costimulatory 
molecules CD80 and CD86 upon exposure to LPS. On the other hand, the surface 
expression of MHC class I (see section 1.5.2) and CD40 is downregulated in 
DRAM-1-null DCs compared to their wild-type counterparts. 
 
CD40, is another T cell co-stimulatory molecule which is facilitates the maturation 
of dendritic cells (DCs), and the subsequent ability of these cells to activate T cells 
(Gerlach, Steimle et al. 2012). The ligation of CD40 on DCs by CD40L leads to an 
upregulation in the expression of CD80 and CD86 molecules on DCs (Cella, 
Scheidegger et al. 1996). Like CD80 and CD86, the ligation of CD40 to its ligand 
also increases the capacity of DC to trigger proliferative responses, in addition to 
IFN-gamma production by T cells (Cella, Scheidegger et al. 1996).  
 
Despite being a strong trigger for CD80 and CD86, the downregulation of CD40 in 
DRAM-1-null DCs does not seem to affect the regulation of CD80 and CD86.  
Furthermore, the deletion of DRAM-1 in DCs and macrophage does not impair the 
ability of these professional antigen presenting cells (APCs) to stimulate T cell 
proliferation upon exposure to the model antigen Ovalbumin (OVA). This suggests 
that DRAM-1-null APCs can still trigger T cell proliferative responses despite 
expressing lower levels of MHC class l and CD40 levels. Albeit this, the production 
of IFN-gamma by T cells upon CD40-CD40L ligation in the absence of DRAM-1 
may be affected, and remains to be elucidated. We have also shown that the loss 
of DRAM-1 (and the subsequent downregulation of CD40) does not affect the 
differentiation of bone marrow progenitors into DCs upon treatment with Flt-3L in 
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vitro. However, the maturation of DCs in vivo upon the loss of DRAM-1 remains to 
be unknown and is worth pursuing.  
 
This suggests a redundancy in DRAM-1 mediated expression of MHC class I and 
CD40. Alternatively, the loss of DRAM-1 can be compensated by other family 
members of the DRAM family. This notion is supported by the cluster analysis of 
DRAM-1, which revealed that DRAM-1 and DRAM-2 are strongly associated with 
regulators of the immune system in papillomas (A. Balmain, personal 
communication). Despite this, the deletion of DRAM-1 in B cells and T cells, or 
facultative APCs like skeletal muscles (as discussed in section 5.1) has yet to be 
investigated and is certainly worth pursuing. 
 
On the other hand, p53 is found to negatively regulate T cell activation. 
Stabilisation of p53 levels in dendritic cells and macrophages with the specific 
Mdm2 antagonist Nutlin-3A impairs the ability of these cells to stimulate CD4+ and 
CD8+ T cell proliferation. In line with this, p53-null DCs are able to stimulate a 
greater magnitude of T cell activation compared to the wild-type counterpart when 
pulsed with OVA. The defect in CD8+ T cell activation upon p53 stabilisation is not 
attributed to a disruption in the presentation of the processed antigenic peptide, as 
DCs incubated with the ‘processed class I MHC peptide’ (OVA 257-264) can 
induce a similar magnitude of T cell proliferation, irrespective of p53 status. The 
impairment in CD4+ T cell activation is partially attributed to the presentation of the 
processed antigenic peptide, as the inhibitory effect of T cell proliferation upon p53 
stabilisation can be partially rescued when DCs were pulsed with the processed 
class II MHC peptide (OVA 323-339).  
 
Further mechanistic studies to elucidate if p53 affects antigen engulfment and 
processing are worth pursuing. For instance, we have yet to establish if the loss of 
p53 affects the expression, or the trafficking of MHC class l and MHC class ll 
molecules, as well as T cell molecules to the cell surface. Albeit this, p53 has been 
shown the positively regulate the transporter associated with antigen processing 
(TAP) 1 and the subsequent transport of MHC class I peptides on a panel of non-
professional antigen presenting cells to facilitate antigen presentation (Zhu, Wang 
et al. 1999). This seem to contradict with our findings in which p53 activation in 
dendritic cells is proposed to inhibit the ability of these cells to activate T cell 
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proliferation/ activation. However, this discrepancy could be attributed to the 
different cell types and the nature of the antigen that are used in the experiments.  
Thus, it would seem plausible to investigate if the loss of p53 in professional 
antigen presenting cells (such as dendritic cells and macrophages) would 
modulate TAP1 activity, or the expression and the trafficking of MHC class I and 
the panels of T cell costimulatory molecules.  
 
The decrease in the ability of DCs to present processed peptide on MHC class ll, 
but not MHC class l upon p53 activation indicates that the surface expression of 
MHC class ll may be downregulated by p53. This reiterates the importance of 
studying the effects of p53 on the expression and the trafficking of MHC class Il 
molecules on antigen presenting cells.   
 
Our system to study antigen processing by MHC class l in DC is limited by the way 
the antigen is introduced (See Section 1.5.2). In this context, Ovalbumin is 
introduced as an extracellular antigen, which is cross-presented on MHC class l. 
Thus, we have yet to establish an accurate model to measure the effects of p53 
and DRAM-1 on intracellular / endogenous antigen processing. One category of 
intracellular antigen that is conventionally recognised by class I originates from 
viruses. To recapitulate viral infection, it would be interesting to introduce 
ovalbumin by infecting DCs with lentiviral vectors expressing 
cytoplasmic  (OVAcyt) (Rowe, Lopes et al. 2006).  This model is proposed to be a 
much more accurate method to stimulate viral infection, and MHC class l 
responses to intracellular / endogenous antigens, since ovalbumin is now 
synthesised within the cells.  
 
The role of p53 in regulating antigen presentation and the efficacy of APCs to 
evoke T cell function has been studied extensively. Human dendritic cells that 
were pulsed with the wild-type p53 protein could induce the specific antitumor 
effect against p53-overexpressing tumors (Tokunaga, Murakami et al. 2005) 
(Nikitina, Clark et al. 2001). The contradictory results between these studies and 
our findings could be attributed to the different nature of stimuli used to pulse DCs. 
The activation of T cells in response to p53 activation is demonstrated upon 
exposure to tumour antigens. On the other hand, the inhibition of T cell activation, 
which is demonstrated in this thesis occurs when DCs were pulsed with ovalbumin 
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and ovalbumin-derived peptides, which are components of allergens and thus is 
classified as extracellular antigens (refer to section 5.1). Furthermore, 
many tumour antigens are intracellular molecules (Noguchi, Kato et al. 2012), 
while ovalbumin is added as an extracellular antigen in our studies. Thus, it 
remains plausible that p53 activation could turn down allergen or extracellular 
mediated T cell activation to promote tumour antigen pulsed-DCs and the 
subsequent T cell activation for enhanced tumour immunity, as illustrated in Fig. 
5.17. 
 
In any case, if the inhibition of the adaptive immune responses via APCs by p53 is 
thorough and effective, it should be accompanied by inhibition of antibody 
production by B cells.  This can be done by irradiating wild-type and p53-null mice 
to activate p53 (in the wild-type), followed by inoculation with OVA and 
recombinant IL-1 (as adjuvant) via intraperitoneal injection.  Two weeks later, mice 
will be irradiated and inoculated with OVA for a second time. Mice will 
subsequently be exsanguinated and the presence of OVA-specific antibodies will 
be detected by end-point ELISA, as illustrated in Fig. 5.18.  If the ability of p53 to 
block antigen processing and presentation in DCs, macrophages (and B cells) is 
robust enough to block activation of humoral immunity this should easily be 
detected in this assay. These aspects would bring us closer to unraveling the role 
of p53 in the mediation of adaptive immune response, and ultimately tumor 
immunity.  
 
The roles of p53 in mediating the immune response - inflammation and 
autoimmunity, have long been established (see section 1.7.2). Our result indicates 
that the stabilisation of p53 in professional antigen presenting cells represses T 
cell activity, resulting in a weaken immune response when challenge with 
pathogen.  
 
Testing this hypothesis in vivo might be limited by the fact that mice are generally 
resistant to infections with human-specific pathogens like HIV, Plasmodium 
falciparum, and Shigella flexneri, especially if the pathogen is administered 
through the natural route of infection (Coers, Starnbach et al. 2009). This limitation 
has led to the development of humanised mouse models of human infectious 
diseases. These mice, which are transplanted with human cells or tissues, have 
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been utilised widely to study the response of the human immune system in 
response to viral infection (Legrand, Ploss et al. 2009). For instance, NOD/SCID 
mice that were transplanted with human hematopoietic fetal liver CD34+ cells and 
previously implanted with human fetal thymic and liver tissues were able to mount 
specific adaptive and innate immune responses to Epstein-Barr virus (EBV) and 
the superantigen toxic shock syndrome toxin 1 (TSST-1) (Melkus, Estes et al. 
2006). Taking this a step further, it would be interesting to modulate p53 and 
DRAM-1 levels in the cells of the immune system prior to exposure to viruses, and 
monitor the magnitude of immune responses.  
 
Despite harnessing anti-tumorigenic potentials, as discussed in this section, our 
results suggest that the stabilsation of p53 downregulates the ability of 
professional antigen presenting cells to stimulate T cell activation upon exposure 
to the extracellular antigen ovalbumin. This finding is important physiologically as it 
may imply that tumour therapy targeted at restoring or stabilising wild-type p53 
levels might sensitise the patients to diseases caused by extracellular pathogen 
attack, and should be approached with caution.  
 
In addition, we also found that Nutlin-3A induces apoptosis in p53+/+ and p53-/- 
DCs, independent of p53. Of p53 status Additionally, p53+/+ and p53-/- DCs that 
were pre-treated with Nutlin-3A were unable to upregulate the T cell activation 
signals, MHC class II and CD40 upon exposure to LPS. The upregulation of MHC 
class l, CD80 and CD86 is yet to be determined. To rule out that this 
downregulation of T cell activation signals is caused by apoptosis, DCs were 
treated with the pan-caspase inibitor, zVAD-fmk, to prevent apoptosis. Given that 
caspase 3 is required for the expression of MHC class II molecules on mature DCs 
(Santambrogio, Potolicchio et al. 2005), the inhibition of caspase(s) also results in 
the downregulation of CD40 in these cells upon exposure to LPS. This observation 
implies that beyond the regulation of cell death, caspases may also play a critical 
role in the regulation of DC maturation, antigen presentiation or T cell activation, at 
least by controlling the expression of MHC class II and CD40 on DCs.   
 
These findings suggest that the administration of Nutlin-3A, and perhaps other 
compounds that modulate p53 and caspase levels can interfere with adaptive 
immunity. Thus these potential therapeutic agents should be used with caution. 
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Chapter 6: Conclusions  
This section summarises the main conclusions of this thesis.  
DRAM-1, a p53 target gene, encodes for a series of splice variants both in human 
and mouse. This implies that the splicing of DRAM-1 may be widespread and 
evolutionarily conserved across species, at least in higher eukaryotes.  
 
In the first part of this thesis (Chapter 3), three of the the DRAM-1 splice variants, 
namely SV 1, SV 4 and SV 5, all which contains the first and the last exons but 
lack different combinations of internal exons, have been characterised. These 
transcripts give rise to different fully functional proteins, all which possessed the 
conserved ‘PYISD’ domain, which is critical for DRAM-1-mediated autophagosome 
formation. DRAM-1 isoforms localise to different cellular compartments spanning 
the secretory pathway - ER, golgi apparatus, endosomes, and lysosomes, in 
addition to autophagosomes and peroxisomes. These isoforms are believed to 
modulate autophagy in parallel, and occasionally coordinatedly in different regions 
of the cell. Isoform 1 is degraded in lysosomes, whereas isoforms 4 and 5 are 
degraded in the proteasome. 
 
DRAM-1 isoforms 1, 4 and 5 cause autophagosome accumulation, with isoform 1 
evoking a stronger effect of GFP-LC3 punctation and LC3 lipidation compared to 
isoforms 4 and 5. The simultaneous overexpression of DRAM-1 isoforms does not 
result in a synergistic accumulation of autophagosomes or an enhanced fusion of 
autophagosomes to lysosomes.  
 
Interestingly, deletion of DRAM-1 does not impair LC3 lipidation upon starvation. It 
is very likely that autophagy mediated by DRAM-1 can be substituted by the other 
DRAM family members, namely DRAM-2, DRAM-3, DRAM-4 or DRAM-5, all 
which show significant homology to DRAM-1 (O'Prey, Skommer et al. 2009). This 
is supported by the observation that DRAM-2, DRAM-3, DRAM-4 and DRAM-5 
mRNA expression is upregulated in different cell types upon DRAM-1 deletion, as 
illustrated in Fig. 6.1.  
 
The autophagic substrates for DRAM-1 appear rather specific. Forced expression 
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of DRAM-1 induces LC3 accumulation, but ectopic overexpression or genetic 
ablation of DRAM-1 isoforms does not enhance long-lived protein degradation and 
ROS, a susbtrate of autophagy which is generated as a byproduct of variuos 
cellular processes (refer to section 1.3.2).  
 
Consistent with previously published results, DRAM-1 is required for p53-
dependent apoptosis (Crighton, Wilkinson et al. 2006). In line with this, the role of 
DRAM-1 in enhancing p53-dependent cell death also occurs in mouse embryonic 
fibroblasts, as discussed previously in this thesis. Although the individual 
overexpression of DRAM-1 isoforms does not modulate cell death, they (or at least 
one - DRAM-1 isoform 1) are required to sustain cellular viability under amino-acid 
and glucose-limiting conditions. 
 
In the second part of this thesis (Chapter 4), the investigation of DRAM-1 has been 
extended to in vivo studies. Dram-1-/-  mice were born at the expected Mendelian 
frequency and are viable, fertile, and appeared normal, with no obvious phenotypic 
defects compared to wild-type and heterozygote controls. Although human DRAM-
1 has convincingly shown to be a strong promoter of autophagy, loss of DRAM-1 
neither affects the lifespan nor predisposes to autophagy-related diseases in either 
heterozygotes or DRAM-1-null mice aged up to 650 days old.  
 
Albeit DRAM-1 is required for effective p53-mediated cell death in human 
osteosarcoma cells (Crighton, Wilkinson et al. 2006) and MEFs, loss of DRAM-1 
does not modulate apoptosis in the small intestine upon exposure to 
gamma irradiation in vivo, regardless of p53 status. This suggests that 
involvement of DRAM-1 in p53-dependent apoptosis is highly specific to the type 
of cell or tissue.  
 
DRAM-1 is required for optimal regeneration in the small intestine, at least in the 
crypts upon radiation-induced injury by promoting cellular proliferation and mitosis. 
In this case, mTOR activity and the population of OLFM4 positive fast-cycling stem 
cells are not affected by loss of DRAM-1, assessed at 72 hours post irradiation.  
  
The reactivation of p53 in the liver has been demonstrated to induce senescence 
and promote tumour regression (Xue, Zender et al. 2007). Albeit DRAM-1 is a p53 
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target gene, the genetic ablation of DRAM-1 is not required for p53-induced 
senescence in the liver. However, human DRAM-1 mRNA expression is 
downregulated during oncogene-induced senescence (Fig.6.2A and Fig. 6.2B). 
Thus, it would be interesting to investigate if DRAM-1 modulates the onset of 
oncogene-induced senescence in vitro and in vivo.  
 
Using the same model, the simultaneous loss of DRAM-1 and p53 activation in the 
liver is very likely to cause mitotic arrest in the metaphase stage, thus leading to 
an increase in apoptosis. This may suggest that DRAM-1 is required to regulate 
the formation of the mitotic spindle and the attachment of sister chromatids to the 
spindle. This also highlights the role of DRAM-1 as a tumour suppressor in the 
liver to maintain the fidelity of mitosis. Thus, it might be worthwhile to confirm the 
role of DRAM-1 as a tumour suppressor using in vivo models of liver cancer. 
 
DRAM-1 knockout mice were not predisposed to spontaneous or radiation-induced 
tumorigenesis. In line with the previous scenario, loss of DRAM-1 could be 
compensated by other DRAM family members. Given this, the deletion of DRAM-1 
in conjunction with other DRAM family members and its impact on the lifespan, 
susceptibility to autophagy-associated diseases and tumourigenesis is of great 
interest.  We also showed that the loss of DRAM-1 does not predispose to 
inflammation-driven colorectal cancer. However, the number of DRAM-1-/- subjects 
in this cohort is relatively small (N=3) because  DRAM-1-/- mice are susceptible to 
DSS treatment. To consolidate this observation, this experiment ought to be 
repeated with a lower dosage of DSS to a reasonable threshold in order to 
increase the number of DRAM-1-/- survivors, at least until a time point where they 
are able to develop colonic polyps for accurate analysis.  
 
In the last section of chapter 4, we found that the loss of DRAM-1 exacerbates 
epithelium erosion, as characterised by the loss of live crypts and goblet cells. 
However, DRAM-1-/- do not exhibit an increase in neutrophil and macrophage 
infiltration to the colon during the early and late stages of inflammation. In future, it 
would be of great interest to determine if DRAM-1 is required for regulating 
inflammation establishing an increase in inflammatory markers, such as cytokine 
secretion and by monitoring the infiltration of other immune cells such as 
monocytes, T and B cells (refer to section 4.3). It may be possible that DRAM-1 
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does not regulate the inflammatory responses, but is required for optimal 
regeneration of colonic crypts after injury. This is yet another facet that is worth 
pursuing.  
 
In the third part of this thesis (Chapter 5), it was found that human DRAM-1 is 
coregulated with regulators of the antigen presentation pathway, and as such 
might be involved in regulating cellular immune responses. In line with this, 
DRAM-1 mRNA expression is upregulated upon exposure to the pathogens, 
bacterial LPS and inflammatory cytokines. Although loss of DRAM-1 in dendritic 
cells affects the upregulation of MHC class I and CD40, other T cell activating 
signals – MHC class II, CD80 and CD86 remains unperturbed upon exposure to 
LPS. However, loss of DRAM-1 in professional antigen presenting cells – dendritic 
cells and macrophages do not affect their ability to stimulate T cell activation. 
Given this, studying the loss of DRAM-1 in B cells (another professional APC) and 
facultative APCs like skeletal muscle cells is worth pursuing.  
 
Instead, stabilisation of p53 in APCs inhibits antigen processing and impairs CD4+ 
and CD8+ T cell stimulation. Given that p53 has been shown to increase TAP1 
expression and the subsequent trafficking of of MHC class I peptides in non-
professional antigen presenting cells (Zhu, Wang et al. 1999), the inhibitory or 
promoting role of CD8+ T cell activation by p53 is possibly cell-type specific. In line 
with this, the thorough effect of p53 on the adaptive immunity and its significance 
in tumour immunity is of great interest.  
 
In efforts to delineate the role of p53 in modulating antigen presentation in 
dendritic cells (DCs), it was found that the p53 modulator, Nutlin-3A, which is a 
potential chemotherapeutic drug in the pre-clinical developmental phase, can 
result in p53-independent apoptosis. Consistent with previous findings in which 
caspase 3 is required for the expression of MHC class II molecules on mature DCs 
(Santambrogio, Potolicchio et al. 2005), the pan-caspase inhibitor zVAD-fmk, 
represses the upregulation of a panel of classical T cell co-stimulatory molecules 
on antigen presenting cells upon exposure to stress signals. 
  
Clearly, efforts to elucidate the role of DRAM-1 in autophagy, apoptosis, 
regeneration, senescence and immunity is complicated due to the fact that the 
  241 
loss of DRAM-1 can likely be compensated by other DRAM family members. Thus, 
studies to identify the role of DRAM-1 should be conducted alongside the studies 
to characterise other DRAM family members.  
 
Additionally, the role of p53 in the modulation of adaptive and tumour immunity is 
worth pursuing in efforts to aid the development of cancer therapeutics.   
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